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Circular RNAs (circRNAs) are an emerging class of non-coding RNA that may regulate 
expression during normal and disease states. Although circRNAs accumulate in in 
vivo models of ageing, their role in this process and its physiological consequences 
remains largely unanswered. In the course of this thesis, I assessed dysregulation of 
circRNA expression in RNA samples from ageing human peripheral blood and 
examined associations of their expression with various ageing outcomes in human, 
mammalian longevity and senescence in human cell types of various lineages, and in 
blood and islet samples from patients with type 2 diabetes; an exemplar disease of 
ageing.  
 
Of the 15 circRNAs validated in this study, I identified 4 (circDEF6, circEP300, 
circFOXO3 and circFNDC3B) that were associated with ageing outcomes (parental 
longevity or hand grip strength) in the InCHIANTI population study of ageing. 
CircFOXO3 and circEP300 also demonstrated differential expression in one or more 
human senescent cell types. 4 ageing outcomes associated circRNAs appeared to be 
conserved in mouse of which circPlekhm1 nominally correlated with median strain 
lifespan.  
 
As type 2 diabetes is an exemplar chronic disease of ageing, I also aimed to examine 
the role of circRNA in this disorder. I first defined the circRNA repertoire in human 
pancreatic islets and assessed their differential expression in conjunction with type 2 
diabetes status and genotype at T2D risk loci.  Following this, I determined their 
responsiveness to diabetomimetic stimuli in the human EndoC-βH1 beta cell line, and 
the potential for use as biomarkers of T2D in human peripheral blood. 4 of the five 
iv 
 
most abundant circRNAs expressed in human pancreatic islets circCIRBP, 
circZKSCAN, circRPH3AL and circCAMSAP1, were associated with diabetes status 
in islets.  CircCIRBP and circRPH3AL were also differentially expressed in β-cells in 
response to elevated fatty acid. Despite this, no associations with T2D diabetes risk 
loci was identified.  Cumulatively, the data generated from my work suggest that 
circRNAs have potential as regulators of gene expression during ageing and age-
related disease, raising the possibility that they may have future utility as biomarkers 
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Ageing is a multifactorial process that leads to gradual deterioration of physical and 
physiological functionality at the cellular, tissue and organ levels. It is the primary risk 
factor for chronic ageing pathologies such as cancer, sarcopenia, diabetes, and 
cardiovascular and neurodegenerative illnesses, which account for the bulk of 
morbidity and mortality in both the developed and the developing world (Goldman et 
al., 2013; Kirkland, 2016). Physiological parameters, such as loss of muscle and bone 
mass, frailty, immobility, cognitive impairment, impaired immune function and a 
reduced ability to respond to stress increase with the risk of developing geriatric 
syndromes (MacIntosh, Morley, and Chapman, 2000). Although time-dependent 
accumulation of cellular damage is widely accepted as one of the key causes of 
ageing, this accumulated damage may provide compensatory advantages to cells that 
would otherwise become hyperplastic and/or transformed (Gems and Partridge, 2013; 
Kirkwood, 2005; Vijg and Campisi, 2008). 
 
While advances in medical technologies and services have contributed to an extension 
of average lifespans of populations, extension of lifespan does not necessarily equate 
to an improvement in healthspan. In fact, ~20-55% of the total healthcare costs is 
needed for the management of ageing-associated chronic comorbidities (Fullfact, 
2018). While some individuals experience relatively disease-free ageing, others may 
encounter ageing outcomes in early midlife. Children of long-lived parents seem to 
have lower rates of ageing disorders or attributed mortalities, and greater life 
expectancies (Dutta et al.,2014; 2013). Many long-lived individuals suffer from multiple 




Offsprings of non-agenarians and centenarians delay or escape age-related diseases, 
have a life-long survival advantage and have lower prevalence of and mortality from 
age-related diseases such as coronary heart disease, type 2 diabetes and cancer 
when they reach middle age.  In fact, 21 “ageing-signature” genes were identified in 
middle-age offsprings which were likely engaged in metabolism, epigenetic control and 
immune function including ASF1A and IL7R. Reduced expression of ASF1A and IL7R 
at middle age might assist in maintenance of chromatin structure and the immune 
system (Passtoors et al., 2012).  
 
Analysis of differential expression of genes involved in lipid metabolism and favourable 
lipid profile between centenarians and their partners show changes in expression of 
several genes (MSR1, TPI1, DBI, AGPAT2 and PLTP) were upregulated while 
several others were (NR1D1, PLCG1, HMGCR and FABP6) were downregulated in 
centenarian compared to their partners. The expression of ADRBK1, F2R, GSR, 
LRRC16A and ARG1 in centenarians also associated with that in their offsprings. This 
might contribute to the lower incidence cardiovascular diseases and kidney 
dysfunction in centenarians and their offsprings (He et al., 2016).  
 
Analysis of DNA methylation levels of peripheral blood mononuclear cells of offsprings 
of semi-supercentenarians reveal they have a lower epigenetic age than age-matched 
controls. In addition, centenarians are younger than expected based on their 
chronological age (Horvath et al., 2015). A study on peripheral blood mononuclear 
cells of healthy octo/nonagenarians and their offsprings showed several transcripts 
dysregulated between the two groups which included changes in gene expression 
associated with increased apoptosis (BAK1), cell cycle regulation (CDKN1B), 
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metabolic process (LRPAP1), insulin action (IGF2R) and increased immune and 
inflammatory response (IL27RA), whereas response to stress (HSPA8), damage 
stimulus (XRCC6), and chromatin remodelling (TINF2). These results suggested that 
systemic telomere maintenance, metabolism, cell signalling, and redox regulation may 
be important for individuals to maintain their healthy state with advancing age and that 
these processes play an important role in the determination of the healthy life-span 
(Rahman et al., 2013). It is known that the efficiency of autophagic/lysosomal 
degradation declines with ageing and leads to increased intracellular accumulation of 
waste products that can lead to age-related neurodegenerative disease and 
cardiovascular disease in the elderly and descendants of these ceneterians may 
partially inherit the trait. The waste-cleaning activity via autophagy may serve as a 
conserved mechanism to prolong the life span across various species, including 
humans (Xiao et al., 2018).  
 
Several comparative studies of offspring of long-lived individuals with age-matched 
controls, such as the Longevity Gene Study, the Leiden Longevity Study, the New 
England Centenarian Study, and the Long Life Family Study show offsprings of long 
lived indviduals display favourable blood lipid profiles, lower prevalence of 
hypertension and metabolic and cardiovascular disease and all-cause mortality 
compared to their peer age-matched controls.  The glucose levels correlate with the 
number of T2D SNPs in the Leiden Longevity Study which might contribute to the 
improved metabolic profile and glucose tolerance in spite of the presence of T2D 
GWAS SNPs. Other studies have identified association of longevity with variants of 
APOE and FOXO3A.  Centenarians and their offsprings may have the potential to 
delay age-related methylation or other epigenetic changes (Ar, 2013). The forkhead 
5 
 
box O3A (FOXO3A) transcription factor contains alleles associated which may 
contribute towards extended lifespan by increasing expression or activity of FOXO3A.  
ApoE is a multifunctional protein that is important for the metabolism of cholesterol 
and TG in an isoform-dependent manner. APOE allele carriers exhibit abnormal levels 
of TC and LDL-C levels. APOE ε4 allele is a frailty gene and has been shown to 
associate with survival to beyond 90 years.  Studies with rodents show the ɛ4 form of 
APOE exhibits an impaired ability to promote amyloid β proteolysis. In fact, 
nonagenarians and centenarians are less likely  to carry an APOEε4 allele which 
decreases the risk of Alzheimer’s Disease while the ɛ2 allele is enriched in long-lived 
individuals (Tindale et al., 2017). An allele in apolipoprotein C3 involved in fat 
metabolism is also enriched in centenarians and may confer them a favourable lipid 
profile over their matched peers (Atzmon et al., 2006).  
 
Other genes with variants enriched in centenarians include those in human telomerase 
reverse transcriptase that is associated with longer telomere length which might lead 
to centenarians and their offspring maintaining longer telomeres that eventually confer 
protection from age-related diseases (Wheeler and Kim, 2011). Other studies have 
shown that 3′-phosphoadenosine 5′-phosphosulfate synthase 2 is significantly higher 
in offspring of long-lived parents. Mutations in host genes of this protein is seen 
skeletal dysplasias patients and might cause premature joint degeneration due to 
impaired proteoglycan sulfation (Yerges-Armstrong et al., 2016).  
 
Irisin which is a type III domain-containing protein 5 of skeletal muscle, acts in the 
white adipose tissue by promoting the acquisition of a brown adipocyte phenotype 
prone to energy expenditure and therefore might help in reducing the risk of obesity 
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and insulin resistance.  Recently two single-nucleotide polymorphisms in the gene 
were shown to be associated with in vivo insulin sensitivity which in centenarians 
maybe associated with insulin sensitivity/signalling.  In addition, it can  help preserve 
vascular function and skeletal muscle mass as well as its levels in circulation can 
predict telomere length in healthy adults (Sanchis-Gomar et al., 2014.).  
 
Sequence analysis of the IGF1 and IGF1 receptor genes of female centenarians, their 
offspring and offspring-matched controls showed overrepresentation of heterozygous 
mutations in the IGF1R gene amongst centenarians and their offsprings. This 
overrepresentation was associated with high serum IGFI levels as well as reduced 
activity of the IGFIR/IGF1 with an inverse relation to insulin sensitivity, all of which 
might have a crucial factor in modulation lifespan and human longevity (Suh et al., 
2008; Vitale et al., 2012).   
 
Results from a study on the response of lymphocytes to the induced oxidative stress 
in semi-supercentenarians, their offspring, elderly controls and young individuals show 
that the ratio of the ROS levels is comparatively similar in centenarian and young 
individuals in almost all subsets of T or B lymphocytes, and NK-cells. The change in 
response to oxidative stress might be due to the observed differences in epigenetics 
and DNA methylation in genes like GGT1, GGT6, GPX5, GPX6, GSTM, and LDHD 
that minimize the oxidative damages and therefore preserve a better cellular response 
especially in the immune system during longevity in humans (Sizzano et al., 2018) .  
 
Association of RNA editing genes ADARB1 and ADARB2   with extreme ageing and 
lifespan has also been reported in four centenarian studies and invertebrate models. 
7 
 
These two genes in the adenosine- to -inosine RNA editing pathway assists in post-
transcriptionally converting adenosine residues to inosine which leads to change in 
gene expression profile and protein function.   Invertebrate mutants of adr-1 and adr-
2 display shorter lifespans possibly due to the declines in ADAR function as a result 
of knockdown of RNA editing genes which result in increased RNAi activity. This 
increased RNAi might target genes downstream of daf-16, thereby reducing the 
increases in lifespan otherwise evident in wild type strains (Sebastiani et al., 2009).  
 
Ageing or senescence increase vulnerability to chronic age-associated diseases. 
Often, the same underlying changes that cause grey hair also inversely affect the 
functionalities of other organ systems. For instance, chronic diseases of ageing, like 
type 2 diabetes (T2D), which affects millions of patients, share molecular mechanisms 
with ageing including inflammation and oxidative stress. Additionally, T2D also leads 
to impairments and comorbidities that are themselves chronic diseases of ageing, like 
kidney impairment and cardiovascular disease (Schernthaner and Schernthaner-
Reiter, 2018). Insulin sensitivity appears to decline with age (Chandler-Laney et al., 
2011). Factors contributing to age-associated insulin resistance include visceral 
adiposity and associated lipotoxicity, inflammation, oxidative stress, mitochondrial 
dysfunction and possibly an intrinsic decline in insulin sensitivity in skeletal muscle 
(Hurrle and Hsu, 2017; Kitada et al., 2019). Ageing is also a strong predictor of acute 
hypoglycaemia. Older patients with diabetic kidney disease, who are under an 
intensive glucose-lowering regimen, are at high risk of severe hypoglycaemia 
(Schernthaner and Schernthaner-Reiter, 2018). Ageing arteries also seem to exhibit 
chronic inflammation similar to that seen in diabetes and related complications like 
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hypertension. In fact, acute hyperglycaemia effects vessel function in T2D (Gordin and 
Groop, 2016).  
 
Although centenarians have some insulin resistance compared with their offspring or 
short-lived individuals, it is possible it may confer protective repair or adaptive 
responses. Offspring of centenarians or those who had one parent who lived into the 
eighth decade of life also tend to have longer healthspans, are healthier and have a 
lower risk of developing diabetes. This may be due to variant genotypes of the 
Forkhead box O3 (FOXO3A) and insulin growth factor receptor (IGF1) genes amongst 
others inherited from their parents (Halter et al., 2014).  
 
The evidence outlined above shows that ageing outcomes, like T2D and others, may 
not be distinct disorders, but instead a cumulative effect of the dysfunction of key 
hallmarks culminating in a decline in health and normal physiology that drives ageing. 
While lifestyle and environmental factors may affect lifespan, inherited genetic 
backgrounds may be attributed to ~25% of the factors affecting lifespan and patterns 
of progression to ageing outcomes as determined by comparing the age of death of 
monozygotic and dizygotic twins in family studies where it is seen that the inluecne of 
genetic factor is more pronounced at older ages and in males  more than in 
females  (vB Hjelmborg et al., 2006; Herskind et al., 1996). In fact, genetic 
backgrounds have even been shown to influence the effects of lifespan extension in 
response to dietary restriction (DR) in mice (Liao et al., 2010; Rikke et al., 2010). 
Therefore, it is important to unlock the factors that modulate this heterogeneous 
pattern of ageing in order to not only extend lifespan, but also extend healthy disability-
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adjusted life years. The following sections briefly outline some of the causal factors 
and consequences of ageing. 
 
 
1.2 Ageing and common disease 
The increase in life-expectancy in the recent decades is associated with significant 
prevalence of chronic co-morbidities. It is estimated that 86% of the elderly population 
have one or more of the chronic ageing disorders. Of these, 56% of the elderly require 
healthcare related to cardiovascular diseases, 46% musculoskeletal, 14% respiratory 
conditions and as much as 30% neurological diseases (Naughton, Bennett, and Feely, 
2006). In England alone, the prevalence of co-morbidities in the ageing population is 
between 40% to 75% (Melzer et al., 2015). There appears to be significant increases 
in these morbidities with advancing age. For instance, the estimated prevalence of 
coronary heart disease increases from 15% in the 65+yrs to 35% in the 85+yrs old 
(Melzer et al., 2015). A similar pattern is seen with heart failure which shows a three 
–fold increase from 65+ to 85+ yrs. There is an estimated increase from 45% to 70% 
for hypertension between the aforementioned age groups. Similarly, the prevalence of 
cancer increases from 5% to 8-16%, the prevalence of osteoarthritis increases from 
20 to 35%  while that of diabetes increases from 15% to 20% from the 65+ to 85+ year 
old age groups (Melzer et al., 2015). 
 
Cardiovascular and metabolic diseases are amongst the common chronic disease of 
ageing. These include chronic ischemic heart disease, heart failure, and arrhythmia, 
as well as type 2 diabetes and the metabolic syndrome. (Ungvari et al., 2010; Zieman, 
Melenovsky, and Kass, 2005).  Amongst other chronic diseases of the ageing is 
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osteoarthritis which results in high rates of severe hip and knee arthritis in the elderly 
(Greene and Loeser, 2015). Mild short-term memory loss and slower processing 
speed also accompany normal ageing and adversely affect cognitive performance in 
personal life such as safe driving. Amongst the disorder associated with cognitive 
impairment is dementia (Ljubenkov and Geschwind, 2016). Alzheimer's disease  (AD) 
is the most common form of dementia accounting for an up to 80% of dementia in the  
65+ years of the elderly population (Alzheimer’s Association 2015).  Elderly with 
dementia often require caregiver support and possibly assistive technologies to 
improve safety on a daily basis  (Ljubenkov and Geschwind, 2016) .  
  
Diabetes is an exemplar disease of ageing, as well as being a risk factor for other co-
morbidities of the ageing such as cardiovascular disease (Odden et al., 2014) amongst 
others. Various genome wide association studies have detected 403 type 2 diabetes 
(T2D) genetic variants influencing multiple processes in tissues and cells such as β-
cells, islet development, islet senescence, islet function, adipocytes, skeletal muscle, 
liver and other tissues (Mahajan et al., 2018). Although each of them has a minute 
effect on the risk of T2D, they explain around 20% of the risk of T2D  (Mahajan et al., 
2018). Because T2D is such a heterogeneous disorder, it demands an individualized 
approach to treatment; therefore, it is necssary to unravel the mechanism or biomarker 
vehicle which we can use to implement the individualized therapeuctic approach.   
 
In non-diabetic individuals, glucose homeostasis in the body is maintained by the 
normal insulin secretory response from the pancreatic β-cells. When blood glucose 
levels are high, hepatic glucose production is suppressed (Cersosimo et al., 2000). 
Instead, glucose uptake is increased by hepatic, gastrointestinal and peripheral 
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tissues especially the muscle which is regulated by glycogen synthesis and mainly 
glycolysis (Cersosimo et al., 2000).  
 
In non-diabetic fat cells, insulin inhibits lipolysis and suppresses the release of free 
fatty acids (Bays, Mandarino, and DeFronzo, 2004). However, insulin resistance 
during T2D prevents insulin from acting on fat cells; this leads to increased lipolysis 
and higher levels of free fatty acid which cause lipotoxicity and further aggravates 
insulin resistance (Kashyap et al., 2003). High levels of free fatty acid levels lead to 
further increase in glucose production which accompanies decline in use of peripheral 
glucose and aggravates impaired pancreatic β-cell function (Kashyap et al., 2003). In 
T2D, decreased peripheral glucose uptake in muscle as well as higher blood glucose 
is evident during insulin resistance (Hunter and Garvey, 1998). Although initially, 
pancreatic β-cells may try to compensate by producing insulin to maintain normal 
blood glucose levels, but eventually β-cell function may progressively deteriorate 
beyond compensatory capacity. In addition to the impaired insulin secretion, there 
appears an aberrant production of the α-cell hormone glucagon due to the inefficient 
release of gastrointestinal incretins after meal intake (Knop et al., 2007). This effect 
may be compounded by the impaired insulin response which would otherwise 
suppress glucose production. This means there is higher than normal levels of 
glucagon levels, which would otherwise in a healthy individual be suppressed during 
hyperglycemia as well as hyperinsulinemia and oppose the effects of insulin, thus 
increasing hepatic glucose production and ensure that glucose supply especially to 
the brain is well-maintained. α-cell dysfunction is also an essential contributor to 
fasting hyperglycemia as a result of the elevated hepatic glucose and elevated 
glucagon (Dunning and Gerich, 2007).  
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The high levels of glucose levels in T2D induce hypoxia and hypoxia-induced 
pathways in β-cells and isolated islets (Wilding, 2014) can lead to decline in the 
function of both β and α-cells although the rate of β-cell apoptosis is higher compared 
to the other cells  (Bloch et al., 2012). T2D individuals with insulin resistance  also 
have  high FFA concentrations (McGarry, 2002) and fat content in insulin-responsive 
tissues like the skeletal muscle or liver (Pan et al., 1997; Krssak et al., 1999; Jacob et 
al., 1999). The high FFA induces reactive oxygen species (ROS) production in the β-
cells   (Carlsson, Borg, and Welsh, 1999; Li, Frigerio, and Maechler, 2008) which 
inversely effects survival of the β-cells through changes in enzyme activity, ion channel 
transport, receptor signal transduction, dysregulated gene expression and apoptosis 
(Keane et al., 2015; Newsholme et al., 2012). 
 
While the pancreas can adapt to conditions of increased insulin demand in normal 
circumstances like  pregnancy by increasing its functional mass, these adaptations 
are provoked by limited hyperglycemic events that lead to very low concentrations of 
IL-1β by the β-cells (Maedler et al., 2002). The low concentrations of IL-1β  in fact 
enhances β-cell proliferation (Schumann et al., 2007).  However, in the face of 
prolonged exposure to nutrients, IL-1β stimulates release of chemokines, which in turn 
leads to the increase in intra-islet macrophages in T2D recruitment of macrophages 
which elevates the levels of IL-1β expression and impair the function of the β-cells 
(Böni-Schnetzler et al., 2008).   Oleate, palmitate and stearate are the most common 
source of FFAs from the diet and also stimulate IL-1β expression not only in islet cells 
but also in muscle (Senn, 2006), macrophage, and adipocyte cell lines  (Nguyen et al., 
2007) and in coronary artery endothelial cells (Staiger et al., 2004). However, β-cells 
appear to be more sensitive to changes in local IL-1β levels than other islet cells due 
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to their high number of IL-1 receptors (Scarim et al., 1997; Böni-Schnetzler et al., 
2009). Other interleukin like IL-6 increases glucagon secretion from α-cells under 
fasting conditions or hypoglycemic conditions in islets (Barnes et al., 2014).  It 
promotes α-cell proliferation and prevents α-cell apoptosis during stress while 
accelerating β-cell apoptosis (Ellingsgaard et al., 2008). It might be a compensatory 
mechanism in the face of impaired β-cell function, which however, leads to 
hyperglucagonemia in the diabetic scenario.  
 
One mechanism linking ageing and T2D is pancreatic β-cell impairment. Even healthy 
individuals with normal glucose tolerance demonstrate impaired insulin secretion with 
age, although β-cell impairment is worse in those with pre-diabetes and T2D (Szoke 
et al., 2008). Differential expression of cell cycle proteins controlling cellular 
senescence, such as p16Ink4A, has also been shown to impair β-cell function (Helman 
et al., 2016). DNA methylation at the promoters of cell cycle genes is seen in ageing 
mouse pancreatic β-cells and may explain the impaired proliferative capacity of these 
cells of the pancreas (Avrahami et al., 2015). Like elderly individuals, patients with 
T2D tend to be overweight and insulin-resistant, which promotes dyslipidaemia and 
atherogenesis (Halter et al., 2014). In turn, insulin resistance and lipotoxicity aggravate 
inflammation and macrophage proliferation, promoting amyloid formation and 
increased ROS, which further contribute to β-cell failure (Halter et al., 2014).  
 
 
1.3 The hallmarks of Ageing 
Most of the common, chronic diseases of ageing are caused by the failure of a few 
basic health maintenance mechanisms collectively titled the ‘Hallmarks’ of ageing 
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(López-Otín et al., 2013).The Hallmarks of ageing (Fig 1) include genomic instability 
(Moskalev et al., 2013b; Mostoslavsky et al., 2006), telomere attrition (Blackburn, 
Greider, and Szostak, 2006), epigenetic alterations (Talens et al., 2012), loss of 
proteostasis (van Ham, Holmberg, et al., 2010), dysregulated nutrient 
sensing (Fontana, Partridge, and Longo, 2010; Harrison et al., 2009), mitochondrial 
dysfunction (Green, Galluzzi, and Kroemer, 2011), cellular senescence (Baker et al., 
2011), stem cell exhaustion (Molofsky et al., 2006; Gruber et al., 2006; Conboy and 
Rando, 2012) and altered intercellular communication (Laplante and Sabatini, 2012; 
Rando and Chang, 2012; Russell and Kahn, 2007; Zhang et al., 2013). 
 
 
Figure 1 Hallmarks of ageing. The current hallmarks are grouped into nine major 
groups. Transcriptional noise is evident in ageing and ageing-related disorders. This 
may lead to the primary hallmarks of ageing that can cause cellular damage. In 
response to initial cellular damage, the cells attempt to compensate through 
antagonistic responses. These compensatory can impose deleterious effect if the 
damage is chronic which eventually can lead to the integrative hallmarks of ageing 
that is cumulatively responsible for the functional decline evident in ageing. 
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1.3.1 Dysregulated nutrient signalling 
Nutrient signalling pathways are cellular pathways that are activated or regulated 
based on nutrient availability some of which affect ageing and are briefly described 
below; for instance, declines in endocrine signalling and function correlate with ageing. 
This disrupts homeostasis and the balance of the stress response due to aberrant 
hormone production. For instance, age-related changes in reproductive hormones in 
both male and females correlate with increasing risk of developing chronic ageing 
phenotypes like heart diseases and impaired cognitive performance, and a decline in 
adrenal steroids is associated with T2D (Jones and Boelaert, 2015).   
 
The conserved insulin and insulin-like growth factor-1 (IGF-1) signalling (IIS) pathway, 
responsible for the regulation of growth, metabolism and resistance to stress in 
response to nutrient availability, has been linked to ageing in worms. The IIS pathway 
is one of the most conserved pathways controlling ageing, and targets many 
conserved factors including the FOXO family of transcription factors and mammalian 
target of rapamycin mTOR complexes (Barzilai et al., 2012; Fontana, Partridge, and 
Longo, 2010; Kenyon, 2010b). Insulin like receptor (daf2) mutant worms and mouse 
models have extended lifespans (Tatar et al., 2001; Blüher, Kahn, and Kahn, 2003; 
Holzenberger et al., 2003). IIS affects lifespan by virtue of its effects on sirtuin 
deactylases, which confer histone modification (López-Otín et al., 2013).  
 
Mice with mutant growth hormone (GH), which regulates IGF signalling, also display 
extension of lifespan (van Heemst 2010). Plasma IGF-1 also correlates with lifespan 
in rodent models (Yuan et al., 2009). IGF-1 and insulin signalling are both glucose 
sensors in cells, and are cumulatively known as the IIS pathway. Functional 
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modification due to genetic polymorphisms of the growth hormone (GH), the Insulin-
like growth receptor 1 (IGF1) and the insulin receptor (INSR) genes, along with genes 
encoding downstream effectors like AKT Serine/threonine kinase 1(AKT), mammalian 
target of rapamycin (MTOR) and Forkhead box (FOXO) family genes. Variants in the 
phosphatase and tensin homolog (PTEN)  or phosphoinositide 3-kinase (PI3K) genes, 
have also been linked to longevity in both human and rodent models (Barzilai et al., 
2012; Fontana, Partridge, and Longo, 2010; Foukas et al., 2013; Kenyon 2010b; 
Ortega-Molina et al., 2012). Downregulation of GH and IGF-1 levels, and thus the IIS 
pathway, is common to ageing (Schumacher et al., 2008). Downregulation of the type 
5-adenylyl cyclase hormone in rodents has also been shown to correlate with 
decreased levels of GH and increased longevity, and is coupled with increased 
resistance to oxidative stress and increased Ras signalling (Yan et al., 2007). Another 
hormone, Klotho, has been shown to supress the IIS pathway and promote longevity 
in rodent models (Imura et al., 2007; Urakawa et al., 2006). 
 
Other signalling pathways such as the transforming growth factor beta (TGFβ) 
pathway are mediated by activation of the SMAD transcription factors DAF-8 and DAF-
14, and the inhibition of DAF-3, which both arrests cell cycle progression and causes 
apoptosis. It is targeted by the FOXO transcription factor DAF-16 in IIS pathway, 
suggesting that both these pathways might act through a common subset of 
downstream adaptors in the ageing physiology (Shaw et al., 2007). Findings from 
invertebrate models investigating the role of the gut microbiome (GM) in longevity have 
shown that depletion of FOXO/DAF-16 prolongs life, indicating that the GM nitric oxide 
also modulates transcription of these pathways to extend lifespan (Gusarov et al., 
2013; Kenyon 2010b; Zhang and Hou, 2013). 
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1.3.2 Dietary restriction and nutrient sensing signalling 
The most efficient environmental intervention to slow ageing is dietary restriction (DR) 
without causing malnutrition. Studies have shown the association of short- or long-
term DR with lifespan extension and the association of splicing factor profiles in mouse 
models, often irrespective of background strain (Lee et al., 2019). DR may enforce its 
influence on lifespan in several ways, including the modulation of inflammation, 
proteostasis, autophagy, mitochondrial dysfunction, oxidative damage and genomic 
instability through IIS, IGF-1, sirtuin- and AMP-activated protein kinase (AMPK) 
mTOR-dependent signalling pathways (Picca, Pesce, and Lezza, 2017; Kenyon 
2010a). Thus, it is not surprising that DR enhances healthspan. Evident pathways in 
DR include those mediated by AMPK and target of rapamycin (mTOR).  
 
In addition, mTOR itself is associated with different aspects of ageing. It is a 
serine/threonine kinase that operates through the mammalian target of rapamycin 
complex 1 and 2 (mTORC1 and mTORC2) complexes (Saxton and Sabatini, 2017). 
The first component is involved in cell growth through its role in protein synthesis, as 
well as turnover in response to growth factors, nutrients, oxygen or DNA damage, and 
lipid/glucose as well as nucleotide metabolism. The second component binds with 
kinases from other signalling pathways to modulate cell proliferation and survival in 
response to IIS (Saxton and Sabatini, 2017). Like IIS mutants, knockdowns of mTOR 
in worms and the use of rapamycin to target mTOR in mice extend lifespan (Vellai et 
al., 2003). In fact, mTOR signalling has been shown to increase lifespan under DR in 




AMPK is also induced by DR and enhances lifespan in rodents (Anisimov et al., 2005; 
Baur et al., 2006; Dasgupta and Milbrandt, 2007; Zhang and Hou, 2013). It 
phosphorylates FOXO and inhibits translation by blocking TOR, suggesting further 
crosstalk between AMPK, IIS and TOR pathways (Greer et al., 2007; Inoki, Zhu, and 
Guan, 2003).  
 
The hallmarks of ageing include loss of transcriptional and protein homeostasis. Pre-
mRNA splicing is a key link between regulation of gene expression and diversification 
of the proteome as mentioned in earlier sections.  Studies with in vitro model show 
that modulation of spliceosome components may prolong healthy ageing. Specifically, 
splicing factor 1 is required for lifespan extension through dietary restriction via the 
AMPK -TORC1 pathway (Heintz et al., 2017).  Dietary restriction also  uses alternative 
splicing  by coupling to nonsense-mediated decay  and induces posttranscriptional 
regulation of longevity genes  to diversify the proteome to allow the remodelling 
required for enhanced longevity in worms and rodent models (Rollins et al., 2019; 
Tabrez et al., 2017).  
 
The commensal GM has been shown to sense nutrients in invertebrate models. 
Treatment with metformin causes an AMPK-dependent increase in lifespan in 
invertebrate models as a consequence of the effect of the drug on microbes as 
opposed to the host (Storelli et al., 2011). An extension in lifespan is observed by the 
effect of the endogenously expressed non-coding RNA (ncRNAs) DsrA of the bacteria 
which suppresses diacylglycerol lipase which leads to decreased longevity in 
invertebrates (Nicholson et al., 2012; Liu et al., 2012). In fact, in humans, the GM 
seems to be stable from the third to the eighth decades of life (Biagi et al., 2010). After 
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100 years of life, the GM seems to show profound adaptive remodelling and be 
composed of highly diverse species (Santoro et al., 2018). While there appears to be 
shrinkage of the dominant symbiotic bacterial species, this shrinkage is 




1.3.3 Mitochondrial dysfunction  
Mitochondria are thought to be key organelles regulating organismal ageing. They 
operate by controlling the cellular metabolic rate, the production and removal of ROS, 
and apoptosis (Wallace, 2005). A decline in mitochondrial quality and activity has been 
associated both with normal ageing and the development of age-related diseases. As 
we age, our mitochondria show a gradual decline in their ability to generate energy 
and an increase in the levels of ROS. ROS can lead to DNA mutation and a 
deterioration in proteostasis (Lesnefsky and Hoppel, 2006; Korovila et al., 2017). ROS 
can also damage the very proteins that control the replication of mitochondria or 
introduce additional errors into the copies of daughter mitochondria (Korovila et al., 
2017). Mitochondria from the elderly look different compared with those from young 
individuals. They have a swollen morphology. Their numbers also decline as they lose 
their ability to efficiently replicate in their dysfunctional state (Gerencser et al., 2008; 
Seo et al., 2010; Figge et al., 2012). In aged flies, mitochondria are round or have 
concentric cristae devoid of sharp ridges, and have disorganized inner membranes. 
Their respiratory activity is also compromised and is accompanied by an increase in 
ROS production (Brandt et al., 2019). Oxygen uptake decreases while peroxide yield 
increases, suggesting that old flies may retain a lot of inactive mitochondria (Cochemé 
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et al., 2011). Mitochondrial respiration is also compromised in hearts of old mice. They 
have wider cristae and less swirls. They are not filled with closely stacked, parallel 
cristae, unlike in young hearts where there is a high level of respiratory activity and 
hence the potential for adenosine triphosphate (ATP) production facilitated by a larger 
membrane area. The larger membrane area in the latter harbours the ATP synthase 
for oxidative phosphorylation (Brandt et al., 2019). However, heart mitochondria 
appear to be protected from oxidative damage, as is suggested by their low and 
unchanging peroxide yield. It might be that, in vital organs like the heart that are slow 
to regenerate, mitochondria are more effectively protected from damage compared 
with those in other organs, like the liver and kidneys, that have high rates of turnover 
of cells. Kidney mitochondria in old mice have morphology that is similar to those of 
apoptotic cells. This might be due to the high rate of continuous turnover and short 
lifespan of kidney cells. The granular appearance of mitochondria in old mice suggests 
that they may contain granules that retain lipids, glycoproteins and denatured 
respiratory chain complexes (Brandt et al., 2019). Like mitochondria from the kidney, 
mitochondria from old livers in mice also have granules and an apoptosis-like 
phenotype. They are also void of a central matrix (Brandt et al., 2019). The lack of 
sharp cristae ridges and junctions in the void membranes suggest that 
these membranes may harbour ATP synthase for efficient oxidative phosphorylation.  
 
 
As many as thousands of copies of mitochondrial DNA can exist per cell, it is believed 
that errors in mitochondrial DNA might need to exceed a threshold of 60% of all 
mitochondria within a given tissue for any significant aberrant phenotypic change to 
appear (Rossignol et al., 2003). Different ways in which mitochondiral dygsfunction 
may affect ageing are illustrated in Fig 2. A process called mitophagy eliminates 
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damaged mitochondria, but this process becomes less efficient with age due to the 
decline in activity of mitochondrial enzymes (e.g. citrate synthase), the decrease in the 
respiratory capacity per mitochondrion (i.e. substrate-dependent oxygen 
consumption), and increases in ROS production and errors passed on to daughter 
mitochondria. This allows dysfunctional mitochondria to survive longer and 
accumulate over time (Luo et al., 2013). Findings from a recent study confirmed that 
stem-like cells, within immortalized human mammary epithelial cell cultures, harbour 
uneven distributions of young and old mitochondria after cell division (Katajisto et al., 
2015). Thus, mitochondria-induced changes in a cell’s metabolic profile maybe 
sufficient to trigger cellular senescence and longevity.  
 
Figure 2  Mitochondrial dysfunction in ageing. Ageing is associated with decline in 
mitochondrial function which includes in decline in mitochondrial numbers and 
inefficient mitophagy. A decline in mitochondrial function leads to malfunction of the 
electron transport chain, decline in ATP generation, accumulation of mtDNA mutation, 
generation of ROS that eventually affect various aspect of physiology of cells during 
ageing (Green=young cell; Red=senescent cell).  
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1.4 Cellular senescence and the senescence-associated secretory phenotype 
(SASP)  
Cellular senescence is a stable arrest of the cell cycle, as well as the cellular growth 
of previously replicative cells. Senescent cells are characterized by flattened and 
granular morphological features, an altered transcriptome, splicing pattern or 
epigenome and the senescence-associated secretory phenotype (SASP) (de 
Magalhães and Passos, 2018; Latorre et al., 2018). Senescence is often induced by 
a persistent DNA damage response (DDR) and accompanies the expression of 
antiproliferatives, like p16INK4a, which lead to the activation of downstream damage 
mediated by pathways involving mTOR and amongst others. The activation of these 
pathways is followed by the downregulation of nuclear lamins, which triggers 
extensive chromatin remodelling as well as secretion of the SASP (Campisi and di 
Fagagna, 2007; Childs et al., 2015; Herranz et al., 2015; Kuilman et al., 2010; Laberge 
et al., 2015). 
 
Potential ways in which senescence might affect ageing at the cellular level is shown 
in Fig 3. During ageing, chronic SASP secretion induces senescence in neighbouring 
cells, and leads to chronic inflammation and impaired tissue homeostasis (Acosta et 
al., 2013; van Deursen, 2014). Despite being non-profliferative, senescent cells are 
metabolically active (Dörr et al., 2013). Senescence can promote impaired tissue or 
organ homeostasis through the cumulative action of disruption of the extracellular 
matrix, aberrant cell differentiation, stimulation of inflammation and ROS-dependent 
gap junction-mediated cell–cell contact induction of contagious paracrine senescence 
signals in neighbouring cells (Nelson et al., 2012). It can also affect ageing in non-
proliferative cells like neurons and cardiomyocytes by inducing SASP (Sikora, Bielak-
Zmijewska, and Mosieniak, 2014).  
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Temporary senescence confers protection in early life through tumour suppression, 
wound healing, tissue repair or embryonic development, when it is cleared by the 
immune system. It is possible that senescence is a cell-intrinsic compensatory 
mechanism for the removal of potentially damaged cells that would otherwise acquire 
oncogenic potential. However, in the absence of renewal of progenitor and stem cells 
to re-establish cell numbers, accumulation of senescent cells and alterations in their 
secretome, i.e. the SASP, may aggravate the damage seen in ageing. The SASP is 
enriched with pro-inflammatory cytokines and chemokines that attract immune cells, 
factors that cause stem cell dysfunction (Beroukhim et al., 2010; Brady et al., 2011; 
Coppé et al., 2006; Kandoth et al., 2013; Liu et al., 2004; Sluss et al., 2004; Xu et al., 
2015).  
 
Age-related decline in immune function leads to a decline in wound healing, reduced 
response to infections and persistent low chronic inflammation known as 
inflammageing, which may be be partially induced by senescent cells producing the 
SASP (de Magalhães and Passos, 2018; Latorre et al., 2018). To test the role of 
cellular senescence, Baker and Deursen (2016) engineered p16Ink4a positive 
senescent cells in mice to die when treated with a drug. The study showed that 
clearance of the p16Ink4a-positive cells reduced age-related dysfunction of the 
kidneys, heart and fat by preserving the performance of glomeruli, cardioprotective 
KATP channels and adipocytes, respectively. The kidneys functioned more efficiently 
and hearts were more resilient to stress, and there appeared to be an extension of 
lifespan after eliminating senescent cells in these mice (Baker et al., 2016; 2011). In 
other studies, the senolytic cocktail which selectively kill sensnencent cells, composed 
of dasatinib and quercetin has been shown to cause selective elimination of senescent 
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cells, and decrease the number of naturally occurring senescent cells and their 
secretion of frailty-related pro-inflammatory cytokines in explants of human adipose 
tissue. Intermittent oral administration of senolytics to both senescent cell-transplanted 
younger and naturally aged mice alleviated physical dysfunction, increased post-
treatment survival by 36% and reduced mortality hazard by 65%. This provides 
evidence that while senolytics can enhance the remaining health- and lifespans in old 
mice, senescent cells can also cause physical dysfunction and decreased survival, 
even in young mice (Xu et al., 2018). Reversal of senescence in cellular models using 
small molecules based on the polyphenol resveratrol leads to the rescue of 
morphology and splicing patterns resembling those of young-passage cells (Latorre et 
al., 2018). One study has suggested that these reversed cells resume the cell cycle 
independently of SIRT1, SASP modulation or senolysis, as there appears to be an 
increase in the number of proliferating cells, which is additionally accompanied by an                               
increase in telomere lengths, resetting the telomere clock (Latorre et al., 2017b).  
Figure 3 Senescent cells are one of the key features of ageing. During ageing cellar exposed to 
various stresses such as DNA damage, mitotic stress, epigenetic stress, ROS /oxidative stress, 
oncogenic mutation, loss of tumour suppression and telomere attrition. All of these may lead the cells 
to senescece and induce senescence through the secretion of SASP in the neighbouring cells. 
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1.5 Stem cell exhaustion  
Stem cells are essential for the maintenance of tissue homeostasis or regeneration. A 
quantitative or qualitative decline in stem cell is one of the many drivers 
of ageing.  Study in worms show germline stem cells are regulators of longevity as 
genetic manipulation to eliminate the germline stem cells leads to doubling of lifespan 
of the worms (Arantes-Oliveira et al., 2002; Hsin and Kenyon, 1999). A decline in the 
regenerative potential of tissues as the result of ageing-related damage stimuli is 
evident in ageing (López-Otín et al., 2013). Decreased cell cycle activity of 
haemopoetic stem cells correlate with the accumulation of DNA damage, 
overexpression of cell cycle-inhibitory proteins and telomere shortening in 
experimental models (Janzen et al., 2006; Rossi et al., 2007). Recent research 
findings indicate that the transplantation of muscle-derived stem cells from young to 
progeroid rodents improves their degenerative potential through the systemic 
secretion of certain entities, even in tissues where donor cells are absent (Lavasani et 
al., 2012), and is evidenced by the fact that deteriorating haematopoiesis leads to 
reduced production of adaptive immune cells during immunosenescence (Beerman et 
al., 2010).  
 
  
1.6 Genomic instability and nuclear architecture  
Exposure to extrinsic factors like chemicals, ionizing radiation, ultraviolet light and 
intrinsic factors like ROS generated within the cell can lead to nuclear and 
mitochondrial DNA damage. DNA damage may accumulate as a result of mutation 
through a variety of nucleotide changes induced by deletions, substitutions, insertions, 
frameshift mutations, the oxidation of nucleotides, deaminations, or through changes 
in DNA configuration as a result of crosslinks and strand breaks (Fig 4). During ageing, 
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the ability to repair DNA damage is increasingly impaired, leading to the replication of 
damaged nuclear DNA in humans as well as mitochondrial DNA in mouse models. 
This is evident not only in normal ageing, but also in outcomes of accelerated ageing 
(Moskalev et al., 2013a; Moro, 2019). This loss of genomic integrity may lead to 
changes in gene expression and protein function at the cellular level that can lead to 
a reduced cell number though cell cycle arrest, either leading to apoptosis or 




Figure 4 DNA damage and mutation during ageing. Throughout the course of an 
organism’s life, cells are exposes to extrinsic and extrinsic mutagens that lead to 
various types of mutation in the nuclear and mitochondrial DNA that may lead to 
dysregulation of gene expression and translation. These can often lead to 
dysregulation of cell cycle which can lead to loss of cells through apoptosis o confer 
them oncogenic potential. 
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Through the course of an organism’s lifetime, it faces endogenous challenges like 
DNA replication errors as well as ROS. The microenvironment of the cells in the body 
also faces continuous exposure to exogenous physical, chemical and biological 
agents. All of these cumulatively lead to the accumulation of DNA disintegrity and 
instability, which cause point mutations, translocations, chromosomal gains and 
losses, telomere shortening and gene disruption due to the integration of mobile 
elements, i.e. viruses or transposons (Dechat et al., 2008; Gonzalez-Suarez et al., 
2009; Liu et al., 2004). Increased chromosomal aneuploidies and copy number 
variations can also lead to ageing phenotypes (Faggioli et al., 2012; Forsberg et al., 
2012; Jacobs et al., 2012; Laurie et al., 2012). The various forms of DNA damage or 
alteration can, eventually, lead to aberrant transcription of many genes during normal 
human ageing. This can result in the dysfunction of cells, which necessitates their 
removal by apoptosis or senescence (Freund et al., 2012; Gregg et al., 2012; 
Ragnauth et al., 2010; Scaffidi and Misteli, 2006; Shimi et al., 2011)  
 
 
1.7 Epigenetic alterations and chromatin remodelling 
 Eukaryotic genomic DNA is compressed into chromatin as nucleosomes consisting 
of histone octamers, made up of two copies each of the core histones H2A, H2B, H3 
and H4, each wrapped by 146 bp of DNA (Luger et al., 1997). In this compressed form, 
gene transcription is blocked due to the inability of transcription factors to access the 
DNA (Lawrence, Daujat, and Schneider, 2016; C. Jiang and Pugh, 2009). Epigenetic 
changes involve alterations in DNA methylation, histone methylation, acetylation 
states, histone post-translational modification and chromatin remodelling that occur 
during the course of a cell’s life (Talens et al., 2012), which together regulate 
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the condensed heterochromatin or relaxed euchromatin states to make DNA less or 
more accessible, respectively, to affect the transcription levels of genes and their 
biological functions.  
 
It is well known that changes in DNA methylation at CpG islands correlate with ageing 
and, as such, are markers of stem cell division and cell ageing in general (Yang et al., 
2016). There appears to be a decrease in global DNA methylation across the genome 
that facilitates deheterochromatization of the genome with advancing ageing. 
However, some promoter regions and CpG islands, like in tumour suppressor genes 
(e.g. CDKN2A, LOX, RUNX3 and TIG1), become aberrantly hypermethylated (Issa et 
al., 2001; 1996; Singhal, Mays-Hoopes, and Eichhorn, 1987; So et al., 2006; Sommer 
et al., 2006; Waki et al., 2003). Thus, it is not surprising that histone demethylases 
have been shown to associate with the IIS signalling pathway, which is key to lifespan 
(Jin et al., 2011; Maegawa et al., 2010). Increased histone H4K16 acetylation, and 
H4K20 and H3K4 trimethylation, as well as decreased H3K9 and H3K27 
trimethylation, have also been linked to age-associated epigenetic changes (Fraga 
and Esteller, 2007; Han and Brunet, 2012). In addition, global loss of heterochromatin 
and redistribution has been linked to the ageing process (Pegoraro et al., 2009). 
Chromatin-remodelling complexes and chromatin regulators such as, alter histone–
DNA interactions and contribute to the global condensation of senescence-associated 
heterochromatin foci (SAHF) (Zhang et al., 2005). The formation of SAHF is thought 
to silence the expression of proliferation-promoting genes, which may contribute to 
senescence-associated growth arrest in ageing (Narita et al., 2003).  
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1.8 DNA double strand breaks and mutations 
Different types of DNA damage can lead to genomic instability. Accumulation of DNA 
double-strand breaks (DSBs) and inefficient DSB repair-causing mutations have been 
reported in both in vitro and in vivo models of ageing. Transposition of transposable 
elements can also lead to mutations (Sedelnikova et al., 2008; 2004; Singh et al., 
2001). The mTOR inhibitor rapamycin has been shown to reduce DNA damage in 
rodents (Dao et al., 2015). Besides mTOR, calorie restriction, which is also linked to 
prolonged lifespan, has also been positively associated with enhanced efficiency of 
nucleotide excision repair and non-homologous end joining (Lee et al., 2011; Stuart et 
al., 2004).  
 
 
1.9 Telomere Attrition  
Telomeres are protective caps, composed of long repetitive sequences of TTAGGG, 
at both ends of chromosomes. They protect the strands from getting shorter during 
cell division. They allow anchorage to telomere-binding proteins as well as confer 
protection against events that could otherwise lead to cell death. Telomere lengths are 
highly heterogeneous and can vary from 5000–15,000 bp at birth. The telotypes of 
individuals depend on the telomere lengths of their parents (Andrew et al., 2006; Codd 
et al., 2010; Hunt et al., 2008; Jeanclos et al., 2000; Levy et al., 2010; Mangino et al., 
2008; Moyzis et al., 1988; Slagboom, Droog, and Boomsma, 1994; Vasa-Nicotera et 
al., 2005).  
 
Normal ageing, age-related pathologies and premature ageing syndromes have all 
been associated with the shortening of telomeres (Aubert and Lansdorp, 2008; 
Johnson, Sinclair, and Guarente, 1999). A demonstrataion of possible role of telomere 
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shortening in ageing in Fig 5. Shortening of telomeres has been linked to decreased 
cellular metabolism in rodent models, where it accompanies mitochondrial dysfunction 
and aberrant Ca2+ signalling, and leads to the disruption of organ homeostasis, e.g. 
affecting the insulin secretory potential of pancreatic β-cells (Guo et al., 2011; Sahin 
et al., 2011). Short telomeres can induce cellular senescence, upregulate the secretion 
of inflammatory factors and alter expression profiles by disrupting the heterochromatin 
states of genes. As they become progressively shorter, telomeres become 
dysfunctional and induce the DDR, resulting in apoptosis and permanent cell cycle 
arrest (Njajou et al., 2007). 
 
 
Figure 5 Telomere attrition. Telomere shortening can lead to loss of genetic material 
with each successive cell division during the course of an organism’s life. This can 
lead to changes in chromatin states of genetic material that affect the expression of 
inflammatory cytokines, induce DNA damage responses as well as replicative 
senescence which can cumulatively lead to loss of stem cell and disrupt organ 






1.10 Altered Transcription  
RNA metabolism involves an array of events coordinated by the interaction of coding 
as well as ncRNAs with RNA-binding proteins (RBPs) for the transcription, maturation, 
post-transcriptional modification, subcellular transport and degradation operated by 
RNP complexes (Glisovic et al., 2008). Ageing has been associated with an increase 
in transcriptional noise, and the aberrant production and maturation of mRNA 
transcripts (Harries et al., 2011). Other studies have reported age-related 
transcriptional changes in genes involved in inflammatory, mitochondrial and 
lysosomal degradation in ageing tissues (de Magalhães, Curado, and Church, 2009). 
Age-related differential expression of ncRNAs is also known to be associated with 
lifespan (Dimmeler and Nicotera, 2013). 
 
 
1.10.1 Regulation of gene expression 
Age-linked differential expression analyses have categorized the regulation of gene 
expression into six hallmarks of cellular ageing. These are: downregulation of genes 
encoding mitochondrial proteins, downregulation of genes of the protein synthesis 
machinery, dysregulation of immune system genes, downregulation of growth factor 
signalling, constitutive responses to stress including DNA damage and the 
dysregulation of gene expression as well as mRNA processing. 
 
The downregulation of genes encoding mitochondrial proteins, such as nuclear-
encoded components of the ETC and mitochondrial ribosomal proteins, is evident in 
diverse types of organisms ranging from humans, rodents and flies to worms (Frenk 
and Houseley, 2018). Although reductions in mRNA levels of mitochondrial proteins 
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are small, they lead to reductions in the ETC, ATP synthase, the tricarboxylic acid 
cycle and mitochondrial ribosomal proteins in humans (Frenk and Houseley, 2018).  
 
The downregulation of protein synthesis machinery, such as ribosomal proteins and 
ribosomes, in ageing might be a protective programme aimed at mitigating age-related 
outcomes. Downregulation of ribosome biogenesis and ribosomal protein genes is not 
causal for ageing, because both caloric restriction and rapamycin treatment extend 
health- and lifespan, but conversely they lead to the downregulation of mRNA levels 
of ribosomal proteins through reduced mTOR activity (Iadevaia, Liu, and Proud, 2014). 
In fact, low expression of ribosomal protein mRNA correlates with longevity in long- 
and short-lived cell types in humans (Baumgart et al., 2016; Seim, Ma, and Gladyshev, 
2016). 
 
Downregulation of genes associated with cell growth is evident in old human and worm 
muscle tissues (Ma et al., 2016; Zahn et al., 2006). Similar patterns of change in the 
expression profiles of GH/IGF-1 signalling pathway genes are seen in aged mouse 
livers (Schumacher et al., 2008) and vascular endothelial growth factor (VEGF), which 
is required for skeletal muscle capillarization, evident in old mice and humans (Ryan 
et al., 2006; Wagatsuma, 2006). In fact, perturbations of the IIS pathway extend 
lifespan and delay ageing pathologies across worms, flies, mice and humans 
(Fontana, Partridge and Longo, 2010). It is also possible that, during ageing, reduced 
mitochondrial activity and protein synthesis lead to the inhibition of cell growth and 
proliferation, due to reductions in the generation of energy and raw materials. It could 
also simply signify an increasing prevalence of senescent cells during ageing as a 
result of transcriptional profile changes that lead to cell cycle arrest, and hence the 
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accumulation of senescent cells (Shelton et al., 1999). Repairing of otherwise somatic 
damage is expensive and, perhaps, takes place only when reproduction is negatively 
impacted (Kirkwood, 1977). 
 
Changes in the expression of stress response-associated genes are observed during 
ageing in flies (Frenk and Houseley, 2018). In fact, exposure of flies to heat stress 
extends lifespan (Sarup, Sørensen, and Loeschcke, 2014). Heat shock proteins are 
also upregulated in ageing worms and mice (Walther et al., 2015; Hamatani et al., 
2004). The Unfolded Protein Response (UPRmt) stress response regulates genes that 
are involved in protein folding and changes in ROS defence, metabolism and 
modulation of the innate immune response (Nargund et al., 2015; Schulz and Haynes, 
2015). It is suggested that activation of the UPRmt extends lifespan in worms carrying 
Clk1 mutations, lowering ROS levels and suppressing the UPRmt (Nargund et al., 
2012). 
 
Dysregulation of gene expression and mRNA processing may be associated with 
highly conserved age-dependent changes in chromatin structure. Transcriptomic 
noise and transcriptional drift result in opposing changes in transcripts of the same 
functional group and increase in organisms during ageing (Rangaraju et al., 2015). 
Manipulation of transcriptional drift, by inhibiting serotonergic signalling, alleviates 
physiological deterioration and enhances lifespan in ageing mice (Southworth, Owen, 
and Kim, 2009). Senescent cells tend to harbour clusters of heterochromatinized DNA, 
i.e. SAHF. This is seen with widespread foci of hypomethylation in senescent human 
myofibroblasts (Narita et al., 2003; Cruickshanks et al., 2013). Increased 
transcriptional variability can also be due to changes in post-transcriptional processing 
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of mRNA. Microarray data from human peripheral blood suggest that pathways most 
likely to be disrupted with ageing are those involving genes associated with mRNA 
splicing, polyadenylation and other post-transcriptional events (Harries et al., 2011), 
and age-linked changes in the transcript levels of splicing factors (Holly et al., 2013). 
Additionally, a correlation is seen between the expression of splicing factors 
HNRNPA1 and HNRNPA2B1, and both lifespan in mice and longevity in humans (Lee 
et al., 2016). In fact, a recent study has demonstrated the effects of global defects in 
pre-mRNA splicing in ageing worms, showing that a homologue of splicing factor-1 
(SFA-1) in worms is required for lifespan extension under DR conditions in a TORC1- 
and alternatively spliced transcript-dependent fashion (Heintz et al., 2017).  
 
Age-related changes in expression are evident in normal ageing, and are also 
associated with lifespan and predictive markers of ageing phenotypes such as 
cognitive function (Harries et al., 2011; 2012; Holly et al., 2013; Lee et al., 2019). 
Altered expression of splicing factors has been reported in peripheral blood in human 
and mouse models, as well as in senescent cell cultures. In fact, in mouse models, 
altered expression of slicing factors is evident in young long-lived mice, indicating that 
the pattern of splicing factor expression in early life may be driver of lifespan in some 
cases, while in other cases it may be a causal outcome of ageing (Lee et al., 2016). 
Likewise, young litters of long-lived mice show enhanced isoforms of trp53 that 
promote cellular growth, while older mice have downregulated Cdknt2a, which 
promotes senescence (Huang et al., 2002; Almog, Goldfinger, and Rotter, 2000; Wu 
et al., 1997; Tominaga, 2015). As stated earlier, the reversal of senescent phenotypes 
in vitro has been achieved through the modulation of expression patterns of splicing 
factors (Latorre et al., 2017a; Latorre et al., 2018).  
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1.11 Splicing and splicing factors  
Constitutive splicing occurs when splicing events do not contribute to isoform 
diversification because constitutive splicing always pertains the way  in which mRNA 
is spliced in exactly the same way every time (Ding and Elowitz, 2019). This is unlike 
alternative splicing which allows generation of isoforms using different exons in 
different orders. Splicing can be executed by the major spliceosome U2 or by the minor 
spliceosome U12 (Fig 6). The spliceosome involved in U2-dependent splicing consists 
of U1, U2, U4, U5 and U6 small nuclear ribonucleoprotein particles (snRNPs), and 
non-snRNPs. The minor spliceosome, like the major spliceosome, contains the U5 
snRNP; however, instead of U1, U2, U4 and U6, it has functionally analogous 
U11, U12, U4atac and U6atac (Patel and Steitz, 2003). Both operate in a similar 
manner, and 99% of human introns are spliced out by the major U2 spliceosome. Most 
U2-dependent introns harbour a 5’ SS with a GTNAG sequence, and 3’ SS end with 
CAG or TAG. However, a common atypical U2-dependent splicing event can occur 
around a 5’ SS that starts with a GC. The introns spliced by the minor U12-dependent 
spliceosome account for small percentage of all nuclear introns, and have a longer 
consensus sequence at the 5' SS and branch points. The minor U12-dependent 
spliceosome carries out non-canonical splicing to remove rare introns with different 
SSs. These introns containing non-consensus AT–AC and a high degree of 
conservation at the 5′ SS instead of the typical GT–AG or relatively variable sequences 
at the 5′SS  (Jackson, 1991).  
 
The assembly of the spliceosome through two transesterification reactions leads to 
the generation of an mRNA from pre-mRNA. The first step of this assembly process 
is the generation of the E-complex, which involves the recognition of the 5’ SS by U1, 




Figure 6  Mechanism of splicing (I) and different types of alternative splicing 
(AS) events and (II). Splicing events can be executed by the major U2 or by the minor 
U12 spliceosome. While the U2-dependent splicing consists of U1, U2, U4, U5 and 
U6 small snRNPs, the minor spliceosome consist of  U11, U12, U4atac and U6atac 
instead of U1, U2, U4 and U6 besides the U5 snRNP. Both operate in a similar manner 






Figure 6 Mechanism of splcing (I)  and different types of alternative splicing (AS) 
events and (II). (A) Exon skipping occurs when an exon is removed alongside the 
introns flanking either side of it; (B) Mutually exclusive exons are generated when one 
exon in exclucded at the expense of other being retained in the transcript; (C) Retained 
intron splicing is formed when an intron is retained in the final transcript; (D and E) 
Alternative promoters and alternative terminators are in transcripts which exons with 
more than one initiator or terminator; (F and G) Alternative 5′ splice site and alternative 
3′ splice site selections are generated from exons with more than one splice site at the 






and the 3’ SS by U2. This is followed by the generation of the pre-spliceosome A-
complex, where U2 binds to the branch point. This event is followed by the generation 
of the pre-catalytic B-complex when U4–6 assemble together. Thereafter, 
conformational rearrangement occurs leading to the assembly of the catalytically 
active C-complex. In this complex, the first reaction allows the binding of U2, U5 and 
U6 to lariat introns and exons. A second catalytic reaction caused by this C-complex 
cleaves off the lariat from the 3’ SS and completes the ligation of exons spanning either 
side of the lariat (Jackson, 1991).  
 
Alternative mRNA splicing (AS) occurs in >95% of multi-exon human genes and 
increases the diversity and function of the proteome. Alternative splicing (AS) is a co-
transcriptional process whereby one gene can generate many mRNAs and proteins. 
It allows the generation of a diverse proteome from 95% of genes (Pan et al., 2008). 
There are seven types of alternative splicing (Fig 6) which are exon skipping, mutually 
exclusive exons, retained intron, alternative promoter, alternative terminator, 
alternative donor site and alternative acceptor site.  Exon Skipping is the most 
common mode of splicing mechanism whereby exons are included or 
excluded from the final transcript. Mutually exclusive splicing event occurs 
when two exons are retained while another is spliced out in a non-independent 
manner. Intron Retention which is thought to permit retaining of the non-
coding portions of the gene and may lead to demornity in the protein 
structure and function. Alternative promoters and alternative terminators are used 
to generate isoforms with more than one initiator or terminator exon.  Other types of 
splicing involve the use of alternative 5′ splice site and alternative 3′ splice site at the 
start or end of an exon (Shi et al., 2018).  
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During transcription, DNA is transcribed to pre-messenger RNA (pre-mRNA) by RNA 
polymerase II. This pre-mRNA is processed to exclude introns, ligate exons, and allow 
the addition of a poly(A) tail at the 3’ end and cap at the 5’ end to protect the mRNA 
from initial degradation (Hocine, Singer, and Grünwald, 2010). Splicing, as described 
earlier, is executed by the spliceosome, which is comprised of a ribonucleoprotein 
(RNP) complex. This complex recognizes highly conserved short sequences at 5’ 
donor splice sites (SSs) of the introns, 3’ acceptor SSs of the introns, branch points 
and polypyrimidine tracts. The polypyrimidine promotes the assembly of the 
spliceosome while the branch point, which always retains A, is located 18–40 
nucleotides (nt) upstream of the 3’ SS and initiates a nucleophilic attack on the 5′ 
donor SS. The branch point is characterized by a partially conserved YNYYRAY 
sequence (Y = pyrimidine, N = any nucleotide, R = purine and A = adenine) (Matera 
and Wang, 2014; Will and Lührmann, 2011). The choice of SS is determined by the 
balance of cis-acting enhancer or silencer elements (exonic splicing silencer ESS, 
intronic splicing silencer ISS, exonic splicing enhancer ESE and 
intronic splicing enhancer ISE), and trans-acting splicing repressors or activating 
factors (SR: serine/arginine-rich family of nuclear phosphoproteins and hnRNPS). 
Generally, the SRs interact with ESE and ISE to promote splicing, while hnRNPs 
interact with ESS and ISS to inhibit AS (Smith and Valcárcel, 2000). 
 
AS is regulated by ratios of trans-acting proteins (activators and repressors) binding 
to cis-acting sites or ‘elements’ (enhancers and silencers) on pre-mRNAs. ESE and 
ISE drive constitutive splicing, while ESS and ISS are crucial in driving AS (Wang and 
Wang, 2014). Splicing activators in the SR protein family bind to splicing enhancers 
(ESE and ISE), while splicing inhibitors (hnRNPs) bind to splicing silencers (ESS and 
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ISS). Their ratio determines donor and acceptor splicing site usage (Ramanouskaya 
and Grinev, 2017). Additionally, splicing factors  (SFs) that serve as activators on 
intronic enhancer elements may also serve as repressors on splicing elements of 
exons and vice versa (Lim et al., 2011). Of the seven types of AS (Fig 6), the most 
common form is cassette exon splicing caused by canonical splicing, whereby an exon 
can be excluded or retained in alternate isoforms. The other six types of AS are 
mutually exclusive exons, retained introns, the use of alternative promoters or 
terminators, and the use of alternative donor or acceptor sites (Sibley, Blazquez and 
Ule, 2016).  
 
Splicing factors have been associated with cellular senescence and linked to organ 
degeneration (Deschênes and Chabot, 2017; Fujita et al., 2009; Latorre et al., 2017a). 
In fact, age-related splicing has been shown to alter metabolism, DNA repair and ion 
channels in neurodegenerative diseases (Tollervey et al., 2011). Dysfunction of the 
splicing proteins hnRNP A1 and PTB1 has also been shown to alter the metabolism 
of cholesterol, and contribute to vascular stiffness and endothelial senescence in 
cardiovascular diseases (Rizzacasa et al., 2017). The pre-mRNA splicing factor 
senescence evasion factor (SNEV), which aids spliceosome assembly and mRNA 
processing, is also known to suppress senescence as well as apoptosis (Dellago et 
al., 2012).  
 
Expression of splicing factors, splicing enhancers, and silencers is dysregulated in the 
blood of ageing humans. This dysregulation can lead to alterations in the SS usage of 
genes, as well as modulate ratios of alternatively expressed transcripts in a tissue-
specific manner (Harries et al., 2011; Holly et al., 2013). In mouse models, lifespan-
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associated copy number variations are also preferentially localized in or within the 
proximities of genes encoding proteins for splicing events (Glessner et al., 2013). The 
expression of hnRNP splicing factors is also associated with normal ageing and 
parental longevity in humans, lifespan in mice and in vitro models of senescence 
(Harries et al., 2011; Holly et al., 2013). Recent findings have shown that two splicing 
factors, HNRNPA2B1 and HNRNPA1, are associated with parental longevity and 
might be key to determining lifespan in humans (Lee et al., 2016). While some hnRNPs 
are upregulated, others are downregulated in the blood of offspring of long-lived 
humans. Long-lived animals also have downregulated splicing factors, which may 
confer an ability to sustain a splicing pattern that promotes healthy ageing as a result 
of cellular plasticity (Lee et al., 2016). It is possible that the balance of splicing 
enhancers and silencers is disrupted during ageing, which may change according to 
the choice of SSs. This may eventually lead to the generation of the dysregulated 
ageing transcriptome that is a feature of ageing outcomes such as tumours, and AD 
and Parkinson’s disease (PD) (Scuderi et al., 2014; Danan-Gotthold et al., 2015; 
Lisowiec et al., 2015).  
 
 
1.12 Proteostasis and mRNA turnover    
Protein homeostasis or ‘proteostasis’ is the process that regulates optimum 
environment for functional proteins within the cell in order to maintain the cellular 
proteome, disruption of which can lead to severe challenged cellular environment in 
pathologies like AD.  Gene expression and therefore proteome content can be 
controlled by the amount of mRNA clearance as well as by the stability and 
accessibility of mRNA to other molecules, differential rates of mRNA translation and 
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degradation. mRNA turnover determines the lifetime of cytoplasmic mRNAs and 
thereby controls gene expression. mRNA granules that harbour the mRNA decay 
machinery involved in translational repression or  transient storage, are therefore also 
contributing factors to expression (Borbolis and Syntichaki, 2015).  The removal of 
aberrant protein aggregates occurs through the ubiquitin-proteasome or the 
autophagosome-lysosome pathway. Targeting of RNA granules to vacuoles can lead 
to efficient PBs/SGs clearance, regulating the abundance of proteins as well as 
simultaneously degrading the mRNAs inside these vacuoles (Buchan et al., 2013).  
 
Mature mRNAs consist of coding regions, with 3’ and 5’ untranslated regions (UTRs) 
that are important for stability and translation. They also have a 5’ cap and a 3’ poly(A) 
tail, both of which protect the mRNA from degradation and facilitate translation 
initiation in the cytoplasm (Cheng et al., 2016; Temperley et al., 2003). The rate of 
transcribed mRNA translation and the fate of an mRNA in the cytoplasm are 
determined by post-transcriptional modifications and packaging of mRNAs with 
proteins into RNPs, which regulate mRNA turnover and degradation. Post-
transcriptional mechanisms can regulate the concentrations and localization of 
mRNAs of translated proteins (Chan et al., 2018). 
 
Proteostasis is the mechanism whereby proteins are stabilized by the correct folding 
and refolding of misfolded peptides. Loss of proteostasis is a key feature in ageing 
and ageing-related outcomes. While a global reduction in mRNA translation might 
prevent the production of aberrant proteins, high levels of non-functional proteins can 
cause proteotoxicity in cells (Ciryam et al., 2013; Walther et al., 2015). Studies using 
invertebrate models of ageing have indicated that a progressive loss of proteome 
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balance occurs during ageing. This loss of proteome balance is a result of decreased 
numbers of ribosomal subunit proteins and regulation of miRNA-mediated 
translational repression (Walther et al., 2015). 
 
It is possible that, with ageing, there is a decline in the cell’s ability to prevent or repair 
ROS-induced oxidative damage, which leads to the accumulation of immobile 
dysfunctional proteins (Beckman and Ames, 1998). This is evident in experimental 
model organisms where the conserved protein degradation system, i.e. autophagy, 
declines with age, preventing the degradation of damaged cellular proteins (Bareja, 
Lee, and White, 2019). Progressive declines in the preservation of a functional 
proteome and the accumulation of defects in protein quality control are evident in age-
related neurodegenerative disorders (Koga, Kaushik, and Cuervo 2011; Vilchez, 
Saez, and Dillin, 2014). In line with this, DR linked to lifespan extension is known to 
induce autophagy-related defective protein clearance (Hansen et al., 2007). Age-
related proteotoxicity can also operate without chaperones and proteases to restore 
or remove misfolded polypeptides, and degrade them in an attempt to renew 
intracellular proteins. It is an attempt to prevent the accumulation as well as chronic 
expression of damaged proteins, which could otherwise lead to the development of 
pathologies such as AD and PD (Powers et al., 2009; van Ham et al., 2010). In fact, 
the two principal proteolytic quality control systems, the autophagy-lysosomal system 
and the ubiquitin-proteasome system deteriorate with age (Rubinsztein, Mariño, and 
Kroemer 2011; Tomaru et al., 2012). Defects in mRNA silencing or decay factors in 
cytoplasmic mRNP granules, i.e. processing defects, have been inversely linked to 
lifespan and stress resistance in invertebrate models (Cornes et al., 2015; Kato et al., 
2011; Rousakis et al., 2014). 
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1.13 Regulation of gene expression by ncRNAs  
Non-coding RNAs (ncRNAs) are RNAs that do not code proteins, such as ribosomal 
RNA, transfer RNA small nuclear RNA and small nucleolar RNAs. Eukaryotic 
regulatory ncRNAs can be broadly divided into long ncRNAs (lncRNAs) (> ~200 nt) 
and short ncRNAs (sncRNAs) (~20–30 nt, e.g. miRNAs). LncRNAs bind with RNA-
binding proteins (RBPs) without processing activity in the RNP complex. They control 
gene expression as well as translation by regulating chromatin modification, 
transcription, splicing, mRNA decay, translation, protein transport and assembly. In 
contrast, sncRNAs bind with RNA-processing proteins that cleave primary transcripts 
into smaller sncRNA pieces, which are assembled into RNP machineries known as 
RNA-induced silencing complexes and mediate RNA interference by complementarity 
to regulate gene expression. Dysregulation of lncRNAs and sncRNAs like miRNAs is 
associated with ageing (Huan et al., 2018; Marttila et al., 2020). 
 
 
1.14 Emerging class of ncRNA: circRNA  
Circular RNAs (circRNAs) are a class of ncRNA that are present in wide variety of 
cells, in various tissue types across species and are thought to modulate gene 
expression. CircRNAs in higher organisms are reported to be produced by back-
splicing events and can be synthesized from all regions of the genome, deriving mostly 
from exons but less commonly, from antisense, intergenic, intragenic or intronic 
regions (Lan et al., 2016). CircRNAs are both spatially and temporally regulated and 
evidence is emerging that they may have importance in normal development of tissues 
or organs but also in disease pathogenesis. Most circRNAs have been reported in the 
brain (Jeck et al., 2013; Veno et al., 2015; Barrett and Salzman, 2016; Legnini et al., 
2017b). They can be found in most cell sub-compartments but the majority localize 
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predominantly to the cytoplasm (Du et al., 2016b). However, they can also be found 
in the nucleus and may have the potential to regulate RNA-Pol-II-mediated 
transcription (Bose and Ain 2018).  They can vary in size from 200-4000 nt and usually 
harbour 1 to 5 exons, ~25% of circRNAs can retain introns. CircRNAs are non-
polyadenylated, single-stranded, covalently closed RNAs, which are generated by 
backsplicing from as much as 20% of genes in mammals. CircRNAs are inherently 
stable by virtue of their closed covalent structure as well as exonuclease resistance 
and are thought to be stable in exosomes (Cocquerelle et al., 1993; Schwanhausser 
et al., 2011; Jeck et al., 2013; Lan et al., 2016; Lasda and Parker, 2016b). This 
observation opens up the interesting possibility that circRNAs, like miRNAs, may have 
roles in paracrine signalling or have roles in cell-to-cell cross talk.  
 
 
1.14.1 Biogenesis of circRNAs 
In conventional linear splicing, the spliceosome joins exons in a 5’ to 3’ configuration. 
In contrast, circRNAs arise when the 3’ ‘tail’ of a downstream exon of a gene is back-
spliced to the 5’ ‘head’ of an earlier exon (which may include itself) leading to the 
circularization of exons in between (Fig. 7) (Cocquerelle et al., 1993). These splicing 
decisions are, as in linear splicing, regulated by trans-acting splicing factors and cis 
sequence elements (Kramer et al., 2015). Several sequence features influencing 
circRNA formation have been described. Firstly, intron length has been reported to 
play a part; introns flanking back-spliced sites tend to be comparatively longer than 
those flanking non-circularised exons (Salzman et al., 2013). This may be because 
larger introns may form more RNA-RNA interactions, facilitating circularization of 
embedded exons; the double-strand RNA-editing enzyme ADAR1, which is capable 
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of melting stem structures within these RNA-RNA interactions, is associated with 
suppression of circRNA expression in C. elegans  (Ivanov et al., 2015). Intronic 
sequences flanking circRNAs are enriched for A-to-I substitutions and hyper-
editing events. Unsurprisingly thus ADAR knockdown leads to accumulation of 
circRNAs (Ivanov et al., 2015). ADAR is an RNA-editing enzyme that binds double-
stranded RNA and deaminates adenosine to inosine base. ADAR1 and ADAR2 
interact with double-stranded ALU repeat. ADAR antagonizes competing RNA-RNA 
interactions of introns during circRNA biogenesis by melting stems within these 
interactions (Ivanov et al., 2015). Secondly, exon length may also be a factor; exons 
of single-exon circRNAs are on average 3-fold longer compared with non-circularised 
exons; longer exons may be sterically preferentially favoured for 3’- 5’ splicing at 
canonical splice sites (Salzman et al., 2012; Jeck et al., 2013; Starke et al., 2015).  
Thirdly, RNAs that are hyper-edited are enriched for circRNA sequences (Ivanov et 
al., 2015). Finally, sequence content may also be important. Repetitive sequences are 
known to promote back splicing; back-spliced exons that form circRNAs are frequently 
enriched in paired ALU tandem repeats that have been shown to promote 
circularization (Jeck et al., 2013). Miniature introns with as few as 30 to 40-nt inverted 
repeats are also sufficient to promote circularization (Liang and Wilusz, 2014).   
 
CircRNA formation may also be dependent on the specific binding of regulatory 
proteins. RNA binding proteins such as Quaking (QKI) and Muscleblind (MBL/MBNL1) 
have been described to bind to introns flanking back-spliced sites and may drive 
circularization (Ashwal-Fluss et al., 2014; Conn et al., 2015).  The MBL gene itself 
encodes a circular form which regulates the expression of its linear transcript and 
modulation of MBL levels strongly affects circMbl expression (Ashwal-Fluss et al., 
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2014). Circular RNA formation has also been shown to depend on the rate of 
transcription of their parent genes. CircRNA producing genes are generally longer and 
exhibit faster transcription than genes that do not produce circRNAs, and artificially 
slowing the rate of transcription with mutant RNA polymerases results in lower levels 
of circRNA biogenesis (Zhang et al., 2016a).  
 
Intronic circRNAs (ciRNAs) can also be generated form lariat introns. CiRNAs are 
devoid of linear fragments spanning the 3′ end of the intron to the branch point but are 
produced by a 2′,5′-phosphodiester bond arising from canonical linear splicing (Zhang 
et al., 2013). A 7-nt GU-rich element occurring close to a 5’ splice site and with an 11-
nt C-rich motif around the branch point within intronic sequences has been reported 
to be important for formation of ciRNAs (Zhang et al., 2013) .  
 
 
         
 
 
Figure 7 Diagram of circRNA generation and possible modes of action. 
Biogenesis of circular RNA (circRNA). The linear primary transcript contains exons 
(blue boxes), introns (black lines), and possibly repetitive elements or sequence motifs 
(grey boxes). Circular exons are generated from back-splicing events between the 
splice donor site of a downstream exon and the splice acceptor site of an upstream 
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exon. This can be mediated by specific sequence elements (grey boxes) or by 
interaction with RNA binding proteins (RBPs). Splicing events are indicated by dashed 
lines with double arrowheads. This may result in the production of a circular RNA and 
a linear RNA which lacks the circularised exons. Proposed roles of circRNA in the 
regulation of transcription and translation. circRNAs may regulate genes at several 
levels. (A) Firstly, nuclear circRNAs can interact with promoter regions of target genes 
and interact with RNA polymerase II (Pol2) to repress or enhance transcription; (B) 
Secondly, circRNAs can sequester RBPs that regulate mRNA processing and, thus, 
alter the splicing patterns of the genes in question, or moderate mRNA stability. RBP 
binding sites are given by dark blue boxes; (C) Thirdly, the biogenesis of circular RNAs 
may results in the production of a linear RNA lacking the circularised exons. The 
formation of circRNAs can thus reduce the amount of linear transcript produced; (D) 
circRNAs can act as micro RNA (miRNA) sponges, sequestering them away from their 
binding sites in target genes, which are given by dark blue boxes; (E) Circular RNAs 
can also be translated. The initiation codon is given by black oval, and the translating 
ribosome and nascent polypeptide are indicated. 
 
 
1.14.2 CircRNA mediated regulation of expression 
Splicing events do not always produce a linear transcript. circRNAs are a class of RNA 
that are emerging as key new members of the gene regulatory milieu, which are 
produced by back-splicing events within genes. In circRNA formation, rather than 
being spliced in a linear fashion, exons can be circularised by use of the 3′ acceptor 
splice site of an upstream exon, leading to the formation of a circular RNA species. 
CircRNAs have been demonstrated across species and have the potential to present 
genetic information in new orientations distinct from their parent transcript. The 
importance of these RNA players in gene regulation and normal cellular homeostasis 
is now beginning to be recognised. They have several potential modes of action, from 
serving as sponges for micro RNAs and RNA binding proteins, to acting as 




1.14.2.1 CircRNAs as miRNA Sponges 
CircRNA can bind specific miRNAs or groups of miRNAs, sequestering them and 
suppressing their function  (van Rossum et al., 2016), in a phenomenon termed the 
competitive endogenous RNA hypothesis (Tay et al., 2014).  CircRNA CDR1as has 
been documented to contain up to 74 binding sites for the miRNA miR-7, and also 
binds Argonaute (AGO) proteins of the RNA-induced silencing complex (RISC) that 
regulate miRNA action (Memczak et al., 2013). There is also some suggestion that the 
relationships between circRNAs and miRNAs may be partly autoregulatory; CDR1as 
also binds miR-671, which induces AGO-mediated cleavage of CDR1as itself, which 
could act to release miR-7 (Hansen et al., 2013). However, circRNAs containing 
multiple binding sites for single miRNAs may be the exception rather than the rule 
since most circRNAs identified to date do not contain enrichment of binding sites for 
specific miRNAs (Guo et al., 2014). Emerging evidence suggests that circRNAs may 
act by sequestration of modules of coordinately regulated miRNAs; the circRNA 
circHIPK3 contains binding sites for 9 miRNAs with growth-suppressive properties 
(Zheng et al., 2016b). The presence of multiple binding sites may not be a prerequisite 
for efficient miRNA regulation however, since circHIPK3 contains only 2 binding sites 
for miR-124, yet retains the ability to regulate this miRNA (Zheng et al., 2016b). Most 
of the research investigating the role of circRNA-miRNA interaction has been 
performed through correlation of the levels of miRNA and circRNA expression in vitro. 
Evidence for circRNAs acting as miRNA sponges can also be seen in data arising 
from the CDR1as knockout mouse. Levels of both miR-7 and miR-671 were seen to 
be lower in knockout animals, and these changes were also correlated with defects in 
synaptic transmission (Piwecka et al., 2017). It is likely that a circRNA with multiple 
binding sites will affect the expression of larger number of miRNA targets. However, 
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experimental validation of the minimal number of miRNA binding sites for a candidate 
circRNA to be functional is still required for many circRNAs. An arena to explore is 
whether a single miRNA binding site would be sufficient for efficient circRNA:miRNA 
sponging interactions. It would be also interesting to know what levels of circRNA 
expression is required for the optimal miRNA sequestration ability of these entities. 
The interaction between circRNAs and miRNAs may also go beyond their role in 
miRNA sequestration; they may also be important for the storage, sorting, and 
localization of miRNAs adding an additional level of regulation to miRNA-controlled 
regulation of target genes (Hansen et al., 2011; van Rossum et al., 2016).  
 
 
1.14.2.2 CircRNAs as Transcriptional and Translational Regulators 
A specific category of circRNAs, nuclear exon-intron circRNAs (EIciRNAs) can also 
interact with the transcription machinery. These variant circRNAs, which retains some 
intronic sequence from their linear gene can interact with the U1 component of the 
spliceosomal machinery, recruiting RNA polymerase II to the promoter region of genes 
and enhancing expression of its target genes (Li et al., 2015c). CircRNAs can also 
modulate the expression of the cognate transcript if the circularisation event includes 
the translation initiation codon of its native gene. This may cause their cognate linear 
mRNAs arising from the same gene to escape translation, thus regulating protein 
expression as in the case of circHIPK3, circDMD and circFMN (Chao et al., 1998; 
Gualandi et al., 2003; Grigull et al., 2004a; Jeck et al., 2013). Recently, circPABPN1 
has been reported to supress binding of PABPN1 mRNA to HuR. PABPN1 translation 
is positively associated with HuR and the interaction of circPABPN1 interaction with 
HuR reduces the translational efficiency of PABPN1 transcripts. Thus, circRNAs like 
51 
 
circPABPN1 can act as competitors with their cognate mRNA for RBPs and can also 
modulate the rate of translation of target mRNAs (Abdelmohsen et al., 2017). 
 
 
1.14.2.3 CircRNAs as Competitors of Linear Splicing 
All isoforms produced from a given gene arise from a common pre-mRNA. It follows 
therefore that the production of a circRNA may have consequences for the abundance 
of the remaining transcripts encoded by that gene. An example of this lies in the 
Muscleblind (MBL) gene. MBL contains sequences that form a circRNA transcript that 
contains binding sites for MBL itself. Production of the circMBL therefore forms an 
autoregulatory loop that regulates the production of the linear transcript in favour of 
the circular form (Ashwal-Fluss et al., 2014). In Arabidopsis, a circRNA derived from 
the SEPALLATA3 gene has been shown to interact with its cognate DNA forming a R-
loop, causing a pause in transcription and also affecting recruitment of splicing factors 
to the nascent transcript and affecting alternative splicing through exon-skipping (Conn 
et al., 2017).   
 
1.14.2.4 CircRNAs as sponges for RNA binding proteins  
In addition to their role as miRNA sponges, circRNAs can also act as sponges for other 
entities such as RNA binding proteins (RBPs) that can regulate gene expression. 
RBPs, like miRNAs, bind specific sequences within their target genes and control all 
stages within the lifecycle of an mRNA from splicing and nuclear export to stability and 
subcellular localisation (Grigull et al., 2004b). CircRNAs interacting with RNA binding 
protein components of the gene regulatory machinery such as HuR have been 
reported (Abdelmohsen et al., 2017).  
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1.15 CircRNA in diseases of ageing 
In accordance with a pivotal role in gene regulation, perturbation of circRNA 
expression is beginning to be reported in association with disease. Altered circRNA 
expression has been reported in several diseases like cancer, heart disease, 
neurological disorders, diabetes and atherosclerosis, although the precise 
mechanisms by which they operate are yet to be disclosed. In post-mitotic cells, 
circRNA turnover is not as fast as linear transcripts which degrade easily. As such 
proliferative cells or cells that become apoptotic are likely to have less circRNA than 
post-mitotic cells (Bachmayr-Heyda et al., 2015; Song et al., 2016).   
Ageing as has been discussed earlier is associated with global changes in splicing 
patterns.   Since, circRNAs are also thought to be generated as isoforms from splicing. 
It is therefore possible that advancing age also affects progressive accumulation of 
circRNAs. In fact, splicing factors hnRNP and SR proteins has been shown to regulate 
Laccase2 circRNA expression in flies (Kramer et al., 2015). In addition, expression of 
34 circRNAs changes in photoreceptor neurons of ageing flies (Hall et al., 2017). 
Similarly ~300 circRNA were dysregulated in mouse (Gruner et al., 2016). Like splicing 
factor FUS was also seen to regulate circRNAs expression in vitro mouse motor 
neurons (Errichelli et al., 2017).  
 
CircRNAs are known to accumulate in ageing brain (Gruner et al., 2016). This may be 
partly due to the endonuclease-resistant nature of circRNA molecules, but at least two 
circRNAs have been previously described to have role in ageing or cellular 
senescence. CircRNA circPVT1 has been demonstrated to suppress cellular 
senescence by sequestration of miRNA let-7, which lifts its inhibitory action on its 
target genes IGF2BP1, KRAS and HMGA2 which act to promote cell proliferation 
(Panda et al., 2017). Conversely, the circFOXO3 circRNA was found to promote 
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senescence in the heart muscle of aged mice and humans through its action on the 
ID1, E2F1, FAK and HIF1A target genes (Du et al., 2016b). This circRNA is also known 
to silence cell proliferation through its regulation of the Cell Division Kinase 2 (CDK2) 
gene and the cyclin dependent kinase inhibitor p21 (Du et al., 2016b). 
 
 
1.15.1 CircRNAs in Cancer 
In accordance with their known role in modulating cell cycle, proliferation and cellular 
senescence as demonstrated in vitro studies, circRNAs have been implicated in 
cancer. CircRNA hsa_circ_001569 (circABCC) may play a role in the modulating gene 
expression in colorectal cancer, by virtue of its action on miR-145. MiR-145 is a 
negative regulator of target genes such as E2F5, BAG4 and FMNL2 which are known 
to be involved in the suppression of proliferation (Xie et al., 2016).  Similarly, CDR1as 
has also been implicated in several cancer subtypes including hepatocellular 
carcinoma (HCC). CDR1as expression is known to be correlated with hepatic 
microvascular invasion in HCC tissue (Xu et al., 2017b) and Hsa_circ_0000520 
(circRPPH1), hsa_circ_0005075 (circEIF4G3), hsa_circ_0066444 (circADAMTS9) 
and hsa_circ_0001649  (circSRPRH) have all been shown to be expressed at different 
levels in HCC compared to adjacent normal liver tissues (Qin et al., 2016; Shang et 
al., 2016). Hsa_circ_0005075 (circEIF4G3) correlated with tumour size while 
hsa_circ_0001649 (circSRPRH) was downregulated and also correlated with tumour 
size in addition to the prevalence of tumour embolus and could be involved in 
tumorigenesis and metastasis of HCC (Qin et al., 2016; Shang et al., 2016). CircRNA 
circZKSCAN1 has also been shown to be lower in tumour and correlated with tumour 
size in HCC (Yao et al., 2017). 
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Large-scale dysregulation of circRNA expression has been noted in bladder 
carcinoma, where microarray analysis revealed that 469 circRNA were differentially 
expressed, 285 showing increased expression in bladder cancer compared with 184 
showing downregulation. Of these, circTCF25 regulates miRNAs miR-103a-3p/miR-
107, with circTCF25 upregulation being associated with increased levels of 13 targets 
associated with cell proliferation, migration and invasion in bladder cancer (Zhong et 
al., 2016). Similarly, increased expression of circRNA circMYLK in bladder cancer 
leads to overexpression of DNMT3B, VEGFA and ITGB1 genes, involved in promotion 
of proliferation, and are molecular targets of miRNA-29a-3p (Huang et al., 2016). 
CircRNA circHIAT1 has also been reported to respond to signalling through the 
androgen receptor to promote tumour migration and invasion in clear cell renal cell 
carcinoma, by enhancement of CDC42 expression through regulation of miR-195-
5p/29a-3p and miR-29c-3p target genes (Wang et al., 2017b). Recently, fusion-
circRNAs (f-circRNA) have been shown to accelerate proliferation rate and instigate 
cellular transformation. Furthermore, f-circRNAs f-circM9 and f-circPR have been 
shown to confer resistance to therapeutics due to protective effects of drug-induced 
apoptosis in cancer cells in vitro via a MAPK/AKT dependent signaling pathway 
(Guarnerio et al., 2016).  
  
 
1.15.2 CircRNAs in Neurological Disease 
CDR1as has been associated with neurodegenerative conditions such as Alzheimer’s 
disease (AD). In patients with moderate to advanced stages of sporadic AD, CDR1as 
expression has been reported to be reduced, which may lead to elevated miR-7 
expression and consequent downregulation of miR-7 dependent mRNAs. One target, 
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ubiquitin protein ligase A, is responsible for the clearance of amyloid peptides in AD 
and other degenerative disorders (Lukiw, 2013). Although most of studies with 
circRNAs have been conducted in vitro, recently Piwecka et. al. generated a knockout 
murine model for Cdr1as. The brains of these transgenic mice had upregulated 
expression of miR-7 genes, such as c-Fos. Cdr1as knockout mice demonstrate 
impaired synaptic transmission and information processing defects (Piwecka et al., 
2017).  CircRNAs also have potential roles in memory; circPAIP2 has been suggested 
to upregulate memory-related gene PAIP2 through the PABP-associated pathway 
(Khoutorsky et al., 2013). A role for circRNAs in major depressive disorder is also 
suggested by the observation that a significant change of hsa_circRNA_103636 
expression was noted in patients after 8 weeks on antidepressant therapies (Cui et 
al., 2016).   
 
 
1.15.3 CircRNAs in Osteoarthritis 
Osteoarthritis (OA) occurs because of degenerative changes in the joint cartilage. 71 
circRNAs were seen to be differentially expressed in the cartilage of patients with OA 
compared with non-OA controls.  The circRNA Circ-CER appears to be of particular 
importance. Circ-CER expression was shown to increase with increased expression 
of pro-inflammatory signalling molecules. Suppression of circ-CER resulted in reduced 
MMP13 expression and remodelling of the extracellular matrix (ECM). The authors 
suggest that this observation arises from a sponging effect of Circ-CER on miR-136, 





1.15.4 CircRNAs in Cardiovascular Disease 
The CDKN2A/CDKN2B locus expresses an alternatively spliced non-coding transcript, 
ANRIL, which encodes a circular form in addition to its linear. CircANRIL has been 
reported to regulate the pescadillo homologue 1 (PES1) gene transcript, which is 
involved in pre-rRNA processing and ribosome biogenesis. Sequestration of this 
essential factor and suppression of these key processes in vascular smooth muscle 
cells and macrophages was shown to cause nucleolar stress and p53 activation, 
resulting in apoptosis and features of atherosclerosis (Holdt et al., 2016). Some 
circRNAs have been shown to be protective in heart function; the circRNA Heart-
related circRNA HRCR has been implicated in protection from cardiac hypertrophy 
and heart failure, by virtue of its binding of the inflammatory onco-miR miR-223 (Taibi 
et al., 2014; Wang et al., 2016). Some RBM20-dependent circRNAs have also been 
reported to be differentially regulated in dilated cardiomyopathy (Khan et al., 2016). 
Similarly, circRNA MFACR has been shown to sponge miR-652-3p in the cytoplasm, 
promoting mitochondrial fission and cardiomyocyte cell death by enhancing translation 
of MTP18 in animal models (Wang et al., 2017a). Similarly, high levels of 
circRNA_000203 and circRNA_010567 have been reported in cardiomyocytes from 
diabetic mice treated with angiotensin II. These circRNAs are thought to downregulate 
miR-26b-5p, miR-141 and miR-141 thereby upregulating the transforming growth 
factor beta (TGFB1) gene. This leads to suppression of fibrosis-associated protein 
resection in Col I, Col III and α-SMA, promoting fibrosis in the myocardium (Tang et 





1.15.5 CircRNAs and Infection 
Microbial lipopolysaccharide induces the activation of Toll-like receptors (TLR) 
pathways leading to activation of NF-κB and modulation of genes which are key to 
antimicrobial defences and adaptive immunity. circRasGEF1B has been suggested to 
modulate the expression of ICAM-1 as part of the lipopolysaccharide response. Knock 
down of this circRNA in vitro leads to 27-39% reduction in ICAM-1epression in vitro  
(Ng et al., 2016). In mouse macrophage cells, activation of TLR4, TLR9, TLR3, TLR2 
and TLR1 receotors all regulate the expression of circRasGEF1B (Ng et al., 2016).  
Genetically modifying circRasGEF1B expression was shown to reduce ICAM1 
expression levels, which under normal conditions, would promote binding of 
leukocytes to endothelium cells and their transmigration into target tissues (Ng et al., 
2016). Thus deficiency of circRasGEF1B may prevent migration of leukocyte cells to 
inflammatory sites and interfere with the healing process and in cancer cells may 
additionally affect the activation of cytotoxic T-lymphocytes, which is needed for driving 
release of cytolytic granules into tumour cells (Ng et al., 2016).   
 
A potential role for circRNA in response to viral infection has been reported.  HeLa 
cells transfected with circRNA demonstrated induced expression of 84 innate 
immunity-related genes, such as RIGI and OASl, which were upregulated by as much 
as 500-fold and 200-fold respectively (Chen et al., 2017b). Concurrent with these 
changes was a 10-fold decrease in infection rate against Venezulan equine 
encephalitis virus, which was shared by nearby non-transfected cells indicating some 
paracrine action respectively (Chen et al., 2017b).  CircRNAs can act as competitors 
with viral mRNA for binding to RNA-binding domain containing immune factor NF90 
and its isoform NF110. These factors can promote circularization by stabilizing the 
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binding of intronic RNA pairs in the nucleus.  However, viral infection results in 
transportation of these immune factors from the nucleus to the cytoplasm.   This, in 
turn, acts to render the circRNA available for binding to viral mRNA and prevention of 
viral infection of the host cell (Li et al., 2017b).  
 
 
1.15.6 CircRNAs in Type 2 Diabetes 
In addition to the role of CDR1as in regulation of insulin secretion through modulation 
of PAX6, recent studies have suggested that circRNAs may have utility as biomarkers 
of diabetes. 489 circRNAs were found to be differentially expressed in the peripheral 
blood of patients with type 2 diabetes, and furthermore, circRNA hsa_circ_0054633 
was found to be capable of predicting pre-diabetes with an area under the curve (AUC) 
of 0.84 (p = <0.001) (Zhao et al., 2017c). In other studies, several circRNAs have been 
shown to be differentially expressed in serum of patients with diabetic retinopathy 
compared to both controls, and diabetes patients without retinopathy.  Of these, 
hsa_circRNA_100750 is derived from stromal interaction molecule 1 which is 
upregulated in diabetic patients. Hsa_circRNA_104387 is known to sequester miR-
29a which is prevent the loss of renal function in diabetic patients. 
Hsa_circRNA_103410 is known as a regulator of miR-126 known to inhibit VEGF and 
MMP9 expression. Thus hsa_circRNA_103410 could promote endothelial injury in the 
retina, while hsa_circRNA_100192, could, by sequestering miR-146, promote NF-κB 
activation, adenosine deaminase-2 expression and inflammatory responses as is 
observed in vitro (Gu et al., 2017). These observations raise the exciting possibility 
that circRNAs expressed in accessible tissues may be useful markers of disease in 
inaccessible organs such as pancreas. CircHIPK3 has been found to be dysregulated 
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in diabetic retinas which may contribute to elevated levels of VEGFC, FZD4, and 
WNT2 expression by virtue of its effects on miR-30a-3p (Shan et al., 2017).  
 
 
1.16 CircRNAs as Diagnostic and Prognostic Markers 
Because circRNAs are highly nuclease-resistant, they are more stable than linear 
transcripts, and may be released into the extracellular space via the exosomes (Suzuki 
et al., 2006; Lasda and Parker, 2016a). Half-lives of circRNAs can vary significantly, 
but can be as much as 50 hrs. On average, their half-lives are around 2.5 fold longer 
than the median half-lives of their linear counterparts (Enuka et al., 2016). A 
substantial number of circRNAs are expressed in blood at comparatively higher levels 
than their linear mRNAs, thus making circRNAs attractive tools for diagnostics to trace 
the mechanism of coded genes otherwise inaccessible by the canonical RNA 
pathways-dependent assays (Memczak et al., 2015).  A selection of circRNAs 
reported as potential biomarkers for different diseases are summarized in Table 1. 
Over 400 circRNAs have been detected to be present in cell-free saliva and could 
potentially be used for non-invasive diagnostics approach (Bahn et al., 2015). 
CircRNAs have been suggested as potential biomarkers for several types of cancer. 
In murine models, tumour-derived exosomal circRNAs in the serum correlate with 
tumour mass (Li et al., 2015b) and thus may be promising biomarkers for cancer 
detection. CircRNA hsa_circ_0001649 (circSHPRH) has shown some utility as a 
biomarker for hepatocellular carcinoma, is downregulated with tumour status and is 
associated with the occurrence of the tumour embolus as well as the size of the tumour 
(Qin et al., 2016). Hsa_circ_002059 (circKIAA0907) is downregulated in gastric cancer 
and is associated with grade and distal metastasis and could therefore be used as a 
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prognostic marker (Li et al., 2015a). Another circRNA, hsa_circ_0000190 
(circDYRK1A), is downregulated in plasma samples of patient with gastric cancer, 
where its expression levels correlated with tumour diameter, lymphatic metastasis, 
distal metastasis (Chen et al., 2017a). Similarly, Hsa_circ_0001895 (circPRRC2B) is 
was also shown to be downregulated in gastric cancer tissues and correlated with cell 
differentiation and Borrmann type (Shao et al., 2017). In hepatitis B infected 
hepatocellular carcinoma (HCC) patients, circRNA_100338 (circSNX27) has been 
shown to regulate levels of miR-141-3p, and its expression correlated with low 
cumulative survival rate and metastatic progression (Huang et al., 2017).   
 
 
1.17 Tools to detect circRNA  
Over the past few years, at least eleven circRNA detection software systems have 
been developed. These tools can recognize circRNA sequence from RNA-Seq data 
based on two different strategies. One approach is the candidate-based, also known 
as the pseudo-reference based approach.  KNIFE, NCLScan and PTESFinder all 
abide by this approach where putative circRNA sequences need to be provided with 
information for gene annotation. Although KNIFE can directly retrieve back-spliced 
junctions prior to gene annotations, the other two softwares generate putative circRNA 
sequences post-alignment with the genome or transcriptome (Jeck and Sharpless, 
2014; Chen et al., 2015; Meng et al., 2017).  
 
CircRNA_finder, CIRCexplorer, DCC, MapSplice, Segemehl, find-circ and 
UROBORUS detect circRNA sequences based on the second approach for 
identification of circRNA sequences which is the fragmented-base or segmented read 
61 
 
approach. In this approach, the software detects back-spliced sites based on reads 
mapped to alignment of multiple split reads against the genome. While find-circ and 
UROBORUS detect back-spliced sequences using the first and last 20 bp after 
mapping the sequences against the genomes, the rest of the detection tools generate 
splice alignment algorithms to identify back-spliced junctions (Jeck and Sharpless, 
2014; Chen et al., 2015; Meng et al., 2017).  Comparisons of the different circRNA 
detection algorithms have now been made, which add information on the relative 
strengths and caveats of these different approaches (Hansen et al., 2016). Searchable 
repositories for circRNA sequences such as circBase  are also now emerging  (Glazar 
et al., 2014), which should prove useful to researchers interested in these RNA 
species in the future.  
 
CircRNA can also be detected indivually using primers designed against the 
backsplice junctions. However, it might be sometimes difficult to amplify using regular 
amplification methods due to the fact that circRNAs may harbour secondary hair-loop 
structures. Moreover, it can make the process cumbersome since each potential exon 
retained withing a circRNA would need to be verified using primers design aginst every 
possible combination of junctions with the succeeding exons. In other cases, the low 
expression of circRNA in samples means samples would have to be treated for 
RNAase R to enrich the circRNA and it is possible that while most will be retained in 




Table 1 Examples of circRNA and their potential role in ageing-related disease. 
CircRNA Pathologic 
condition 
Possible mode of function Potential Application  
Cdr1as hepatocellular 
carcinoma 
May be a sponge for miR-7 Biomarker with the ability to predict hepatic microvascular invasion;  
expressed in hepatocellular carcinoma tissues 
 (Xu et al., 2017a). 
circ-ITCH  hepatocellular 
carcinoma 
May inhibit Wnt/beta-Catenin pathway Potential prognostic marker with the ability to predict survival; expressed 
in hepatocellular carcinoma tissues (Guo et al., 2017). 
circZKSCAN1 hepatocellular 
carcinoma 
May modulate expression of apoptotic genes 
RAC2, EFNA3, and caspase 3 and cell  
proliferation related genes TGFB1, ITGB4, 
CXCR4, BIRC5 and CCND1; may modulate 
promoted cell proliferation, migration, and 
invasion in vitro 
Expressed in tumour tissues (Li et al., 2017b). 
hsa_circ_0058246 gastric cancer   Potential prognostic marker with the ability to predict clinical outcome; 
expressed in tumour tissues (Fang et al., 2017). 
hsa_circ_0001017, 
hsa_circ_0061276 
gastric cancer   Prognostic with the ability to predict disease-free survival; expressed in 





gastric cancer   May predict the early recurrence of stage III gastric cancer after radical 
surgery; expressed in tumour tissues (Zhang et al., 2017).  
circPVT1 gastric cancer May act as sponge for miR-125 family; may 
promote cell proliferation  
Potential prognostic marker with the ability to predict overall survival and 







May act as sponge for miR-7 regulating target 
genes PRKCB, EPHA3, BRCA1 and 
ABCC1;potential role in lung metastasis 









May be involved in response to oxidative 
stress; endocytic traffic in actin cytoskeleton; 
could promote lipid breakdown and increase 
free fatty acid levels; could alter LPS immune 
response 
Potential biomarker  expressed in peripheral blood mononuclear cells 







  Potential biomarker expressed in peripheral blood mononuclear cells 
(Ouyang et al., 2017). 
hsa-circ-0005870 hypertension May at as sponge miRNAs, hsa-miR-6807-3p, 
hsa-miR-5095, hsa-miR-1273g-3p, hsa-miR-
5096 and hsa-miR-619-5p possibly affecting 
TGF-beta pathway important in hypertension 
Potential biomarker  expressed in plasma (Wu et al., 2017).   
hsa_circ_0124644, coronary 
artery disease 












May promote expression of transient receptor 
potential cation channel subfamily M member 
3 by inhibiting hsa-miR-130a-3p 





May act as an inhibitor of miR-221/miR-222 Potential diagnostic biomarker  and expression demonstrated in serum 
(Bazan et al., 2017). 
hsa_circ_0054633 diabetes    Potential biomarker with the ability to predict pre-diabetes and type 2 




1.18 Research Hypothesis 
Given the importance of correct gene regulation in maintaining homeostasis during the 
ageing process, I hypothesised that circRNAs may have roles to play in ageing, 
longevity and in age related diseases such as type 2 diabetes.  
 
1.19 Aim and Objectives of thesis 
CircRNAs have increasingly been implicated in age-related diseases including cancer 
and degenerative disease. They have also been reported as potential prognosis 
biomarkers for various disorders (Table 1). The objective of this thesis is to 
characterise the circRNA portfolio in the peripheral blood of ageing people, and also 
in the pancreatic islets of donors with T2D, as an exemplar disease of ageing. Finally, 
I aimed to determine whether circRNAs associated with T2D in diabetic islets had 
potential as biomarkers of this disorder in human patients. 
 
My objectives were to: 
1) Produce the first circRNA profile in a large cohort of ageing people, and then 
follow up specific circRNA in relation to ageing phenotypes in a human 
population, to cellular senescence in aged human cells of different cell types 
and to median strain lifespan in mouse strains with differing longevity. 
2) Explore circRNA expression in relation to diabetes status and co-localisation to 
the GWAS association signals in the pancreatic islets of donors with T2D, an 
exemplary disease of ageing and in beta cell models subjected to 
diabetomimetic stresses.  
3) To assess the utility of differentially-expressed islet circRNA as biomarkers of   




1.19.1 Chapter 3: CircRNAs expression in human peripheral blood could change with 
age and predict age-related disease outcomes 
The aim of this chapter was to investigate if circRNA expression is deregulated in 
ageing. To address this, we generated the first circRNA profile from samples of pooled 
‘old’ of median age 87 years and ‘young’ of median age 33 years for age-related 
expression differences in peripheral blood RNA samples from the InCHIANTI study of 
ageing, which is a population cohort from the Chianti region of Tuscany, Italy. This 
population has been followed from 1988 until 2014.  I selected the top 15 circRNAs 
showing the most discrepant expression with age for further study in this human 
cohort. 
 
Following this, I investigated if the expression of the circRNAs associated with ageing, 
frailty (measured by grip strength) and longevity as measured by attained parental 
age. I also assessed the differential expression of these circRNAs in vitro model of 
senescence in cells of different origins (fibroblasts, endothelial cells, astrocytes and 
cardiomyocytes), and where bioinformatics evidence of sequence conservation 
existed, in two tissues from 6 mouse strains of different median strain lifespan (A/J, 
NOD.B10Sn-H2b/J, PWD/PhJ, 129S1/SvImJ, C57BL/6J and WSB/EiJ) obtained in 
collaboration with the Jackson Laboratory Nathan Shock Center of Excellence). 
 
1.19.2 Chapter 4: CircRNA expressions islets may be associated with common genetic 
variation at the GWAS loci associated with T2D 
The aim of this chapter was to determine if circRNA expression was also dysregulated 
in chronic disorders of the ageing. I selected T2D as an exemplary disease of the 
ageing and investigated if circRNA expression in islets correlates with T2D status or 
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is driven by the genotype of the lead SNP of previously established T2D-GWAS signal.  
We have generated one of the first comprehensive circRNA profile from human 
pancreatic islets. I identified 13 circRNAs corresponding to 6 genes which co-localise 
to the genomic regions containing T2D-GWAS signals. This led to the hypothesis that 
the expression of these circRNAs may correlate with T2D status and may be driven 
by the variant of the lead SNP of the concerned GWAS recombination window.  
 
I established a tissue expression profile of each circRNA indicating that circRNAs 
could be regulated independently from the corresponding linear mRNAs derived from 
the parental gene.  I examined if the expression of these circRNAs correlated with T2D 
status, the genotype of the lead SNP at the T2D risk loci with which they overlapped 
and stress responses mirroring the diabetic environment in vitro models of diabetes.    
 
1.19.3 Chapter 5: circRNAs expressed in human primary islets may have potential as 
diagnostic markers for T2D 
I have identified 4 circRNAs which are abundantly expressed in human islets and 
display associations with diabetes status. Should these also be expressed in 
peripheral blood, they may serve as novel dagnostics or therapeutic biomarker for 
T2D, since they are stable and have longer half-lives than linear mRNAs. I assessed 
the expression of circRNAs that differed in expression by T2D status in peripheral 












































2.1 Human Samples 
 
2.1.1. Peripheral blood samples 
Samples of RNA and clinical data were available from the InCHIANTI study of ageing 
and the EXETER 10K/DARE study. Details of participant recruitment and follow-up 
procedures have been described in previous studies (Holly et al., 2014; Ferrucci et al., 
2000). The InCHIANTI study is a longitudinal population study from the Tuscany region 
of Italy. Participants were assessed at three follow-up visits (FU2: 2004–2006, FU3: 
2007–2010 and FU4: 2012–2014) after the baseline visit (Ferrucci et al., 2000). Data 
for ageing cohort were generated using the RNA samples from FU3 and the 
clinical/phenotypic data from the assessments at both FU3 and FU4. Clinical and 
demographic data used from the follow-up visits included measurement of potential 
confounding factors such as body mass index (BMI), sex, level of education (none, 
elementary, secondary, high school or university), study site, smoking and white blood 
counts (neutrophil, lymphocyte, monocyte and eosinophil percentages). Informed 
consent for the InCHIANTI study was obtained from all participants and ethical 
approval was obtained from the Instituto Nazionale Riposo e Cura Anziani institutional 
review board, Italy. Characteristics of the participants used for each study are provided 
in the relevant chapter.   
 
The EXETER 10K study was used for chapters 4 and 5. The study consisted of 
samples collected from volunteer individuals recruited since 2010 ans used in previous 
study. They had been living in the South West of England and were predominantly of 
Caucasian British origin. The participants were either non-diabetic, had impaired 
glucose tolerance or were diabetic. Whole-blood samples were collected in 2011/2012 
using the PAXgene system (Debey-Pascher et al., 2009) and extracted using a 
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PAXgene Blood RNA kit (QIAGEN, Paisley, UK). Written informed consent was 
obtained from all participants. Ethical permission was granted through the National 
Institute for Health Research Clinical Facility (REC 09/H0106/75). Patient 
demographics are provided in the relevant chapter. 
 
  
2.1.2 Human islet samples 
RNA samples from islets RNA extractions done by RNAlater-ICE and ProCell Biotech 
for snap-frozen islets purchased from (Newport Beach, CA) or from the Integrated Islet 
Distribution Program islet repository (https://iidp.coh.org). RNA extraction was done 
using the miRVana isolation kit (ThermoFisher Scientific, USA). The protocol is 
discussed later in this section.  
 
 
2.2 Primary cultures of in vitro models of senescence  
Primary cultures with four different origins have been used to study the role of 
circRNAs in senescence as a substitute in vitro model to understand the ageing 
process. The primary cultures were generated from cells that were directly obtained 
from tissue or organs via dissection(“Primary Culture - an Overview | ScienceDirect 
Topics” n.d.). Thus, they provided a physiologically relevant tool reflecting the in vivo 
microenvironment with minimal culture variability. The cells I worked with in chapter 3 
had undergone senescence and RNA extraction before the onset of my work by Dr 




2.3 Culture protocols for cellular senescence 
Human senescent cell culture had been previously carried out by Dr Alice Holly and 
Dr Eva Latorre, as described in the following publications (Lye et. al. 2019; Latorre et 
al., 2017a; Latorre and Harries, 2017; Latorre et al., 2018). β-Gal staining on 
senescent cells was performed by Dr Eva Latorre. Each culture requires a different 
time period to reach senescence. For instance, endothelial cells attain confluency 
within 3 days in early passages but 10 days in late passages, while fibroblasts slow 
from 4–27 days. To obtain senescence, cells were counted and equal numbers of cells 
seeded at each passage. Each passage was then grown continuously at the 
respective optimal conditions until growth slowed to <0.5 population doubling/week. 
Briefly, the cells were fixed, washed in phosphate-buffered saline (PBS) and stained 
with freshly prepared staining solution, which resulted in blue precipitation in cells. 
Cells were then washed again with PBS and evaluated by light microscopy. SA β-Gal-
stained cells were stored in mounting medium such as glycerol instead of PBS if they 
were to be visualized by microscopy at a later date.  
 
 
2.4 Cultivation of EndoC βH1 cells as an in vitro model to study T2D 
Human EndoC-βH1 cultured cells (EndoCells, Institut national de la santé et de la 
recherche médicale, France) were used as an in vitro model to dissect the potential 
role of circRNAs in T2D. The treated RNA was available from cultured EndoC-βH1 
human beta cells subjected to different diabetomimetic stresses was provided by Dr 
Nicola Jeffery. The cell line, which was derived from human foetal pancreas, was 
transduced with a lentiviral vector expressing an oncogene that is under the control of 
the insulin promoter. The cells were then transduced with human telomerase reverse 
transcriptase and grafted into severe combined immune-deficient (SCID) mice to 
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generate pancreatic tissues. The grafted and differentiated human β-cells expressed 
a Simian Vacuolating Virus 40 Tag (SV40LT) alongside insulin and formed 
insulinomas. These insulinomas were transduced with a lentiviral vector expressing 
human telomerase reverse transcriptase and once again transplanted into other SCID 
mice to amplify proliferating β-cells. The tissues were then removed from the mice and 
expanded via in vitro culture to generate immortalized EndoC βH1 cultures. The 
cultures are stable for at least 80 passages, express many β-cell specific markers and 
secrete insulin, especially in response to glucose stimulation (Ravassard et al., 2011). 
 
EndoC-βH1 cells (Endo Cells, INSERM, France) were generated in extracellular 
matrix (ECM)-coated (2 μg/mL, Sigma-Aldrich, Steinheim, Germany) yellow-capped 
T25 flasks (Sarstedt, Nümbrecht, Germany) containing culture media consisting of 
Dulbecco's Modified Eagle's medium (DMEM)  (4.5 g/L, ThermoFisher Scientific, 
Waltham, MA, USA) and matrigel fibronectin (100 μg/m from bovine plasma, Sigma-
Aldrich, Steinheim, Germany). The EndoC-βH1 cells were then cultivated in culture 
media containing DMEM (1 g/L glucose, ThermoFisher Scientific, Waltham, MA, USA), 
Bovine Serum Albumin (BSA) fraction V (2% Merck Chemicals, Darmstadt, Germany), 
nicotinamide (10 mM, Sigma-Aldrich, Steinheim, Germany), β-2-mercaptoethanol (50 
μM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), penicillin (100 U/mL) and 
streptomycin (100 μg/mL, Sigma-Aldrich, Steinheim, Germany) at 37°C with CO2. 
After 3 days, 50% of the culture medium was replaced with fresh medium and cells 
were split when they reached ~90% confluency. Cells were treated to glycaemic, 
lipotoxic, cytotoxic and hypoxic stress as described in a recent study from our group 
(Jeffery et al., 2019). The treated EndoC βH1 cells were used for the generation of 
partial data for chapter 4 of the current project.  
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2.5 Peripheral blood RNA extraction 
Whole-blood samples for RNA analysis were collected using the PAXgene system 
(Debey-Pascher, Eggle and Schultze 2009). The PAXgene Blood RNA Tube (BD 
Biosciences), which contains stabilization reagents to maintain transcript levels at the 
level they were at the time of bleed. This minimizes handling variability without 
impacting intracellular RNA profiles and the integrities of the RNAs for downstream 
workflows. Since the PAXgene system stabilizes intracellular RNA in blood for 3 days 
at room temperature and for 5 days at 2–8°C, it allows for fluctuations in room 
temperature to up to 25°C during transportation. Additionally, variability is minimized 
because all of the steps prior to RNA extraction, i.e. collection, stabilization, transport 
and storage, are executed in a single tube that is used to draw blood samples from 
subjects. 
 
For this study, PAXgene tubes were shipped on dry ice. Samples were then stored at 
ultra-low temperatures for later use. For RNA extraction, samples were thawed for at 
least a few hours. Supernatants were removed following centrifugation and 
ribonuclease (RNase)-free water was added to pellets. Successive centrifugation 
ensured the removal of more supernatant. Addition of lysis buffer lysed the cells and 
an automated QIAcube system was used to manage the subsequent stages of 
proteinase K incubation to digest proteins, further fragmentation of cell debris using a 
PAXgene shredder column and the addition of ethanol to facilitate the precipitation of 
nucleic acids. A PAXgene RNA spin column (Qiagen) was then used to sieve the RNA. 
The column was washed followed by DNase I treatment to eliminate DNA, and RNA 




2.6 RNA extraction from mouse tissues 
Stocks of spleen and skeletal muscle RNA from young and old mice from six different 
strains was available. These strains (A/J, NOD.B10Sn-H2b/J, PWD/PhJ, 
129S1/SvImJ, C57BL/6J and WSB/EiJ) had varying median strain lifespans (623–
1005 days), and RNA was originally extracted by Dr Ben Lee. These samples have 
been verified by the. These tissue samples were kindly provided by the Jackson 
Laboratory Nathan Shock Center of Excellence and were shipped using the snap-
frozen RNAlater-ICE Collection protocol (Life Technologies, Carlsbad, CA). The 
basic principle of the SNAP-frozen procedure involves freezing RNA samples at -
196C in liquid nitrogen. The RNAlater RNA stabilization solution contains 
ethylenediaminetetraacetic acid (EDTA), sodium citrate and ammonium sulphate, all 
of which can penetrate cells rapidly and inactivate RNases to prevent the degradation 
of RNA. The samples can stay stable for 1 week at room temperature and pressure. 
The dissected tissues samples were immersed in this solution and then snap-frozen. 
The snap-frozen samples were stored at -80C and later shipped in dry ice. The 
samples were then stored at -80C until they were defrosted for RNA extraction.   
 
TRI Reagent was used to extract RNA from mouse tissues using the 
phenol:chloroform principle. TRI Reagent, i.e. TRIzol, is composed of phenol and 
guanidium isothiocyanate (RNA work and RNA qauntification was done by Dr Ben 
Lee). It lyses cells, denatures proteins and eliminates RNases, thus preventing the 
degradation of many RNA entities. Chloroform added to the supernatant facilitates 
phase separation, which means that RNA is confined to the aqueous phase, protein 
to the organic phase and DNA to the interface between the two. This facilitates the 
isolation of RNAs, DNAs and proteins from each same sample simultaneously. In this 
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protocol, MgCl2 in the protocol stabilizes long RNA to interact with smaller RNA, and 
this enables enriched extraction of smaller RNA entities and enhances the recovery of 
small RNAs by stabilizing the phosphate backbones of the RNA entities (Hummon et 
al., 2007). The reagent also inhibits RNases and allows the segregation of RNA into 
the aqueous layer.  Beads added with the magnesium buffer are used to homogenize 
tissue samples. The centrifugation step helps to separate the phases containing RNA 
from that containing DNA. Overnight incubation with isopropanol at -20C aids 
precipitation of the RNA. The final ethanol washes remove any residue reagents. The 
washed pellets are then suspended in Tris-EDTA (1x TE) buffer or RNase-free water 
and stored at -80C for future use.  
 
Briefly, RNAlater tissues were placed in TRI Reagent® solution containing MgCl2. 
Samples were homogenized using a bead mill (Retsch Technology GmbH, Haan, 
Germany) followed by phase separation using chloroform. Total RNA was precipitated 
from the aqueous phase through overnight incubation with isopropanol at −20°C. RNA 
pellets were then ethanol‐washed, re-suspended in RNase‐free dH2O and stored at -
80°C for later use. 
 
 
2.7 RNA extraction from donor islets  
Islet RNA extractions were originally carried out by Dr Jonathan Locke. RNAlater-ICE 
was used to ship some samples of islet cells, while other donor islet samples were 
shipped in the form of snap-frozen islets purchased from ProCell Biotech (Newport 
Beach, CA) or from the Integrated Islet Distribution Program islet repository 
(https://iidp.coh.org). Snap freezing involves the rapid freezing of tissues using either 
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dry ice, a dry ice/ethanol slurry or liquid nitrogen. The process maintains the integrity 
of samples by reducing the chances of water being present in cells and tissues, thus 
preventing the formation of ice crystals during the freezing process, and by reducing 
the activities of proteases and nucleases in samples, which would otherwise lead to 
extensive degradation of RNA or proteins.  
 
Islet samples harvested as above can later be used for total RNA extraction using the 
miRVana isolation kit. The protocol involves the use of organic acid-phenol:chloroform 
extraction and a glass fibre filter under specialized binding to efficiently isolate RNA 
entities as small as 10-mers (ThermoFisher Scientific, USA). Samples are first 
denatured with lysis buffer. Ethanol is then added and the samples filtered through a 
cartridge containing a glass filter that immobilizes the RNAs. The filter is then washed 
a few times and the RNA eluted with a low-ionic-strength solution.  
 
 
2.8 RNA extraction from cultured cells  
Confluent cell cultures were seeded in 6-well plates and grown in their optimal culture 
conditions unless otherwise mentioned. RNA was extracted using TRI Reagent®. 
Briefly, cells were washed twice with 500 mL Dulbecco’s PBS. TRI Reagent® (Sigma-
Aldrich, Steinheim, Germany), MgCl2 (10 μL, ThermoFisher Scientific, Waltham, MA, 
USA) and chloroform (200 μL, ThermoFisher Scientific, Waltham, MA, USA) were then 
used to harvest RNA. Samples were centrifuged at 14,800 rpm at 4°C for 20 min. The 
clear aqueous layer was removed from the centrifuged samples and isopropanol (500 
μL, ThermoFisher Scientific, Waltham, MA, USA) was added for overnight 
precipitation. Precipitated samples were centrifuged at 14,800 rpm at 4°C for 45 min 
to allow RNA pellet formation. The pellets were then repeatedly washed using ethanol 
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(75% molecular grade, ThermoFisher Scientific, Waltham, MA, USA). The washed 
pellets were air dried, resuspended in RNase-free dH2O (20 µL, Fisher Scientific, New 
Hampshire, USA) and stored at -80°C for later use. Diluted samples were used to 
determine the RNA concentration using a Bionalyzer. RNA used in this work was 
extracted by Dr Nicola Jeffery. 
 
 
2.9 cDNA synthesis from cell cultures, tissues and islets  
RNA is a single-stranded unstable molecule that is used to quantify the expression of 
transcripts by quantitative PCR (qPCR). RT-PCR allows the amplification of RNA to 
complementary DNA (cDNA) from an original RNA template using genetically 
engineered reverse transcriptase. The SuperScript® VILO™ cDNA synthesis kit 
contains a reaction mix containing random primers, MgCl2 and deoxyribonucleotide 
triphosphates (dNTPs) in its buffer. It also includes an RNAseOUTTM recombinant 
RNase inhibitor, and a genetically modified Moloney Murine Leukaemia Virus enzyme 
(reverse transcriptase) that has reduced RNAse H activity and high thermostability for 
highly efficient cDNA synthesis at a wide range of temperatures (42–60°C). The 
enzyme is not inhibited by rRNA or tRNA. Thus, it allows the use of total RNA to make 
cDNA. The reduced RNase H activity means that the RNA from the RNA–DNA hybrid 
is not rapidly degraded. The RNase inhibitor is a non-competitive inhibitor protein that 
protects against RNase A-, RNase B- or RNase C-mediated degradation of RNA. The 
protocol facilities cDNA synthesis with as little as 2.5 µg of total RNA in a 20-µL 
standard reaction. The RNAseOUTTM recombinant ribonuclease inhibitor prevents 
degradation of the template RNA, which might occur in the presence of ribonuclease 




In the first step, an RNA–DNA hybrid is generated. The reverse transcriptase RNase 
H degrades the RNA from the RNA–DNA hybrid. The single-stranded DNA strand is 
then extended to a cDNA by the DNA-dependent DNA polymerase activity of the 
reverse transcriptase. This cDNA is then used as a template in subsequent steps for 
amplification like a normal PCR. 
 
RNA was normalized during all the reverse transcription as the concentrations of RNA 
were adjusted to 100 ng/μL before using them as template for reverse transcription.  
cDNA synthesis was carried out with random primers and dNTPs, as recommended 
by the SuperScript® VILO™ cDNA synthesis kit protocol, for the study of the islet 
samples and the generation of data for tissue panels (ThermoFisher Scientific, 
Waltham, MA USA). The reaction mix contained SuperScript® (2.0 µL), VILO™ buffer 
(4.0 µL), dH2O (Fisher Scientific New Hampshire, USA) and 100 ng/μL RNA in a final 
reaction volume of 20 μL. Reaction conditions were 25°C for 10 min, 42°C for 60 min 
and 85°C for 5 min.  
 
Like the VILO™ kit, the enzyme mix in the EvoScript kit contains a Protector RNase 
inhibitor alongside the reverse transcriptase enzyme. The reverse transcriptase can 
execute cDNA synthesis at high temperatures and over a broad range of 
temperatures. However, the EvoScript reverse transcriptase has RNase activity, which 
facilitates degradation of the RNA from the RNA–DNA hybrid and allows PCR primers 
to bind easily to the cDNA. This is why the enzyme has to be added as the last reagent 
when using this kit for RT. Additional reagents include a reaction buffer containing 
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random primers, oligo(dT)18, dNTPs and Mg(OAc)2. The oligo(dT)18 allows the efficient 
synthesis of cDNAs from RNA templates with difficult secondary structures. 
 
cDNA synthesis was performed with the EvoScript kit using Universal cDNA master   
mix (Roche Life Science, Burgess Hill, UK). Samples were normalized to 100 ng/μL 
RNA prior to RT. Similar to the VILO™ kit, the enzyme in this kit is also thermostable 
during the high-temperature denaturing step. However, as mentioned earlier, the 
enzyme mix does have RNase activity. Therefore, the enzyme was added last to avoid 
digestion of the sample. Cycling conditions were 42C for 30 min and 85C for 5 min 
and 65C for 15 min.  
 
 
2.10 High-capacity cDNA synthesis  
RT is the process by which single-stranded cDNA is synthesized and amplified in a 
qPCR from template RNA with the help of a reverse transcriptase enzyme. The High-
Capacity cDNA Reverse Transcription Kit facilities the quantitative conversion of as 
little as 0.2–2 µg of total RNA to high-quality, single-stranded cDNA in a single 20-µL 
reaction.  
 
cDNA synthesis was carried out using the High-Capacity cDNA Reverse Transcription 
Kit containing RT buffer (1.0 µL of 10x RT buffer), dNTPs (0.4 µL of 25x dNTPs), RT 
random primers (1.0 µL of 10x RT random primers), nuclease-free dH2O (2.4 µL, 
Fisher Scientific, New Hampshire, USA) and RNA (5.0 µL) in a final reaction volume 
of 10.0 µL per sample. Reaction-containing samples in 96-well plates were run at 25°C 
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for 10 min, 37°C for 120 min and 85°C for 5 min, followed by an inactivation period at 
95°C for 10 min.  
 
 
2.11 CircRNA probe design 
Custom-designed RT-qPCR assays for the quantification of relative expression were 
designed for unique backspliced circRNA junctions (ThermoFisher Scientific, Foster 
City, USA). Each target sequence was checked for the presence of single nucleotide 
polymorphisms (SNPs) in potential primer- or probe-binding regions prior to ordering. 
Assays were shipped in custom single tubes from ThermoFisher Scientific (Foster 
City, USA). For the mouse studies, sequences were first assessed for species 
conservation by alignment of human backspliced junctions to the mouse genome 
using the University of Santa Cruz genome browser (https://genome.ucsc.edu). Those 
predicted to have conserved backspliced junctions in humans and rodents were taken 
forward for analysis in mouse models of ageing.  
  
 
2.12 Pre-amplification of template cDNA 
Since circRNAs are often expressed at low levels, it can be difficult to detect the 
differential expression of these entities from the minute amounts of RNA or cDNA that 
are used for downstream high-throughput expression protocols like open arrays. Pre-
amplification allows the enrichment of limited amounts of RNA samples, while keeping 
gene expression profiles unaltered by retaining the relative copy numbers of the 
starting target cDNA sequences. Up to 100 targets can be pre-amplified 
simultaneously using pooled assays of target TaqMan® gene expression assays with 
as little as 1–250 ng of cDNA samples. A standard real-time PCR reaction starts with 
80 
 
RT of total RNA using random primers, and is followed by real-time PCR using gene-
specific primers and probes. In contrast, the TaqMan® PreAmp amplification protocol 
incorporates an intermediate step between RT and real-time PCR, through which the 
cDNA is enriched 1000–16,000-fold through a pre-amplification reaction for 10–14 
cycles. The resulting pre-amplified cDNA samples can be diluted and used as starting 
templates for subsequent high-throughput singleplex real-time PCRs with pools from 
each TaqMan® assay.  
 
Intially pre-amplification was done on few random samples using 1, 2.5 and 5 ng/µL 
of RNA in a 10 µL reaction, each of which was diluted to 1:10, 1:15 and 1:20 dilutions. 
qPCR was using housekeeper genes to detect the optimum cDNA quantity and 
concentration to achieve comparable Ct. This indicated 2.5 ng/µL at the dltuion of 1:10 
to be optimum template for pre-amplification.  Pre-amplification was carried out in 96-
well plates using the TaqMan® PreAmp Master Mix (5 µL of 2x mix, ThermoFisher 
Scientific, Waltham, MA, USA), pooled assay mix (2.5 µL, Thermo Fisher) and cDNA 
(2.5 µL) in a final reaction volume of 10 µL per sample. cDNA input was already 
normalized since 2.5 µL was used in this step from a 20 µL revrese transction 
reachtion mix each containing 100ng of RNA as described earlier. Reactions were run 
at 95°C for 10 min with 14 cycles consisting of 95°C for 15 sec and 60°C for 4 min, 
followed by 95°C for 10 min. Deactivation was performed for 10 min at 85C to 
minimize variability in Ct values, as the pre-amplified products were used for 




2.13 Quantitative expression assays using RT-qPCR  
RT-qPCR is a process by which gene expression can be assessed based on the 
relative input of cDNA reverse transcribed from RNA samples. RT-qPCR allows the 
quantitative detection of amplified products at the end of each PCR cycle. The assays 
used to conduct RT-qPCR contain PCR primers and oligonucleotide probes, which 
are short oligonucleotides that are complementary to a target sequence on the 
template amplicon. TaqMan® probes are dual-labelled hydrolysis probes that contain 
a reporter dye like fluoresceins FAMTM or VICTM at the 5’ end, and a minor-groove 
binder (MGB) moiety containing a non-fluorescent quencher at the 3’ end. The MGB 
stabilizes the binding of the probe to the complementary target amplicon and increases 
the melting temperature without requiring a longer probe. This results in low 
background fluorescence and a higher specificity of amplification can be attained using 
shorter oligonucleotide probes. 
 
Initially, a high temperature of 95C denatures the double-stranded cDNA. When the 
temperature is lowered in the next step to 60C, primers and probes anneal to the 
target sequence. When the probe is intact, there is no emission from the reporter dye. 
As primers at both ends of the target execute extension, the 5’ Taq DNA polymerase 
cleaves the reporter from the probe at the 5’–3’ exonuclease cavity causing the 
separation of the 5’ fluorophore and the 3’ quencher moieties linked to the probe. This 
results in the emission of a fluorescent signal from the reporter dye when the enzyme 
reaches the TaqMan probe. The fluorescent signal thus emitted is proportional to the 
number of probes cleaved and hence the number of amplicons amplified in a given 
cycle. This in turn reflects the amount of input RNA that was reverse transcribed to 
cDNA. Removal of the probe from the target strand also allows the completion of 
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primer extension. With subsequent PCR cycles, additional reporter dye molecules are 
cleaved resulting in an increase in fluorescence intensity that is proportional to the 
number of amplicons produced. High expression indicates that a greater amount of 
the starting copy number cDNA template is present in the sample. A greater amount 
of template cDNA causes an increase in fluorescence to be detected over a shorter 
period of time. As a result, more and more dye molecules are proportionately released 
in the exponential phase.  
 
Quantification of the expression of target genes is done by real-time RT-qPCR, using 
template cDNA that has been reverse transcribed from RNA extracted from sample 
tissues and cells. TaqMan® assays, i.e. oligonucleotide probes designed against target 
sequences or the backspliced junctions of circRNAs, hybridize to template cDNAs and 
stimulate the DNA polymerase enzyme to add dNTPs. MgCl2 in the reaction mix acts 
as a cofactor for the Taq polymerase to allow the annealing of primers, and the 
removal of phosphates from the dNTPs for the formation of phosphodiester bonds 
between 3’ OHs of adjacent nucleotides and 5’ phosphates of subsequent nucleotides.  
 
The TaqMan® assays, as described earlier for RT-qPCR, comprise a fluorescent 
fluorophore reporter at the 5’ end and a quencher fluorophore at the 3’ end, probes 
and primers. The reporter most commonly used is FAM™, which emits a green 
fluorescence signal, and the quencher is Black Hole Quencher Dye 1. An ideal target 
sequence for amplification should be 75–200 bp to prevent primer dimer formation, 
have 50–60% GC content and have no secondary structure. Primer design should 
take these factors into consideration and ensure that the melting temperature is 
between 50 and 66C. In addition, primers should not be designed against secondary 
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structures or long repeats of G/C, the 3’ ends of the primer pairs should not be 
complementary to avoid primer dimer formation and, where possible, G/C should be 
at the ends of the primers. The probe should ideally be <30 bp in length and have a 
melting temperature 5–10C above that of the primers. The probe should ideally have 
30–80% GC content, and more Cs than Gs so that the target sequence has more Gs 
than Cs. Additionally, it should not have G at the 5’ end as this quenches the 
florescence signal even after hydrolysis has taken place.  
 
Uracil-DNA glycosylases (UNGs) are a superfamily of six enzymes that are named 
after the uracil-N-glycosylase gene. They are well-preserved DNA repair enzymes that 
eliminate uracil incorporated in DNA/cDNA. They remove uracil from single- or double-
stranded dU-containing DNA by catalysing hydrolysis of the N-glycosylic bonds 
between uracil residues and sugars. UNG activation allows the degradation of 
misprimed or non-specific products, resulting in the existence of only nucleic acid 
templates intended for PCR amplification in samples. However, UNGs cannot be fully 
heat deactivated and can degrade amplified products. They can also be inactivated 
during 50–55C RT steps during RT-PCR. Thus, they are not able to eliminate or 
degrade dU bases from the first cDNA strands synthesized during RT-PCR. Therefore, 
UNG-containing reaction mixes were not used in the course of this research project. 
 
RT-qPCR was performed to assess the expression of target genes and circRNAs. The 
reaction mixes used for RT-qPCR included TaqMan® Universal PCR mastermix II (2.5 
μL, no AmpErase® UNG) (ThermoFisher Scientific, Waltham, MA, USA), dH2O (1.75 
μL, Fisher Scientific, USA), cDNA (0.5 μL) and TaqMan® gene assay (0.25 μL, 
ThermoFisher Scientific, Waltham, MA, USA) in 5 μL final reaction volumes. The 
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reaction mixes were centrifuged at 3000 rpm, vortexed and centrifuged again at 3000 
rpm, and then transferred to 384-well qPCR plates. qPCR was run at 50°C for 2 min, 
95°C for 10 min and 50 cycles each consisting of 15 s at 95°C, 30s and 1 min at 60°C. 
Samples assays were conducted in triplicate. To ensure quality control for RT-qPCR, 
‘no template control’ was used for each assay in every qRT-PCR run. In addition, three 
endogenous control genes were used to normalize candidate transcript Ct value 
relaive to the the three housekeeping genes for each experiment.  
 
2.14 High-throughput expression assays using OpenArray®  
The TaqMan® OpenArray® allows high-throughput expression profiling of as many as 
3072 reactions on each plate. Four such plates can be run simultaneously. Each of 
these plates harbours 48 subarrays containing 64 300-μM wells, which each have 
hydrophilic and hydrophobic coatings to ensure that the small amounts of reaction mix 
are confined to their respective wells. The reaction mixes are loaded onto the plates 
by a robot, which is immediately followed by each plate being sealed with oil to prevent 
evaporation of samples from the arrays (ThermoFisher Scientific, Waltham, USA).  
 
High-throughput expression of circRNAs was assayed using 2x OpenArray® Real-
Time Master mix (2.5 µL, ThermoFisher Scientific, Waltham, MA, USA), diluted pre-
amplified cDNA (1.2 µL) and RNase-free dH2O (1.3 µL, Fisher Scientific, USA) on 
custom OpenArray® plates (ThermoFisher Scientific, Waltham, USA). The resulting 






2.15 Relative quantification using RT-qPCR  
During RT-qPCR, an algorithm allows threshold cycle Ct, which reaches beyond the 
baseline of the reference dye for each sample, to be measured during the exponential 
phase of the PCR cycle. In this phase, the PCR product doubles efficiently and is 
directly proportional to the amount of template cDNA. Therefore, in this phase, the 
increase in the reporter’s fluorescence signal is directly proportional to the number of 
amplicons generated. As the qPCR reagents continue to be consumed, the reaction 
tends to slow and transitions to a linear phase. At this stage, amplification ceases to 
double at each successive cycle, until it reaches the endpoint or plateau stage when 
the reaction halts. When a PCR reaction starts, Taq polymerase digests the 
oligonucleotide probe at the 5’ end, and cleaves the quencher from the 3’ end once 
the template cDNA has been duplicated or elongation is complete (ThermoFisher 
Scientific, Waltham, USA). This allows the FAM™ reporter to fluoresce. The 
fluorescence signal can be detected by the optical media of QuantStudio12.0 at each 
cycle. This allows quantification of expression at each subsequent cycle. The Ct value 
relating to the fluorescence signal is then used to relatively quantify gene or circRNA 
expression. The Ct value is the number of the PCR cycle when fluorescence has 
increased beyond the background signal and, inversely, relates to the exponentially 
amplified cDNA. It represents the comparative levels of RNA in the original non-
reverse-transcribed RNA samples. A low Ct value signifies a high amount of initial 
template cDNA and therefore higher expression, and vice versa. Relative 
quantification of gene expression in any given sample is assessed by the comparative 
Ct method, in which expression is compared relative to a set of reference 




The ΔΔCt method was used to determine relative expression throughout this thesis 
(Livak and Schmittgen 2001; Rutledge 2004; Schmittgen and Livak 2008). Although 
relative expression can be assessed relative to the means of endogenous 
housekeeping genes, expression was assessed relative to the global geometric mean 
of the entire set of transcripts. Throughout this project, the geometric mean across all 
transcripts for each sample was used for the initial normalization of ΔCt. The 
expression of each individual circRNA was normalized to the global mean of 
expression of each circRNA across the samples throughout this thesis, since 
expression of the housekeeping genes was not stable.  
 
As mentioned earlier, the threshold Ct, at which florescence is above the background 
fluorescence for each transcript but within the exponential phase of the amplification 
curve in qPCR, can be used to determine the relative fold-change or relative 
quantification of one sample compared to another. The Ct values of endogenous 
control or housekeeping genes were used as the first filter for the normalization of 
gene expression for each sample because these genes are thought to display stable 
expression under varying conditions, since they are needed for key fundamental 
processes such a survival. RefFinder online software was used to determine if 
housekeeping genes were the most stable (https://www.heartcure.com.au/reffinder/). 
Throughout the course of this project, geometric means across all transcripts for each 
sample were used for initial normalization. ΔCt was calculated by subtracting the 
geometric mean from the Ct value of each transcript for a sample. The ΔΔCt was next 
calculated by subtracting the ΔCt of a sample compared to the median ΔCt of a control 
group. Since the Ct was collected in the exponential phase, a transformation of ΔΔCt 
to 2_ ΔΔCt transforms this relative change in cycle number, i.e. CT, into a fold-change 
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representing the doubling during the PCR phase of the qPCR. Data were transformed 
to ensure a normal distribution where samples numbers were high and outliers were 
removed based on the z-scores beyond ±3 standard deviations (SPSS, IMP, USA). 
 
 
2.16 Statistical Analysis  
Multivariate linear regression analysis was carried out to assess the association of 
expression of circRNA in the peripheral blood with age and ageing-related outcomes 
using StataSE15 (StataCorp, Texas, USA). In the multivariate regression model, 
adjustments were made for potential confounders like BMI, sex, level of education 
(none, elementary, secondary, high school or university), study site, smoking and 
white blood counts (neutrophil, lymphocyte, monocyte and eosinophil percentages). 
Age was additionally adjusted for all other measures of association, i.e. hand grip 
strength and parental longevity score. Statistical analysis was completed using 
StataSE15 (StataCorp, Texas, USA).  
 
Differential expression of circRNA, in vitro cultures of senescent cells and treated 
EndoC βH1 cells were assessed by one-way analysis of variance ANOVA using 
StataSE15 (StataCorp, Texas, USA). Any potential correlation of expression level was 
then correlated with diabetic status (no diabetes or impaired glucose intolerance i.e. 
IGT, T2D or overt diabetes) and islet genotypes were assessed by one-way ANOVA 
using StataSE15 (StataCorp, Texas, USA). Adjustment was made for potential 





2.17 Generation of a circRNA profile using RNA-Sequencing  
The first step in RNA-Sequencing (RNA-Seq) is to construct a strand-specific library 
from total RNA that can be treated to remove rRNAs, poly(A) mRNAs or small RNAs, 
depending on the target research question. While poly(A) pull-down RNA-Seq libraries 
are used for mRNA transcriptome profiling in most cases, ribosomal-depleted or total 
RNA libraries are mostly used for circRNA profiling (Barrett and Salzman, 2016). To 
retain the transcriptional direction include direct ligation of RNA adaptors before RT, 
direct ligation of DNA adaptors to single-stranded cDNA, RT of in vitro poly(A) RNA 
fragments followed by intramolecular ligation, and the incorporation of dUTP during 
second-strand synthesis and digestion with uracil-N-glycosylase. (Podnar et al., 
2014). Poly(A) mRNA removes ncRNAs and therefore retains information on protein-
coding genes. On the other hand, removal of rRNA allows enrichment of poly(A) 
mRNAs, ncRNAs, and intermediates or by-products of RNA biogenesis, but demands 
complicated downstream analysis (Podnar et al., 2014). A comparison of RNAse R- 
and rRNA-treated samples can yield evidence of real circRNA enrichment (Barrett and 
Salzman, 2016).  
 
The first step in library preparation is fragment size selection depending on the RNA 
species to be investigated. The next generataion sequencing (NGS) platform can 
analyse millions of short fragments ranging from 25–450 bp in a single run, allowing 
data outputs of up to 50 GB (Mutz et al., 2013). The read depth varies according to 
the platform used. For example, the Illumina platform can allow read lengths of 30–
100 bp (Marguerat and Bähler, 2010). The target library insert length is achieved by 
time-controlled heated digestion of RNA in the presence of magnesium or zinc cations 




Once the RNA fragments are generated, end repair is executed by blunting the ends. 
They are then phosphorylated at their 5’ ends, as well as A-tailed at their 3’ ends to 
permit the ligation of adaptors, and purified using beads (Head et al., 2014; Podnar et 
al., 2014). The final library always consists of fragments ligated to ~120-bp adaptors 
at their 5’ and 3’ ends, and this step is followed by the hybridization of an RT primer to 
allow RT (Podnar et al., 2014). The library is then fed onto beads or into flow cells to 
allow fragments to hybridize on the flow cell surface, and amplified as a clonal cluster 
through bridge amplification by PCR to amplify the cDNA (Podnar et al., 2014; 
Marguerat and Bähler, 2010). Adaptor dimers and other artefactual by-products are 
generally cleaned up using beads or agarose gels (Head, 2015). In order to compare 
differential expression between groups or samples, different barcoded adaptors are 
used in each sample or are introduced using barcoded PCR primers during PCR 
amplification (Head et al., 2014).  
 
NGS technology involves fluorescent signals being emitted at each sequencing cycle, 
when bases matching the template sequence are incorporated into the sequencing 
reaction. These signals are converted from raw outputs to short base-read sequences 
in FASTQ format in the form of images by base-calling algorithms. These images of 
short sequences are used for base calling in downstream analysis (Podnar et al., 
2014). The sequences are aligned to a reference genome as transcriptome data are 
not easily available. Spliced read-mapping software splits unmapped read fragments 
and aligns them independently, in order to take into account genomic intron–exon 




RNA-seq library preparation was done by Dr Karen Moore and RNA-seq analysis was 
performed by DR Ryan Ames as described below. To generate a circRNA profile, we 
subjected our samples to ribosomal removal and RNase R treatment to exclude linear 
mRNAs. In this study, circular RNA profiles were generated using a modified 
‘CircleSeq’ procedure (Lopez-Jimenez et al., 2018), carried out by the Exeter 
sequencing service. Circle-Seq involves RNase R treatment of the samples before the 
library preparation to eliminate linear RNAs leaving the circRNAs intact. However 
higher amount of total RNA is needed in this protocol. So, in addition rRNA-depletion 
is done for high-throughput sequencing after which reads are directly mapped to de 
novo genomic positions to identify backspliced reads. Breifly, the RNA samples were 
in BR5 buffer containing RNAse inhibitor. Riborsomal RNA was removed using rRNA 
depletion magnetic beads (Illumina Ribo-Zero, Illumina, Inc., USA) which bind 
rRNA.  The remaining cirRNA and mRNA was concentrated using RNAClean beads. 
The samples were cleaned using RNAClean beads in order to remove this buffer and 
replace with for water before moving to the next step of RNAseR digestion since the 
BR5 buffer with inhibitor would otherwise limit the RNAseR lead digestion of linear 
transcript.   The quality of the cleaned and concentrated RNA was checked on the 
Tapestation before digestion. This method is an enriched bias-free unlike a candidate-
based approach and permits the identification of novel circRNAs. This is because this 
approach additionally allows the alignment by considering the two terminations of a 
single read for mapping them separately based on the backsplice properties of the 





Figure 8 Steps for the preparation of sample for RNA-Seq. Samples are prepared 
from total RNA for enrichment of circular RNAs with RNAse R treatment after 
ribosomal depletion for sequencing processing and subsequently data analysis. 
(López-Jiménez, Rojas, and Andrés-León 2018).  
 
 
Each RNA sample was divided into two aliquots. One aliquot was treated with RNAse 
R (Epicentre, Madison, USA) at 30C for 30 min to remove linear RNA, while the other 
was treated with RNase-free water as a mock-treated sample. Both aliquots were 
cleaned and concentrated using RNA Clean beads (Beckman Coulter, Indianapolis, 
USA) to remove RNAse R. The high sensitivities of RNA samples were confirmed with 
screentape (Agilent, Santa Clara, USA). rRNA was removed, and the concentrations 
of indexed sequencing libraries determined by qPCR and adjusted for size using 
Tapestation D1000 analysis (Agilent, Santa Clara, USA). Libraries were denatured, 




2.18 Analysis of circRNA profiles 
In our study, RNase R and mock-treated sequence data were assembled against the 
reference human genome (hg19), and putative circular RNAs were identified using 
PTESFinder (Izuogu et al., 2016) using Tophat v2.1.0 with pre-set sensitive alignment 




(PTES) is a term used to describe RNA entities that harbour unusual splice junctions 
(Izuogu et al., 2016). PTESFinder analyses reads that fail to fully map to reference 
sequences. It splits such unmapped reads in to two or more segments, and aligns the 
split reads to unlock the rearranged splice junctions by genome-wide alignment or by 
comapring the two paired-end reads that map in an unusual configuration to reference 
transcriptomes (Izuogu et al., 2016).The numbers of reads mapping to each exon of 
each gene were calculated using FeatureCounts v2.0.0 (Liao et al., 2013; Liao et al 
2014). In addition to circular RNA detection using PTESFinder, reads from all samples 
were also mapped to the human genome reference (hg19) obtained from iGenomes 
using Tophat v2.1.0 with the pre-set sensitive alignment parameters in paired-end 
mode (Trapnell et al., 2009). The number of reads mapping to each exon of each gene 
was then calculated using FeatureCounts v2.0.0 with parameters for unstranded 
alignment, paired reads, count multimapping reads and assigning reads to overlapping 
features (Liao et al., 2013; Liao et al., 2014). To calculate a comparable measure of 
circular RNA abundance between samples, we used a measure termed back-spliced 
reads per million mapped reads (bpm) for each circular RNA. This measure is 
designed to be similar to the commonly used reads per kilobase per million mapped 
reads (RPKM) metric used regularly to estimate each exon expression from RNA-Seq 
data across samples. 
 
 
2.19 Pathway analysis of genes generating the circRNAs  
The plug-in ClueGO (Cytoscape version 2.5.2) was used to assess pathways that 
could be affected by the host genes generating the top 10% of circRNAs in terms of 
abundance circRNAs (Bindea et al., 2009). The host genes generating 10% most 
abundant circRNAs in the circRNA profiles were queried against Kyoto Encyclopedia 
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of Genes and Genomes (KEGG_20.11.2017), REACTOME_Pathways_20.11.2017 
and WikiPathways_20.11.2017. Outputs obtained from enrichment analyses were 
based on a two-sided hypergeometric test with Bonferroni correction for p-values for 
the selected ontology reference set of candidate genes. The functional pathways were 
groups based on the gene ontology (GO) terms and the kappa score. 
 
 
2.20 Whole-genome amplification  
Whole-genome amplification was done using a REPLI-g® Mini Kit (QIAGEN, Hilden, 
Germany). The REPLI-g® technology uses isothermal multiple misplacement 
amplification (MDA) combined with a gentle alkaline denaturation step to uniformly 
amplify genomic loci. MDA involves the binding of random hexamers to denatured 
DNA followed by strand displacement synthesis at a constant temperature. The strand 
synthesis step is executed by a high-fidelity phage-derived Phi29 polymerase with 3’–
5’ proofreading exonuclease activity. This enzyme delivers 1000-fold higher-fidelity 
products compared with Taq DNA polymerase. Phi29 polymerase can generate 
fragments as big as 100 kb through its proofreading ability, can override secondary 
structures such as hairpin loops and does not dissociate during amplification.  
 
Denaturation of genomic DNA is often achieved through harsh methods such as 
incubation at elevated temperatures or high alkalinity. However, the REPLI-g® Mini Kit 
denatures DNA via mild alkaline incubation, permits very low levels of DNA 
fragmentation and leads to the generation of longer amplified DNA fragments with high 
integrity. Additionally, in contrast to other whole-genome amplification protocols, which 
use heat-induced denaturation leading to the generation of damaged template DNA 
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and biased underrepresented fragments, the exonuclease-resistant primers and buffer 
system in the REPLI-g® protocol ensure high yields of long, unbiased genomic 
fragments. 
 
Whole-genome amplification was done using genominc DNA that co-eluted during 
RNA  extraction (2.5 µL) and 2.5 µL buffer D1 (0.5 µL reconstituted buffer DLB and 
2.0 µL RNase-free dH2O (Fisher Scientific, New Hampshire, USA), and incubated at 
15–25°C for 3 min. Next, 5.0 µL of buffer N1 (0.7 µL stop solution and 4.3 µL RNase-
free dH2O (Fisher Scientific, New Hampshire, USA)) was added, the reaction mixed 
by brief vortexing and centrifuged briefly. Then, 15 µL of ice-cold master mix containing 
REPLI-g® mini reaction buffer (14.5 µL) and REPLI-g® mini DNA polymerase (0.5 µL) 
was added, making a final reaction volume of 20 µL. The reaction mix was incubated 




The TaqMan® Genotyping protocol can be used to amplify and detect specific SNP 
alleles using a 5’ nuclease assay. TaqMan® genotyping (SNP) assays use a pair of 
unlabelled primers, a reporter VIC® dye at the 5’ end of the allele 1 probe, a 6FAM™ 
dye at the 5’ end of the allele 2 probe, and an MGB and nonfluorescent quencher 
(NFQ) on the 3’ end. Each MGB probe anneals to the complementary sequence 
between the forward and reverse primers.  
 
PCR amplification is done using a chemically modified form of AmpliTaq® DNA 
polymerase for efficient hot-start PCR (ThermoFisher Scientific, Waltham, MA, USA). 
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DNA polymerases can be active, although to a lesser degree, at temperatures lower 
than the ideal temperature range for extension, i.e. 68–72°C. Primers tend to bind non-
specifically at temperatures below ideal annealing conditions, leading to non-specific 
amplification, even if reaction mixes are prepared on ice. This can be prevented by 
using polymerase inhibitors like antibodies, which dissociate from the DNA 
polymerase by denaturation only when a certain temperature is reached during hot-
start PCR. The AmpliTaq Gold® DNA polymerase does not facilitate extension at room 
temperature, and thus prevents any extension or subsequent amplification that could 
otherwise occur due to low-stringency mispriming events at room temperature. When 
the AmpliTaq Gold® DNA polymerase reaches probes hybridized to the target 
sequence, it separates the reporter dye from the quencher dye. This separation leads 
to an increase in fluorescence of the reporter during PCR amplification, indicating the 
presence of an allele of the respective dye. The probes remain intact in the absence 
of a complementary target sequence. This keeps the quencher dye in close proximity 
to the reporter dye and prevents any emission of fluorescence. Thus, the fluorescent 
signal generated by PCR amplification corresponds to the allele in the sample. 
 
Genotyping was done using TaqMan® Genotyping Master Mix (2.5 μL, ThermoFisher 
Scientific, Waltham, MA, USA), TaqMan® gene assay (0.25 μL, ThermoFisher 
Scientific, Waltham, MA, USA), dH2O (1.75 μL, Fisher Scientific, New Hampshire, 
USA) and whole-genome amplified template (0.5 μL) in a 5-μL final reaction volume.  
 
PCR was also used for genotyping. PCR amplifies and detects DNA sequences using 
DNA polymerase in the presence of magnesium buffer and nucleotides. It involves a 
three-phase cycle of denaturation, annealing and elongation for about 20–40 cycles. 
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The double-stranded DNA templates are heat-denatured to allow primers to anneal to 
single-stranded DNA strands. The DNA polymerase then extends along the template 
strand in the elongation phase, producing two copies from the original double-stranded 
template DNA strand in each cycle.  
 
PCR performance can be affected by the GC content of the original template. A high 
GC content renders the template more stable, often due to the presence of secondary 
structures such as hairpin loops. Such structures may demand higher denaturation 
and annealing temperatures, and shorter annealing times, to prevent non-specific 
binding of GC-containing primers. Additional reagents like dimethyl sulfoxide (DMSO), 
glycerol and betaine can help to unlock GC-rich secondary structures and facilitate 
denaturation.  
 
The advantage of using MegaMix-Royal to amplify DNA is that it is a complete, 
freeze/thaw-stable, high-performing master mix. It contains optimum amounts of all of 
the core components, including chemically modified Taq polymerase, MgCl2 buffer, 
dNTPs, blue MiZN loading dye and an enzyme stabilizer. Since it contains a blue 
agarose gel loading dye, it enables easy visualization on electrophoresis gels following 
amplification. The dye does not inhibit restriction enzymes or fluoresce. The modified 
Taq polymerase also stays inactive until denaturation has taken place. Thus, it can 
prevent non-specific binding of primers and primer dimer formation.  
 
Genotyping was done using a primer mix (2.4 µL, containing a 1:1 ratio of 
forward:reverse primers, ThermoFisher Scientific, Waltham, MA, USA), MegaMix-
Royal (4 µL, Microzone ͧ , Brighton, UK) and cDNA (1.60 µL) in a final reaction volume 
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of 8 µL. Reaction conditions for PCR were 95°C for 12 min; 40 cycles consisting of 
95°C for 30 s, annealing for 1 min and 72°C for 1 min; followed by a final phase of 









































Chapter 3-Data chapter 
 
Circular RNAs expressed in human peripheral blood 
are associated with human ageing phenotypes, 






Circular RNAs (circRNAs) are an emerging class of non-coding RNA molecules that 
are thought to regulate gene expression and human disease. Despite the observation 
that circRNA are known to accumulate in older organisms, and have been reported in 
cellular senescence, their role in ageing remains relatively unexplored. Here, we have 
assessed circRNA expression in ageing human blood, and followed up age-associated 
circRNA in relation to human ageing phenotypes, mammalian longevity as measured 
by mouse median strain lifespan, and cellular senescence in four different primary 
human cell types. We found that circRNAs circDEF6, circEP300, circFOXO3 and 
circFNDC3B demonstrate associations with parental longevity or hand grip strength in 
306 subjects from the InCHIANTI study of ageing, and furthermore, circFOXO3 and 
circEP300 also demonstrate differential expression in one or more human senescent 
cell types. Finally, four circRNAs tested showed evidence of conservation in mouse. 
Expression levels of one of these, circPlekhm1, was nominally associated with 
lifespan. These data suggest that circRNA may represent a novel class of regulatory 
RNA involved in the determination of ageing phenotypes, which may show future 





Ageing is a multifactorial process leading to gradual deterioration of physical and 
physiological functionality at the cellular, tissue and organ level. It is the primary risk 
factor for chronic ageing pathologies such as cancer, sarcopenia, diabetes, 
cardiovascular disorders and neurodegenerative illnesses that account for the bulk of 
morbidity and mortality in both the developed as well as developing world (Kirkland,  
2016). Physiological parameters such as loss of muscle mass, frailty, immobility and 
cognitive impairment increases the risk of developing geriatric syndromes (Fabbri et 
al., 2016; Narici and Maffulli 2010). The molecular processes that decline with 
advancing age underpin the phenotypes of ageing. At the cellular level, hallmarks of 
ageing include genomic instability, telomere attrition, epigenetic alterations, loss of 
proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular 
senescence, stem cell exhaustion and altered intercellular communication (Lopez-Otin 
et al., 2013).  
 
Changes in gene expression have been reported in many age-related diseases (Yang 
et al., 2015). In addition to an increase in transcriptional noise and aberrant production 
and maturation of mRNA transcripts (Bahar et al., 2006; Harries et al., 2011), studies 
report associations between gene expression and the development of age-associated 
syndromes of the muscle (Welle et al., 2004) as well as neurodegenerative conditions 
such as Alzheimer’s disease and Parkinson’s disease (Miller et al., 2017; Shamir et 
al., 2017). Differential expression of genes involved in inflammatory, mitochondrial and 
lysosomal degradation in ageing tissues has also been reported (de Magalhaes et al., 
2009). Gene expression is regulated at many levels. Changes in the regulation and 
pattern of alternative splicing are associated with age in several human populations 
and are also evident in senescent cells of different lineages, where they may drive 
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cellular senescence, since restoration of levels reverses multiple senescence 
phenotypes (Latorre et al., 2017; Latorre et al., 2018a; Latorre et al., 2018b; Latorre 
et al., 2018c; Lye et al., 2019). Notably, non-coding RNAs also demonstrate 
associations with ageing or senescence and may be of equal importance 
(Abdelmohsen et al., 2012; Boulias and Horvitz, 2012; Gorospe and Abdelmohsen 
2011).  
 
Circular RNAs (circRNAs) are a recently discovered class of non-coding RNA 
molecules that are thought to have important roles in regulation of gene expression 
and human disease (Haque and Harries, 2017). CircRNAs are formed by the back 
splicing of downstream exons to the 3’ acceptor splice site of upstream exons and 
result in a covalently closed circular structure containing one or more exons.  They 
have been proposed to be key regulators of gene expression by various mechanisms 
including sequestration of RNA-binding proteins and miRNAs or by acting as a 
competitor of linear splicing of their cognate genes (Memczak et al., 2013). The 
possibility that a single circRNA could sequester several such RNA regulators 
suggests that these class of non-coding RNAs could modulate many cellular and 
physiological processes through multiple pathways. CircRNAs are known to 
accumulate in older organisms (Gruner et al., 2016), and some have been reported to 
be implicated in cellular senescence (Du et al., 2017; Du et al., 2016). Despite these 
promising findings, their role in ageing remains relatively unexplored.  
 
We hypothesized that expression of some circRNAs may be associated with 
advancing age, ageing phenotypes, lifespan or cellular senescence. Changes in 
circRNA expression over a five-year period were assessed in relation to age, 
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combined parental longevity score (PLS) and hand grip strength. We then assessed 
expression levels of 15 circRNAs in early passage and late passage primary human 
dermal fibroblasts, cardiomyocytes, astrocytes and vascular endothelial cells. Finally, 
the junction sequences of relevant exons were examined for conservation between 
mouse and humans and where evidence was present that the back-spliced junction, 
and thus the circular RNA were conserved, we assessed expression in relation to 
longevity in 6 strains of mice with differential median strain longevities.  
 
We present here evidence that although effects on age itself did not replicate in the 
wider sample set, the expression levels of circEP300 (β=-0.065, p= 0.001) and 
circFOXO3 (β=-0.060, p= 0.002) were negatively associated with parental longevity 
score. CircDEF6 was positively associated with parental longevity score (β=0.070, p= 
0.024) although this did not reach multiple testing thresholds. CircFNDC3B was also 
nominally associated with hand grip strength (β=0.004, p= 0.039). 7/12 (58%) 
circRNAs expressed in senescent human primary astrocytes, endothelial cells, 
fibroblasts or cardiomyocytes also demonstrated dysregulated expression in one or 
more cell types. Comparative sequence analysis suggested that four circRNA may be 
conserved in mice. When assessed, circPlekhm1 transcript level in spleen was also 
demonstrated to be positively-associated with mouse median strain lifespan (β = 
0.0025; p = 0.017). These results suggest that some age-related circRNAs may play 
roles in molecular drivers of ageing such as cellular senescence, and hence may 





3.2.1 InCHIANTI cohort and selection of participants 
The InCHIANTI study of Ageing is a population study of ageing (Ferrucci et al., 2000). 
The present study used participants from the third and fourth follow-up visits (FU3 and 
FU4). RNA samples and clinical/phenotypic data were already available for 698 
participants at FU3. During the FU4 interviews in 2012/13, blood and 
clinical/phenotypic data were collected from 455 study participants. These data were 
cross-checked against RNA samples and clinical/phenotypic data already held from 
FU3, to ensure that sample and phenotypic data was available from both collections. 
Sample-associated data included measures of potential confounding factors. 
Characteristics of the study population are given in Table 2. Informed consent and 
ethical approval were obtained from all participants and the Instituto Nazionale Riposo 






Table 2 Participant demographics. Population demographics and clinical 
characteristics of InCHIANTI study participants assessed in this work. A. 
Demographics B. Clinical characteristics. 
 
A n % 
Participants 306 100 
Age (years)   
30–39  24 7.84 
40–49  37 12.09 
50–59  31 10.13 
60–69  32 10.46 
70–79  116 37.91 
80–89  63 20.59 
90–100 3 0.98 
 
Gender   
Male  143 46.73 
Female  163 53.27 
 
Pack years smoked (lifetime)   
None 164 53.59 
<20  79 25.82 
20–39 43 14.05 
40 + 20 6.54 
 
Study site   
Greve  146 47.71 
Bagno  160 52.29 
 
Education level attained   
Nothing 22 7.19 
Elementary  124 40.52 
Secondary 56 18.30 
High school  50 16.34 
Professional school  34 11.11 
University or equivalent  20 6.54 
 
 
B n Mean  SD Min  Max 
Age (years) 306 66.96 16.06 30.00 94.00 
BMI   305 27.15 4.35 15.01 42.99 
White blood cell count (n, K/ul) 305 6.40 1.59 2.10 13.00 
Neutrophils (%) 305 56.59 8.35 34.20 81.20 
Lymphocytes (%)  304 31.69 7.67 9.80 51.20 
Monocytes (%)  304 8.04 2.20 3.90 21.30 
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Eosinophils (%) 304 3.18 2.17 0.00 21.50 
      
Parental longevity score  206 -0.02 0.81 -2.46 1.71 
      
Mean hand-grip strength (Kg)      
Follow-up3 305 29.65 12.49 2.50 70.75 






3.2.2 Generation of circRNA profiles from old and young human peripheral blood 
Circular RNA profiles were initially generated in parallel from two sets of pooled 
peripheral blood total RNA samples using a modified ‘CircleSeq’ procedure (Lopez-
Jimenez et al., 2018). 2 µg RNA (RNA integrity number; RIN = 6.4) was assessed in 
two separate pools from 20 ‘young’ samples (median age=33 years, range 30-36 
years, 55% female, 45% male; RIN 5.6) and 20 ‘old’ samples (median age 87 years, 
range 86-95 years, 90% female 10% male, RIN 7.7). Each pooled sample was divided 
into two aliquots; one of which was treated with 20 units RNAse R (Epicentre, Madison, 
USA) at 30˚C for 30 minutes to remove linear RNA, the other sample being mock-
treated using 1 µl RNase-free water in place of the enzyme. Both aliquots were 
cleaned and concentrated using 2 volumes of RNA Clean beads (Beckman Coulter, 
Indianapolis, USA) to remove the enzyme. The results of the RNase R treatment were 
confirmed on a high sensitivity RNA screentape (Agilent, Santa Clara, USA). 
Ribosomal RNA was removed and indexed sequencing libraries made using the 
libraries was determined by qPCR and adjusted for size using Tapestation D1000 
analysis (Agilent, Santa Clara, USA). Ribosomal RNA was removed and indexed 
sequencing libraries made using the Illumina RNASeq protocol. The libraries 
concentrations were determined by qPCR and adjusted for size using the data from 
the Tapestation D1000 analysis. Libraries were pooled in equimolar quantities, 
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denatured and diluted to 12.0 pM + 1% PhiX for clustering and then underwent 125 
paired-end Illumina sequencing in four lanes using TruSeq SBS reagents (V3).   
 
 
3.2.3 Analysis of circRNA profiles 
RNase R and mock-treated sequence data were assembled and putative circular 
RNAs were identified using PTESFinder (Izuogu et al., 2016) with the human genome 
(hg19) reference files provided with the software, a segment size of 65 and a 
uniqueness score of 7. The remaining parameters were left to default settings. To 
calculate a comparable measure of circular RNA abundance between samples we 
used a measure termed back spliced reads per million mapped reads (bpm) for each 
circular RNA i is defined as: 
 
𝑏𝑝𝑚𝑖 =  (
𝑗𝑖
∑ 𝑗𝑎 + 
𝑛
𝑎=1 ∑ 𝑐𝑏 
𝑛
𝑏=1
) . 106 
 
Where Ji is the number of reads mapped to the backspliced junction of the circular 
RNA, c is the number of reads mapped to canonical sites of the gene with the circular 
RNA and n is the number of circular RNAs identified. This measure is designed to be 
similar to the commonly used reads per kilobase per million mapped reads (RPKM) 
metric used regularly to estimate gene expression from RNA-Seq data. 
 
In addition to circular RNA detection using PTESFinder, reads from all samples were 
also mapped to the human genome reference (hg19) obtained from iGenomes using 
Tophat v2.1.0 with the pre-set sensitive alignment parameters in paired end mode 
(Trapnell et al., 2009). The number of reads mapping to each exon of each gene was 
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then calculated using FeatureCounts v2.0.0 with parameters for unstranded 
alignment, paired reads, count multimapping reads and assigning reads to overlapping 
features (Liao et al., 2013; Liao et al., 2014). Counts were used to calculate RPKM per 




3.2.4 Pathway analysis of differentially-regulated circRNA host genes 
CircRNAs showing expression differences between the pooled old and the pooled 
young samples were ranked by RPKM and fold change. To assess whether circRNAs 
demonstrating expression differences between ‘young’ and old’ pools were enriched 
in genes derived from specific molecular or biochemical function groups, we carried 
out a Cytoscape version 2.5.2 plug-in ClueGO analysis. This platform queries over-
representation of query genes in specific KEGG, REACTOME and WikiPathways 
(Bindea et al., 2009). The linear genes hosting the top 10% most abundantly-
expressed circRNAs in ‘young’ and ‘old’ pools for the circRNA profile were queried 
against KEGG_20.11.2017, REACTOME_Pathways_20.11.2017 and 
WikiPathways_20.11.2017. Outputs were selected based on ‘enrichment/depletion’ 
through a two-sided hypergeometric test with Bonferroni step down for p-value 
correction with the selected ontology reference set of chosen genes. The GO terms 
were used to group functional pathways and the leading functional grouping was 




3.2.5 Design of qPCR assays for circRNA validation  
Levels of individual circRNA in ‘young’ and ‘old’ pools were ranked by abundance. 
CircRNAs demonstrating evidence of altered expression with age fell into three 
classes: those expressed exclusively in old, those expressed exclusively in young, and 
those expressed in both young and old, but with evidence that levels were different 
between the pools. We selected 5 circRNAs exclusively expressed in young 
(circITGAX, circPLEKHM1, circDEF6, circATP6V0A1 and circASAP1), 5 exclusively 
expressed in the old (circFOXO3, circFNDC3B, circAFF1, circCDYL and circXPO7), 
as well as 5 expressed in both pools but demonstrating evidence of altered expression 
(circMIB1, circMETTL3, circBCL11B, circZC3H18 and circEP300), where sequence 
and assay design constraints allowed for to design specific assays to unique back 
spliced junction for qRTPCR follow up. Standard curves for the assays are shown in 
appendix (Fig A1). 
  
 
3.2.6 CircRNA probe design 
Custom designed qRTPCR assays for quantification of relative expression were 
designed to unique backspliced circRNA junctions (Thermo Fisher, Foster City, USA), 
the sequences of which are given. Each target sequence was checked for the 
presence of single nucleotide polymorphisms in potential primer or probe binding 
regions prior to ordering. Assays were ordered as custom single tube assays from 
Thermo Fisher (Foster City, USA). Each circRNA probe was validated using standard 
curve analysis using 1:10 serial dilutions of synthetic oligonucleotides homologous to 
the back spliced junctions. 
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Table 3 Assay information for age-associated circRNA assessed in this study.  
 
    
CircRNA Forward primer Probe Reverse primer  
CircAFF1 CCTGCCAAAGCCAAGCT TCTCAGTCAGTTGAGTTTGT AGCAGGTTTCTGTCGTCATTGT 
CircASAP1 AGGAGGAAGTGTTCAGTCAAGAATG CACATGCCACATTTCT ACTTATCAGCTGTTTTCAAGCCATCT 
CircATP6V0A1  CGCCGTCAGTATTTGAGGAGAAA CTTCTTGAAATAGCAAATGC AGCCAAACAAAGAGGTCATGAAGAT 
CircBCL11B AAAGGCATCTGTCCCAAGCA CAGCCTCTGCAATGTT GCGGCCTCCACATGGT 
CircCDYL CATGGCCACAGGCTTAGCT CAATCCTTTCAACCTTTCCC CGAACCAAATACTCTGTCTTCCCTTTT 
CircDEF6 GGGAGTGAAGAGTGCAAAGAGAAA TCCACCTCCACGCAGCAG GCTGAGTACCTTTTTCAGCAGGTAT 
CircEP300 GTTGCATATGCTCGGAAAGTTGAAG CATTCCCATTCGATTGTTTG GCTGTCCAGGATTCTGAGTATATGG 
CircFNDC3B  AGCCCAAAGTCGAATGATTCAGA TTGCAAGGTGATTGAAGATA CCGGCGGACTCCAGTAC 
CircFOXO3 AGGCTGAAGGATCACTGAGGAA ATGGAGTTCTGCTTTGCC CGACTATGCAGTGACAGGTTGT 
CircITGAX  GAGGATGAAGGCCGAAGTCA CCGTACCTGAGTCCCC TCGAAGGAGCTACTGCTTGTG 
CircMETTL3 GAACCAACAGTCCACTAAGGAACAA CAGAGCAAGAAGATCTAC ACAATGCTGCCTCTGGATTCC 
CircM1B1 GGCATTGATGAAGATCATGACATTGT ATGCTTGATGCCTATTGCC TTGCTGGCGGCAGGTAT 
CircPLEKHM1 CTGGGCACAGCAAATGCT CTGCAAGAACACATCATC CGTCAGGTGCTCCAACTCT 
CircXPO7 TGTTGATGGTGTTAAACGAATACTGGAA CCCACAGGCAGACACC AGAGGCTATTTTTCTGTGCTTGGT 
CircZCH3H18 GGAGCGGGAGAAGGAGAAG CAGCCGCCAAGACTCG CCAAAACCGCTCAATTTCATAGTCATAA 
 
   
 
   
Endogenous 
controls  Assay ID 
Supplier  
 
IP08 Hs00183533_m1   Thermofisher Scientific  
P0L2RA Hs00172187_m1   Thermofisher Scientific  
TFRC Hs00174609_m1   Thermofisher Scientific  
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3.2.7 Assessment of associations between circRNA expression and ageing 
phenotypes in the InCHIANTI cohort. 
RNA samples and phenotypic data were available from 306 individuals at both follow 
up 3 (FU3) and follow up 4 (FU4) of the InCHIANTI study of Ageing. Characteristics of 
participants are given in Table 2. We assessed the expression of 15 age-associated 
circRNAs demonstrating the most marked differential expression with age between 
young and old pools as described above. Ageing parameters assessed were age itself, 
parental longevity score (PLS) and hand grip strength. Participants aged 65+ years 
were categorised for PLS based on the age at death of their parents. Short, 
intermediate and long-lived cut-offs were calculated separately for mothers and fathers 
based on the normal distribution of age-at-death in the cohort, as described in (Dutta 
et al., 2013a). Mothers and fathers aged <49 years or <52 years at death respectively 
were classed as premature and excluded. To standardize parental age of death, a Z-
score was generated for combined maternal and paternal measures of parental 
longevity. Hand-grip strength was measured in kilograms using a dynamometer, with 
repeated measurements at both FU3 and FU4.  
 
 
3.2.8 Reverse transcription and pre-amplification of circRNAs in human peripheral 
blood RNA  
cDNA synthesis was carried out using 100ng total RNA using the High-Capacity cDNA 
Reverse Transcription Kit (Thermo Fisher, Foster City, USA) according to 
manufacturer’s instructions (Fisher Scientific New Hampshire, United States) in a final 
reaction volume of 10.0µL per sample. Reactions (samples in 96-well plates) were run 
at 25°C for 10min, 37°C for 120 min, 85°C for 5 min followed by an inactivation period 
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for 95°C for 10 min. Pre-amplification of circRNA expression was carried out using 5µl 
TaqMan PreAmp master mix (Thermo Fisher, Foster City, USA), 2.5µL pooled assay 
mix and 2.5µL cDNA in a final reaction volume of 10µL per sample. Cycling conditions 
were one cycle of 95°C for 10 min followed by 14 cycles of 95°C for 15 sec with 60°C 
for 4 min followed by 95°C for 10min. Pre-amplified samples were then diluted 1:10 
and maintained on ice prior to analysis.  
  
 
3.2.9 Assessment of associations between circRNA expression in peripheral blood 
RNA and human ageing phenotypes  
The expression profiles of selected circRNAs were then measured in total peripheral 
blood mRNA using custom-designed OpenArray® plates on the Thermo Fisher 12K 
Flex platform (Thermo Fisher, Foster City, USA). The differential expression of 
circRNA measured in a customized open array platform allowed a maximum of 18 
probes to be assessed. Therefore, there was no room for linear assays to be assessed 
in this part of the thesis. The differential expression of circRNA in the RNA-Seq profile 
was assessed in 20 samples pooled from young and old participants. Based on this 
initial difference in expression, a follow-up, on a larger cohort which was not pooled, 
was assessed using blood samples.  Reaction mixes contained 2.5 µl 2✕ OpenArray® 
Real-Time Master mix, diluted pre-amplified cDNA (1.2µL) and RNase-free dH2O 
(1.3µL) (Thermo Fisher, Foster City, USA). CircRNA expression was measured 
relative to the geometric mean of the entire set of transcripts, with the expression of 
each individual circRNA normalised to the global mean of expression of that circRNA 
across the samples. Samples were run in 3 technical triplicates. Association of 
circRNAs with age in InCHIANTI was carried out by multivariate linear regression, 
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adjusted for potential confounders BMI, sex, level of education (none, elementary, 
secondary, high school and university), study site, smoking and white blood counts 
(neutrophil, lymphocyte, monocyte, eosinophil percentages) while age was 
additionally adjusted for all other measures of association in the ageing human cohort. 
We assessed association of circRNA with hand grip strength and parental longevity 
score (PLS) (Dutta et al., 2013b; Dutta et al., 2013c) as a proxy measure of longevity 
in humans. Statistical analysis was completed using StataSE15 (StataCorp, Texas, 




3.2.10 Assessment of circRNA expression in human primary senescent cells of 
different lineages 
The expression levels of the 15 candidate circRNAs analysed above were also 
assessed in relation to cellular senescence, in senescent and early passage primary 
human primary fibroblasts, endothelial cells, astrocytes and cardiomyocytes using 
high-throughput qRTPCR on the 12K Flex OpenArray platform (Thermo Fisher, Foster 
City, USA). Samples were run in 3 biological replicates and 3 technical replicates. 
Senescent cells had been generated and characterised in previous work by our group, 
and culture conditions and details of assessment of senescence are reported 
elsewhere (Latorre et al., 2017; Latorre et al., 2018a; Latorre et al., 2018b; Latorre et 
al., 2018c; Lye et al., 2019). RNA samples from this work were available for use. 
CircRNA levels were assessed in three biological and three technical replicates from 
early and late passage human primary cells of 4 different cell types. Early passage 
‘young’ cells were at population doubling (PD) of 24 for astrocytes, 28 for 
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cardiomyocytes, 24 for endothelial cells and 25 for fibroblasts, whilst late passage 
senescent cells were at PD = 84 for astrocytes, 75 for cardiomyocytes, 65 for 
endothelial cells and 63 for fibroblasts. Senescent cell load in these samples was 
~75% for fibroblasts, ~55% for endothelial cells, ~38% for cardiomyocytes and ~36% 
for cardiomyocytes (Latorre et al., 2017; Latorre et al., 2018a; Latorre et al., 2018b; 
Latorre et al., 2018c; Lye et al., 2019). In all cases, growth of the culture had slowed 
to less than 0.5 PD/week.  Differential circRNA expression in senescent cells was then 
assessed by one-way ANOVA using StataSE15 (StataCorp, Texas, USA).  Figures 
were generated using GraphPad Prism 8.1.2 (GraphPad Software, San Diego, USA). 
 
 
3.2.11 Assessment of circRNA conservation between mouse and human  
We assessed whether the 15 circRNAs identified in our human study were likely to be 
conserved in mouse by aligning the mouse and human exon junction sequences using 
the Blat tool in the UCSC genome browser (https://genome.ucsc.edu). Quantitative 
real-time PCR assays were developed to unique back-spliced junctions of conserved 
circRNAs. Probe and primer sequences are given. CircRNA expression was then 
measured in mouse spleen and muscle tissue and assessed in relation to lifespan by 
analysis of levels in 6 strains of male mice (A/J, NOD.B10Sn-H2b/J, PWD/PhJ, 
129S1/SvlmJ, C57BL/6J and WSB/EiJ) selected on the basis of divergent median 
strain longevity lifespan ranging from 623 to 1005 days (Yuan et al., 2009). Samples 
from male mice were obtained from Jackson Laboratory Nathan Shock Center of 
Excellence in the Basic Biology of Ageing for this study. Animal husbandry, handling, 
animal characteristics and sample preparation protocols have been previously 
described (Lee et al., 2016). Tissue samples were obtained from cross-sectional study 
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conducted in the same compartment and in the same period of time as described in 
(Yuan et al., 2009). At the age of 6 and 20/22 months, CO2 asphyxiation was used to 
euthanize the animals. Spleen and quadriceps muscles tissues were excised 
immediately after sacrifice and shipped from the Jackson Laboratory using RNAlater-
ICE Collection protocol (Life Technologies, Carlsbad, CA). In this method, tissues are 
submerged in RNAlater® stabilization solution, an aqueous tissue storage reagent 
used to rapidly permeate tissues and stabilize RNA from fresh specimens and stored 
at –20°C or below for later use. 
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Table 4 Assay details for mouse circRNAs assessed in this work. 
CircRNA Forward primer Probe Reverse primer  
CircMib1 AACTACAACTCGAACCGTCTG CCAAGTGGCAATAGGCATCAAGCA CGGCAGGTATCACACATAGTT 
CircPlekhm1  TCTGAGGAACCCATGTCCTAT CCGACAGGTCTCTGCAAGAACACA AAGACCAGGTGCTCCAAATC 
CircXpo7  GGCCAACTTTCTCTCTCATCTT TCCACAGGCAGACACAACTCATCC GTCTCGGAAAGAAGAGGCTATTT 
CircFoxo3  CTGAAGGATCACTGAGGAAAGG TGGAGTTCTGCTTGCCCATTTCC TCATTCTGAACGCGCATGA 
 
   
Endogenous 
controls  Assay ID 
Supplier  
 
Ip08 Mm.PT.39a.22214844 Integrated DNA Technologies  
Pol2ra  Mm.PT.39a.22214849 Integrated DNA Technologies  






3.2.12 RNA extraction and reverse transcription from mouse tissues 
Total RNA was extracted using the TRI®reagent/ chloroform phase separation 
according to manufacturer’s instructions. Briefly, tissues stored in RNA later were 
drained, and then placed in 1 mL TRI Reagent® solution containing 10 mM MgCl2. 
Samples were homogenized for 15mins (spleen) or 30mins (muscle) using bead mills 
(Retsch Technology GmbH, Haan, Germany). This was followed by a phase 
separation using chloroform. Total RNAs in the separated RNAs were precipitated 
from the aqueous phase through overnight incubation with isopropanol at −20 °C. The 
following morning, RNA pellets were washed twice with ethanol and resuspended in 
RNase‐free dH2O. Complementary DNA (cDNA) was generated from 100ng RNA 
using the Evocript® Universal cDNA Master Synthesis kit according to the 
manufacturer’s instructions (Roche, Switzerland).  
  
 
3.2.13 Assessment of circRNA expression in mouse spleen and muscle  
CircRNAs selected on the basis of inter-species sequence conservation were 
validated in mouse spleen and muscle tissue. Considering, grips-strength as a 
measure of frailty was assessed in the human cohort, the effect of expression in mice 
models of different longevity was also assessed. While the differential expression of 
circRNAs was measured in human, in the absence of blood samples in mice models, 
spleen which is rich in cells of the vascular system was used. Expression levels of 
conserved circRNAs were assessed in relation to median strain lifespan by relative 
quantification. Quantitative qRTPCR was carried out for circRNAs (circFoxo3, 
circMib1, CircPlekhm1 and circXpo7) in relation to the Pol2ra, Trfc and Ipo8 
endogenous control genes, selected on the basis of lack of age-association in a 
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previous study (Harries et al., 2011). Reaction mixes contained cDNA (0.5 μL) , 
Taqman® Universal PCR mastermix II (2.5 μL, no AmpErase® UNG,  (Thermo Fisher, 
Foster City, USA), dH2O (1.75 μL, Fisher Scientific , United States), and 
Taqman®gene assay (0.25 μL, Thermo Fisher, Foster City, USA) in a 5 μL final 
reaction volume. The reaction mixes were centrifuged at 3000 rpm, vortexed and 
centrifuged again at 3000 rpm and transferred to 384 well qRTPCR plates. qRTPCR 
was run at 50 °C for 2 min, 95 °C for 10 min and 50 cycles of 15 s at 95 °C for 30 s 
and 1 min at 60 °C. Each sample assay was conducted in 3 technical triplicates. 
Expression levels of circRNAs in young and old mouse tissues were measured relative 
to the geometric mean of the entire set of transcripts, with the expression of each 
individual circRNA normalised to the global mean of expression of each circRNA 
across the samples. Linear regression analysis was carried out to assess the 




3.3.1 CircRNA profile in peripheral blood of ageing humans  
166-167M reads were obtained from the RNAse R-treated pools and 157-163M reads 
from the mock-treated pools with a mean Q score of 34.6-35.1 and total error rate of 
0.47-0.53%. A total of 2207 circRNAs were expressed in human peripheral blood. Of 
these, 184 circRNAs were found in both the young and old samples, 431 were 
exclusively expressed in the ‘young’ sample pool and 1592 were exclusively 
expressed in the ‘old’ sample pool (Online Resource 1). We selected 15 circRNAs for 
further analysis; 5 expressed exclusively in the young pool, 5 expressed exclusively in 
the old pool, and 5 expressed in both pools but showing the most discrepant 
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expression for further study. These were circITGAX, circPLEKHM1, circDEF6, 
circATP6V0A1 and circASAP1 which showed exclusive expression in the young; 
circFOXO3, circFNDC3B, circAFF1, circCDYL and circXPO7 which showed exclusive 
expression in the old; circMIB1, circMETTL3, circEP300, circZC3H18 and circBCL11B 
that were expressed, but differentially so in both sample pools.  
 
Figure 9 Circular RNA junction schematics for the top 5 most abundant circular 
RNAs uniquely found in young (A) and old samples (B). Also shown, are junction 
schematics for the top 2 and 3 most abundant common circular RNAs found in young 
(n=20) and old samples (n=20) respectively (C). Each schematic shows the identified 
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backsplicedd exon or exons. The relative read depth at each backsplicedd junction is 
shown by the number of bars above each junction and is scaled by linear interpolation, 
where the backsplicedd junctions with 1 and 10 bars represent the junctions with the 
lowest and highest read depth respectively. Black and grey bars show relative read 




3.3.2 Pathway analysis of circRNA expressed in ageing humans 
Pathway enrichment for the genes hosting the top 10% most abundant circRNAs in 
each of young and old pooled peripheral blood samples was performed using ClueGO 
cytoscape (Bindea et al., 2009). In the young peripheral blood, the top 10% most 
abundant circRNAs derived from genes associated with negative regulation of ATP 
metabolic processes and in transmission of synaptic signals. The leading-edge genes 
hosting circRNAs for negative regulation of ATP processes were SNCA, STAT3 and 
UFSP2, whilst those associated with synaptic vesicle endocytosis were FCH02, 
PICALM, PIP5K1C and SNCA. Genes hosting circRNAs were primarily localised in 
pathways involved in phagocytosis, circadian regulation, cancer pathways and golgi-





Table 5 Pathways enriched in age-associated circRNAs The ClueGo pathways 
results for pathways potentially targeted by genes generating the top 10% of circRNAs 
differentially expressed with age are presented here aligned to the hg19 genome 
alignment. Number of genes = number of differentially-expressed genes in each 
pathway. 




Expressed only in old        
Fc gamma R-mediated 
phagocytosis 
0.005 4 ARPC1B, ASAP1, PIP5K1C, VASP 
Exercise-induced Circadian 
Regulation 
0.006 3 CRY2, NCOA4, TAB2 
Pathways Affected in Adenoid 
Cystic Carcinoma 
0.018 4 ERBB2, FOXO3, KANSL1, MGA 
Endometrial cancer 0.041 3 AXIN1, ERBB2, FOXO3 
trans-Golgi Network Vesicle 
Budding 
0.035 3 DNAJC6, IGF2R, PICALM 
Clathrin derived vesicle 
budding 
0.049 3 DNAJC6, IGF2R, PICALM 
Golgi Associated Vesicle 
Biogenesis 
0.069 3 DNAJC6, IGF2R, PICALM 
Cargo recognition for clathrin-
mediated endocytosis 
0.062 5 FCHO2, IGF2R, PICALM, REPS1, 
UBQLN1 
Clathrin-mediated endocytosis 0.049 8 DNAJC6, FCHO2, GAPVD1, IGF2R, 




Expressed only in young 
  
Negative regulation of ATP 
metabolic process 
0.004 3 SNCA, STAT3, UFSP2 
Synaptic vesicle recycling 0.009 4 FCHO2, PICALM, PIP5K1C, SNCA 
Presynaptic endocytosis 0.018 4 FCHO2, PICALM, PIP5K1C, SNCA 









0.014 2 ATP5C1, EP300 
Pyruvate metabolism_Homo 
sapiens_hsa00620 








3.3.3 CircPLEKHM1, circMETTL and CircFNDC3B expression levels are associated 
with ageing phenotypes in humans 
The structures of the 15 circRNAs selected for follow up were predicted based on the 
sequencing read depth for each exon and are presented in Fig. 9. Although we 
demonstrated no associations with age itself, we did identify associations between 
some circRNAs and human ageing phenotypes. CircEP300 and circFOXO3 both 
demonstrated negative associations with combined parental longevity score (β=-0.065 
and -0.060; p = 0.001 and 0.002 respectively), after adjustment for multiple testing. 
CircDEF6 was positively correlated with parental longevity scores but demonstrated 
nominal significance only (β=0.070, p= 0.024) (Table 6, Fig. 10). A positive association 
was also identified both cross-sectionally (β=0.004, p=0.039) and longitudinally 
(β=0.004, p=0.038) between circFNDC3B expression and hand grip strength (Table 
7, Fig. 11), although these were nominal only.   
Table 6 CircRNA expression in relation to combined parental longevity score.  
Beta co-efficients, p values and 95% confidence intervals (95% CI) are given for associations 
between circRNAs expression and combined parental longevity (PLS) score from multivariate 
regression analysis. 291 samples were assessed. Genes demonstrating statistically 
significant results below the multiple testing limit of 0.003 are indicated in bold, underlined 
type, whilst those demonstrating nominal associations only are given in bold type. 
CircRNA β-coefficient p-value 95 % CI 
CircAFF1 -0.012 0.485 -0.048 - 0.023 
CircASAP1 -0.044 0.064 -0.090 - 0.003 
CircATP6V0A1 0.036 0.223 -0.022 - 0.094 
CircBCL11B 0.042 0.136 -0.013 - 0.097 
CircCDYL -0.030 0.109 -0.067 - 0.007 
CircDEF6 0.070 0.024 0.009 - 0.131 
CircEP300 -0.065 0.001 -0.103 - -0.026 
CircFNDC3B 0.025 0.239 -0.016 - 0.066 
CircFOXO3 -0.060 0.002 -0.098 - -0.021 
CircITGAX 0.019 0.440 -0.030 - 0.068 
CircMETTL3 0.007 0.730 -0.034 - 0.049 
CircMIB1 -0.018 0.310 -0.052 - 0.017 
CircPLEKHM1 -0.009 0.493 -0.035 - 0.017 
CircXPO7 0.038 0.162 -0.016 - 0.093 




Figure 10 CircRNA expression is associated with combined parental longevity. 
Forest plot illustrating the association between peripheral blood circRNA expression 
and combined human parental longevity score (PLS) in participants from the 
InCHIANTI study of Ageing. N= 291 individuals. The beta coefficient of the association 
measured by multivariate regression analysis is given on the X-axis and the identity of 
the gene is given on the Y axis. Lines attached to each data point represent 95% 
Confidence intervals (95% CI). Statistical significance is indicated by stars. * = <0.05, 





Table 7 CircRNA expression in relation to grip strength Beta co-efficients, p values 
and 95% confidence intervals (95% CI) are given for associations between circRNAs 
expression and hand grip strength. 306 individuals were assessed. Associations were 
assessed cross-sectionally using multivariate regression (Expression data FU3 and 
clinical outcome FU3) and longitudinally (Expression data FU3, clinical outcome FU4). 
All associations identified here were nominal only and are given in bold type.  
CircRNA Grip-strength β-coefficient p-value 95 % CI 
CircAFF1 cross-sectional -0.001 0.508 -0.004 - 0.002 
  longitudinal -0.003 0.081 -0.007 - 0.000 
CircASAP1 cross-sectional -0.001 0.713 -0.005 - 0.004 
  longitudinal 0.000 0.854 -0.005 - 0.004 
CircATP6V0A1 cross-sectional 0.000 0.965 -0.005 - 0.005 
  longitudinal -0.002 0.403 -0.008 - 0.003 
CircBCL11B cross-sectional 0.002 0.443 -0.003 - 0.007 
  longitudinal 0.000 0.914 -0.006 - 0.005 
CircCDYL cross-sectional -0.001 0.665 -0.004 - 0.003 
  longitudinal 0.000 0.828 -0.004 - 0.003 
CircDEF6 cross-sectional 0.000 0.903 -0.005 - 0.006 
  longitudinal 0.002 0.599 -0.004 - 0.008 
CircEP300 cross-sectional -0.004 0.060 -0.007 - 0.000 
  longitudinal -0.003 0.112 -0.007 - 0.001 
CircFNDC3B cross-sectional 0.004 0.039 0.000 - 0.008 
  longitudinal 0.004 0.038 0.000 - 0.008 
CircFOXO3 cross-sectional 0.002 0.402 -0.002 - 0.005 
  longitudinal 0.000 0.834 -0.004 - 0.003 
CircITGAX cross-sectional 0.000 0.997 -0.004 - 0.004 
  longitudinal -0.001 0.658 -0.006 - 0.004 
CircMETTL3 cross-sectional -0.003 0.139 -0.007 - 0.001 
  longitudinal -0.001 0.680 -0.005 - 0.003 
CircMIB1 cross-sectional 0.000 0.906 -0.003 - 0.003 
  longitudinal 0.002 0.305 -0.002 - 0.005 
 CircPLEKHM1 cross-sectional 0.000 0.799 -0.002 - 0.003 
  longitudinal -0.001 0.614 -0.003 - 0.002 
CircXPO7 cross-sectional -0.003 0.236 -0.008 - 0.002 
  longitudinal -0.004 0.139 -0.009 - 0.001 
CircZC3H18 cross-sectional 0.001 0.761 -0.003 - 0.004 







Figure 11 Peripheral blood circFNDC3B expression is nominally associated with 
hand grip strength. Forest plot illustrating the association between circRNA 
expression and hand grip strength in participants from the InCHIANTI study of Ageing. 
Associations with grip strength from multivariate regression analysis are shown both 
(A) cross-sectionally from follow up 3 (FU3) and (B) longitudinally, from follow up 4 
(FU4). N = 306 individuals. The beta coefficient of the association is given on the X-
axis and the identity of the gene is given on the Y axis. Lines attached to each data 
point represent 95% Confidence intervals (95% CI).  Statistical significance is 




3.3.4 CircRNAs are differentially expressed in early passage and late passage cells  
12 of 15 circRNAs tested were expressed in astrocytes, endothelial cells, fibroblasts 
or astrocytes. 7 (58%) of these demonstrated differential expression between early 
and late passage cells of one or more cell type (Table 8, Fig. 12). CircAFF1 and 
circFOXO3 demonstrated associations in more than one cell type although direction 
of effect was concordant only for circFOXO3 (in cardiomyocytes and fibroblasts). 
CircCDYL, circEP300, circMIB1, CircZC3H18 and circMETTL3 were differentially-
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expressed in only one cell type. CircBCL11B, CircDEF6 and CircITGAX were not 





Figure 12 Differential expression of circRNAs in senescent cells of various 
lineages. CircRNAs are dysregulated in senescent astrocytes (A), cardiomyocytes 
(B), endothelial cells (C) and fibroblasts (D). Some circRNAs are dysregulated in 
multiple cell types. Differential expression assessed by one-way ANOVA. N = 6 
samples. CircRNA is shown on the X-axis and the relative expression of the circRNA 





Table 8 CircRNA expression in early and late passage primary human cells IQR 
= interquartile range of gene expression.  N=6 samples.  Results reaching statistical significance from 
one-way ANOVA analysis are indicated in bold underlined typeface.  
CircRNA Median (IQR) p-value 
Early passage Late passage 
Astrocytes 
CircAFF1 0.58 (0.55-0.68) 0.84 (0.79-1.09) 0.040 
CircASAP1 1.39 (0.97-1.48) 1.22(1.18-1.36) 0.878 
CircATP6V0A1 1.60 (1.14-1.87) 1.14 (1.05-1.41) 0.229 
CircCDYL 0.71 (0.67-0.74) 0.90 (0.90-0.93) 0.001 
CircEP300 1.01 (0.95-1.04) 1.05 (1.00-1.07) 0.329 
CircFNDC3B 0.96 (0.85-1.10) 1.38 (1.20-1.48) 0.059 
CircFOXO3 0.88 (0.80-0.89) 0.89 (0.80-0.98) 0.646 
CircMETTL3 0.97(0.92-1.08) 0.69 (0.66-1.02) 0.180 
CircMIB1 0.71(0.69-0.86) 1.03 (0.99-1.04) 0.008 
CircPLEKHM1 1.05 (1.00-1.09) 0.76 (0.61-1.17) 0.306 
CircXPO7 1.25 (1.12-1.58) 1.54 (0.81-1.62) 0.987 
CircZC3H18 1.50 (0.67-2.24) 0.88 (1.00-1.07) 0.346 
 
Cardiomyocytes 
CircAFF1 1.15 (1.09-1.26) 1.42 (1.04-1.52) 0.357 
CircASAP1 0.74 (0.71-1.05) 0.84 (0.83-1.02) 0.643 
CircATP6V0A1 0.57 (0.44-0.80) 0.41 (0.39-0.54) 0.249 
CircCDYL 1.47 (1.29-1.48) 1.42 (1.25-1.64) 0.855 
CircEP300 1.27 (1.02-1.48) 1.10 (0.84-1.45) 0.596 
CircFNDC3B 1.03 (0.83-1.09) 1.93 (0.96-1.97) 0.139 
CircFOXO3 1.00(0.99-1.07) 0.82 (0.79-0.92) 0.015 
CircMETTL3 0.88(0.69-0.99) 0.66 (0.63-0.79) 0.186 
CircMIB1 0.96 (0.81-1.02) 1.16 (0.97-1.25) 0.129 
CircPLEKHM1 0.85 (0.84-1.05) 0.82(0.71-1.22) 0.983 
CircXPO7 0.89 (0.74-0.94) 1.32 (0.75-1.63) 0.227 
CircZC3H18 0.83 (0.63-1.43) 0.85 (0.77-1.12) 0.862 
Endothelial cells 
CircAFF1 0.94 (0.91-1.27) 1.07 (0.49-1.11) 0.548 
CircASAP1 1.03 (0.94-1.28) 1.69 (0.68-1.76) 0.467 
CircATP6V0A1 0.37 (0.16-0.58) 0.48 (0.48-0.48) 0.821 
CircCDYL 0.90 (0.76-1.11) 0.89 (0.84-1.02) 0.942 
CircEP300 0.99 (.75-1.45) 0.58 (0.53-0.80) 0.128 
CircFNDC3B 1.74 (1.49-3.18) 7.84 (3.18-9.97) 0.080 
CircFOXO3 0.38 (0.20-1.98) 0.14 (0.04-0.22) 0.275 
CircMETTL3 1.02 (0.54-1.08) 0.39 (0.39-0.56) 0.072 
CircMIB1 1.36 (0.98-1.54) 1.11 (1.03-1.43) 0.640 
CircPLEKHM1 1.02 (0.99-1.42) 1.47(0.83-4.85) 0.380 
CircXPO7 0.97 (0.72-1.18) 0.87 (0.31-1.22) 0.620 
CircZC3H18 1.02 (0.98-1.15) 1.51 (1.51-1.51) 0.047 
 
Fibroblasts 
CircAFF1 1.06 (0.95-1.16) 0.58 (0.52-0.65) 0.003 
CircASAP1 0.51 (0.38-1.07) 1.05 (0.85-1.10) 0.196 
CircATP6V0A1 1.39 (1.00-1.41) 1.10 (0.46-1.35) 0.375 
CircCDYL 1.13 (0.72-1.17) 0.90 (0.81-1.06) 0.640 
CircEP300 0.96 (0.78-0.98) 0.38 (0.38-0.69) 0.023 
CircFNDC3B 0.50(0.48-0.94) 0.90 (0.85-0.91) 0.182 
CircFOXO3 1.91 (1.72-2.01) 1.60 (1.47-1.61) 0.025 
CircMETTL3 1.23(1.00-1.26) 1.39 (1.58-1.66) 0.030 
CircMIB1 1.20 (1.14-1.47) 0.85 (0.69-1.11) 0.072 
CircPLEKHM1 1.00(0.90-1.00) 0.84 (0.79-1.14) 0.716 
CircXPO7 1.03(0.48-1.08) 0.57 (0.39-1.18) 0.645 
CircZC3H18 0.93 (0.72-1.21) 0.74 (0.53-0.94) 0.432 
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3.4.5 Differential expression of circRNAs between mice of different median strain 
longevities 
In silico analyses suggested that 4 circRNAs (circFoxo3, circMib1, CircPlekhm1 and 
circXpo7) may have conserved back-spliced junction in the mouse. Associations with 
longevity were then assessed in spleen and muscle tissue from young (6 months) and 
old (20-22 months) mouse strains of 6 different median strain longevities. CircMib1 
and circXpo7 were expressed only in spleen, whereas circFoxo3 and circPlekhm1 was 
expressed in both tissues (Table 9). The expression of circPlekhm1 demonstrated a 
nominal positive correlation with median lifespan in young and old (β =0.0013, 
p=0.016) as well as in spleen of young mice (β =0.0025, p=0.017), although these 
were not significant after adjustment for multiple testing (threshold p = 0.013). No 



























Table 9 Differential expression of conserved circRNAs in mice of differential 
median strain longevities. CircRNA expression is reported here in relation to median 
strain longevity. Data are assessed separately for young and old animals of each 
strain. N=67 (muscle); 90 (spleen). IQR = interquartile range. ND = Not detected. 
Results reaching statistical significance from regression analysis are indicated in bold 
underlined typeface. 
CircRNA  Tissue  β-coefficient p-value  95% CI 
CircFoxo3 muscle  0.00 0.403 -0.0010  0.0024 
 young (muscle) 0.0001 0.936 -0.0028  0.0031  
old (muscle) 0.0008 0.478 -0.0015  0.0031 
  spleen -0.0003 0.815 -0.0027  0.0021 
 young (spleen) 0.0002 0.922 -0.0039  0.0043 
  old (spleen) -0.0005 0.757 -0.0037  0.0027 
CircMib1 muscle  ND ND ND  ND 
 young (muscle) ND ND ND  ND 
 old (muscle) ND ND ND  ND 
  spleen 0.0001 0.924 -0.0023  0.0026 
  young (spleen) -0.0018 0.150 -0.0044  0.0008 
  old (spleen) 0.0021 0.299 -0.0020  0.0062 
CircPlekhm1 muscle  0.0003 .813 -0.0022  0.0028 
 young (muscle) -0.0022 0.161 -0.0054  0.0010 
  old (muscle) 0.0016 0.365 -0.0020  0.0053 
 spleen 0.0013 0.016 0.0002  0.0024 
  young 
(spleen) 
0.0025 0.017 0.0005  0.0046 
  old (spleen) 0.00001 0.967 -0.0008  0.0009 
CircXpo7 muscle  ND ND ND  ND 
  young (muscle) ND ND ND  ND 
 old (muscle) ND ND ND  ND 
 spleen 0.0009 0.509 -
0.0019 
 0.0038 
  young (spleen) 0.0003 0.894 -
0.0040 
 0.0045 







Circular RNAs (circRNAs) are an emerging class of regulatory RNA molecule thought 
to play a role in human disease (Haque and Harries, 2017). These molecules have no 
free ends, and as such are exonuclease resistant. CircRNAs accumulate in aged 
organisms (Gruner et al., 2016) and have been suggested to play a role in cellular 
senescence (Du et al., 2017; Du et al., 2016). We hypothesised that the human 
circRNAome may differ in aged humans compared with younger subjects, and that 
these changes may also be associated with cellular senescence, or with longevity in 
animal models. We identified >2000 circRNAs in total RNA from human blood, some 
of which were expressed exclusively in samples from older donors. GSEA pathways 
enrichment analysis of genes hosting the top 10% most abundant circRNAs in elderly 
donors suggested that pathways involved in phagocytosis, circadian regulation, 
cancer pathways and golgi-associated vesicles were the most enriched in these 
genes. We demonstrated that 3 circRNAs (circDEF6, circFOXO3 and circEP300) were 
associated with measures of parental longevity, and one (circFNDC3B) was 
associated with hand grip strength both longitudinally and cross-sectionally. 
Furthermore, 7/12 circRNAs expressed in human senescent cells of different cell types 
demonstrated dysregulated expression in one or more cell type and 1/4 circRNAs 
demonstrating conserved expression were associated with median strain longevity in 
spleen tissue from young mice. These findings are consistent with the hypothesis that 
some circRNAs have roles in molecular ageing and the determination of mammalian 
ageing phenotypes. 
 
CircRNAs generated from the FOXO3 and EP300 genes were negatively associated 
with measures of human parental longevity, and also demonstrated dysregulated 
expression in human senescent cells. CircRNAs deriving from the FOXO3 gene have 
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previously been demonstrated to regulate cell cycle when manipulated by gene 
knockdown in mouse embryonic fibroblasts, cardiac fibroblasts or mammary cancer 
cell lines (Du et al., 2016). Furthermore, FOXO3 circular RNAs also demonstrate 
elevated expression and association with cellular senescence in the heart tissue of 
mice and humans (Du et al., 2017). It is not clear whether the previously reported 
circular FOXO3 transcripts have the same structure as the one we have identified, 
since previous studies do not give its exon structure. A circRNA from the FOXO3 gene 
identical to the one we have identified has also previously been demonstrated to inhibit 
myoblast differentiation in mouse cells (Li et al., 2019). Genetic variation in the FOXO3 
gene itself has previously been associated with extreme longevity (Flachsbart et al., 
2017; Fuku et al., 2016), and has also been associated with maintenance of telomere 
length (Davy et al., 2018).  
 
CircRNAs deriving from the EP300 gene have not been previously reported. EP300 
encodes the repressor histone acetyltransferase protein p300, which also has roles as 
a transcriptional corepressor protein. EP300 has been implicated in modulation of 
FOXO3 activity (Mahmud et al., 2019) and in antagonism of the FOX03a/SIRT1 
signalling axis (Jeung et al., 2016). Inhibition of EP300 has been shown to mimic 
calorific restriction in human and mouse cells (Pietrocola et al., 2018); calorific 
restriction is of course a well-known modifier of lifespan in many species (Austad, 
1989; Hansen et al., 2008; Kapahi et al., 2004; Mitchell et al., 2010). This protein is 
also a master regulator of autophagy, which is a pivotal factor in stem cell maintenance 




CircFNDC3B was positively associated with hand grip strength. Although these 
associations were nominal only, they were present both cross-sectionally and 
longitudinally. An average person may lose ~20-40% of skeletal muscle mass as well 
as muscle strength from by the time they reach 80 years of age (Carmeli et al., 2002; 
Doherty, 2003) and decline in skeletal muscle strength is predictive of disability and 
mortality in humans (Giampaoli et al., 1999; Rantanen et al., 1999; Rantanen et al., 
2012). Circular RNAs originating from this gene have been reported previously, and 
suggested to possess tumour suppressor activity (Liu et al., 2018).  
 
The results generated from our mouse data suggest that circPlekhm1, which was 
associated with median strain longevity may drive longevity, rather than being 
consequential to it, since the associations are present in the spleen RNA of young 
mice alone. The Plekhm1 gene encodes a multivalent adaptor protein that integrates 
endocytic and autophagic pathways at the lysosome (McEwan and Dikic, 2015). Its 
role in lifespan may therefore stem from moderation of lysosomal trafficking since 
lysosomes play a critical part in successful ageing and longevity (Carmona-Gutierrez 
et al., 2016; Simonsen et al., 2007).  
 
Our study has both strengths and weaknesses. It represents one of the first circRNA 
profiles in ageing human peripheral blood, and provides data not only population-level 
epidemiological evidence for a role in human ageing phenotypes, or mammalian 
lifespan, but also in vitro evidence that some circRNA may influence cell senescence 
phenotypes. Weaknesses include a relatively low power to detect effects of in the 
population study, which might be attributed to the biological variation in circRNA levels 
and limitations in samples size and power. While differential expression of circRNA by 
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sex has been mentioned in a study on patients with sporadic parathyroid adenomas  
suggesting the role of epigenetics in the gender specific differences of these patients 
(Yavropoulou et al., 2018). Another study shows sexual dimorphism of circRNAs in 6 
organs of the 8 organs i.e brain, heart, lung, liver, kidney, muscle, testes and thymus 
in rats. However, liver was relatively devoid of such sexual dimorphism (Mahmoudi 
and Cairns, 2019). Sex-related circRNA expression is also found in rhesus macaque 
brain like in the rat brain from the previous study (Xu et al., 2018). Gender-specific 
expression changes were also observed with the expression of circRNAs derived from 
male-specific host genes including circCD99, circPREX1, and circTSPAN15. 
Additional gender-specific circRNAs included circEFCAB2 for males and circPCTP 
and circZNF484 for females (Sekar and Liang 2019). Another study reveals that 
approximately 50% of circRNAs between both sexes are common in nonsex organs, 
indicating not all circRNAs might serve as biomarkers for both sexes. However, the 
study also shows that the number of common circRNAs between both sexes increased 
with age for most organs except heart, spleen, and thymus in rats (Gong et al., 2011).   
In this study, we presented here data and selected candidate circRNAs for follow-up 
from pooled male and female samples.  
 
The circRNA profile was also generated from RNA samples with relatively low RNA 
integrity number (RIN) value. RNA sequencing is widely used for generating gene 
expression profiles. Prior to such RNA sequencing, the quality of the RNA is assessed 
using RIN. RIN affects the gene coverage and false positives in differential expression. 
Ideally, high RIN of 8 would be used for RNA sequencing experiments. However, RNA 
is susceptible to degradation and obtaining high quality RNA from certain clinical 
tissues is often impossible or when samples collected in a certain way is the sole 
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source for addressing specific questions. This is important since not all transcripts are 
degraded at the same rate and therefore it is not possible to have a linearly reduced 
library size that can be corrected solely by normalization. One study revealed that RIN 
introduce inter-run variation because  
degradation introduces of variance in the RNAseq outputs reducing library complexity 
when assessing profile for linear transcripts, using a protocol that does not rely on 
PolyA selection or RiboZero or by using 3’ Tag Counting (Sigurgeirsson, 
Emanuelsson, and Lundeberg 2014). However, in another study, it was shown that 
standard normalizations fails to compensate for the effects of degradation but using a 
linear model framework can compensate for the majority of these effects and therefore 
extract biologically meaningful data from degraded samples having low RIN value 
(Gallego Romero et al., 2014). This is important since excluding rare samples would 
leave those questions unanswered or result in low power in studies than having to 
globally correct for RIN values to only include samples with high RIN.  
 
Nevertheless, we were able to identify some interesting associations, which likely 
represent the largest effects. Future work could include validation of epidemiological 
data in larger sample sets, and also functional delineation of the molecular effects of 
the circRNA in question. Our data provide evidence that circRNAs may play an 
important role in the determination of mammalian ageing phenotypes. CircRNAs are 
inherently stable, due to their exonuclease resistance, and are found not only in 
tissues relevant to human diseases, but also in the circulation, raising the possibility 
that they may prove useful as biomarkers of disease or targets for molecular therapies 














Chapter 4 – Data chapter 
 
Islet-expressed circular RNAs are associated with 





























Circular RNAs are an emerging class of non-coding RNA molecule with gene 
regulatory potential; dysregulation of circRNAs has been reported in association with 
several human diseases. Here we aimed to produce an enriched circRNA profile for 
human pancreatic islets, and explore the relationship between circRNA expression, 
diabetes status, genotype at T2D risk loci and measures of glycaemia (insulin 
secretory index; SI and HbA1c) in human islet preparations from healthy control 
donors and donors with type 2 diabetes. We also assessed the effect of elevated 
glucose, cytokine and lipid and hypoxia on circRNA expression in the human beta cell 
line EndoC-βH1. We identified over 2600 circRNAs present in islets, of which 47 had 
not been previously described in other tissues. Of the five most abundant circRNAs in 
human islets, four (circCIRBP, circZKSCAN1, circRPH3AL and circCAMSAP1) 
demonstrated marked associations with diabetes status. CircCIRBP also 
demonstrated an association with insulin secretory index in isolated human islets and 
circCIRBP and circRPH3AL displayed altered expression with elevated fatty acid in 
treated EndoC-βH1 cells. No associations between circRNA expression and genotype 
at T2D risk loci were identified in our samples. Our data suggest that circRNAs are 
abundantly expressed in human islets, are differentially regulated in the islets of 
donors with type 2 diabetes, and some may derive from genes with roles in exocytosis 








One of the key difficulties in dissecting the factors driving progression of multifactorial 
polygenic chronic diseases such as type 2 diabetes (T2D) is the degree of 
heterogeneity that it presents. Although the development of diabetes like other 
common chronic disorders has a large lifestyle contribution, there is a substantial 
genetic component (Xue et al., 2018). 70% of individuals with prediabetes eventually 
develop diabetes (Bansal, 2015; Tabak et al., 2012), with increasing evidence 
suggesting that diabetic complications such as peripheral nephropathy and 
retinopathy may initiate at the pre-diabetic stage (Tabak et al., 2012). Identifying 
people at risk of type 2 diabetes, or those likely to progress from impaired glucose 
tolerance to overt disease is thus an important aim. Understanding the molecular 
causes of T2D, and identification of sensitive and specific biomarkers to indicate those 
at risk of pre-diabetes, or of transition from pre-diabetes to overt disease is therefore 
a key aim for research. 
 
Genome wide association studies (GWAS) for T2D have identified over 143 risk loci 
associated with susceptibility to T2D (Xue et al., 2018). More than 85% of these 
disease-associated variants reside in non-coding regions of the genome (Edwards et 
al., 2013). Over 80% of the human genome is predicted to display some degree of 
functionality (Qu and Fang, 2013), so it is likely that the many of the diabetes-
associated genetic variants may act via dysregulation of gene expression. Disruption 
of the activity or function of non-coding RNAs that moderate gene activity, such as 
microRNA (miRNA) or long non-coding RNA (lncRNA) may have particular relevance 




Circular RNAs (circRNAs) are an emerging class of non-coding RNA (ncRNA) 
generated by the back splicing of downstream exons to the 3’ acceptor splice site of 
upstream exons and result in a covalently closed circular structure containing one or 
more exons (Haque and Harries, 2017). Their mode(s) of action remain to be fully 
elucidated but they have been suggested to manipulate gene expression by 
moderation of transcription (Bose and Ain, 2018), interaction with cellular proteins (Luo 
et al., 2019), sequestration of RNA-binding proteins (Zang et al., 2018) or sponging 
miRNA (Kulcheski et al., 2016). Their covalently closed structure means that they are 
resistant to exonucleases; accordingly, they have half-lives on average 19-24 hours 
(Enuka et al., 2016), being significantly more stable than linear mRNAs from their 
cognate genes which have half-lives typically in the region of 4-9 hours 
(Schwanhausser et al., 2011). Data on circRNA abundance can be extracted from 
conventional NGS data, but such data may also include aberrant back spliced 
sequences from linear transcripts as well as genuine circRNAs.  
 
Cell-type specific circRNA expression has previously been reported in human 
pancreatic β, α and δ cells (Kaur et al., 2018), but these profiles were not circRNA-
specific, being extracted from published NGS data in the absence of RNAse R 
treatment to remove linear RNA. Other human islet circRNA profiles have been 
generated using microarray approaches, which will capture only known circRNAs 
(Stoll et al., 2018).  
 
We present here an enriched whole circRNAome profile from primary human 
pancreatic islets which we have generated using a modified circleSeq technique 
(Lopez-Jimenez et al., 2018). This included an RNAse R step to remove linear RNA 
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and enrich for circRNAs. We then aimed to determine firstly whether expression of the 
most abundantly-expressed islet circRNAs were associated with insulin secretory 
index (SI), donor HbA1c or donor diabetes status in human primary islets. Secondly, 
we aimed to determine whether circRNAs localising to the genomic regions 
encompassing the GWAS association signals for type 2 diabetes were differentially-
expressed according to donor risk genotype. Thirdly, we aimed to explore whether 
abundantly-expressed circRNAs were responsive to diabetomimetic stimuli (hypo- or 
hyperglycaemia, hypoxia, elevated fatty acids or inflammatory cytokines), in the 
human beta cell line EndoC-βH1.  
 
4/5 circRNAs most abundant in human islets (circCAMSAP1, circCIRBP, circRPH3AL 
and circZKSCAN1) were differentially-expressed in the islets of patients with type 2 
diabetes compared with control samples. The linear transcripts of CAMSAP1, CIRBP 
and ZKSCAN1 also demonstrated associations with T2D status, as did the linear 
transcript of RHOBTB3. 1 of 5 of the most abundantly-expressed circRNA species in 
primary human islets (circCIRBP) demonstrated a nominal inverse correlation with 
insulin secretory index in islets from non-diabetic donors. No circRNA mapping to T2D 
GWAS loci however demonstrated associations between their expression and T2D 
risk genotype and associations with donor HbA1c were identified. 2 of the 5 most 
abundantly expressed circRNAs (circCIRBP and circRPH3AL) also demonstrated 
differential expression in response to elevated free fatty acids in treated EndoC-βH1 
cells.  To conclude, we have produced the first global circRNA-only profile in human 





4.2 Methods  
4.2.1 Pancreatic islet preparations 
Snap-frozen islet preparations were purchased from ProCell Biotech (Newport Beach, 
CA, USA) where islets had been collected with ethical permission at source. Islet purity 
and viability was determined by dithizone and fluorescein diacetate/propidium iodide 
staining, respectively. RNAlater-ICE (Life Technologies, Carlsbad, CA, USA) was 
used to transition the tissue to a state where RNA could be extracted using the 
miRVana miRNA isolation kit, as per the manufacturers’ instructions and using the 
total RNA extraction protocol. RNA Integrity Number (RIN) was determined for all 
samples using an Agilent Bioanalyser (Agilent, Santa Clara, USA). 53 islet samples 
were available from healthy donors, and 20 from donors with T2D. Islet donor 
characteristics are given in table 10. 
 
 
4.2.2 Generation of human primary islet circRNA profile  
Circular RNA profiles were initially generated from 5 individual islet total RNA samples 
from individuals without T2D which were pooled and profiled for circRNA expression 
using a modified ‘CircleSeq’ procedure. Samples derived from 3 females and 2 males, 
with an average age of 50.2 years and an average BMI of 26.4. Islet preparations had, 
an average viability 94.4% and an average purity of 81%. 2 µg RNA (RIN 6.4) was 
divided into two aliquots; one aliquot was treated with 20 units RNAse R (Epicentre, 
Madison, USA) at 30˚C for 30 minutes to remove linear RNA, one samples was mock-
treated using 1 µl RNase-free water in place of the enzyme. Both aliquots were 
processed in parallel using 2 volumes RNAClean beads (Beckman Coulter, 
Indianapolis, USA) to remove the enzyme. The results of the RNase R treatment were 
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confirmed on a high sensitivity RNA screentape (Agilent, Santa Clara, USA). 
Ribosomal RNA was removed and indexed sequencing libraries made using the 
TruSeq direction library preparation kit with Ribozero depletion (Illumina, San Diego, 
USA). Concentration of the final libraries was determined by qPCR and adjusted for 
size using Tapestation D1000 analysis (Agilent, Santa Clara, USA). Libraries were 
pooled in equimolar quantities, denatured and diluted to 9.0 pM + 1% PhiX for 
clustering and 100 paired-end Illumina sequencing in a single lane using HiSeq Rapid 
SBS reagents (V2). 62M reads were obtained from the RNAse R-treated sample and 
41M reads from the mock-treated sample with a mean Q score of 38.9-39.1 and total 





Table 10 Sample and donor characteristics for human pancreatic islet samples 
used in this work. A. Characteristics of human islet preparations from donors with (n 
= 20) and without (n = 50) T2D for assessing association of gene expression with 
diabetic status in the islets.  SD = standard deviation. Differences in parameters 
between islet groups was determined by t-test. B. Characteristics of human islets from 
non-diabetic donors (n=53) for association of gene expression with genotype in islets. 
SNP-1 = major alleles; SNP-2 = minor alleles. 
  Control (n=50) T2D (n = 20) p-value  
  Mean  SD Mean  SD  
Age  40.66 14.25 53.55 9.22 <0.001 
BMI  28.30 6.83 33.05 10.31 0.027 
SI 2.45 1.26 - - - 
HbA1c 5.44 0.36 - - - 
Purity 89.28 6.00 80.38 14.92 <0.001 
Viability  93.53 4.80 89.73 4.54 0.003 
Sex  F (40%);  M (60%) F (45%) M (55%) 0.706 
Ethnicity  white (74%) other (26%) white (45%)  other (55%) 0.348 
 
B. 
  p-value  SNP-1 SNP-2 
    Mean  SD Mean  SD 
rs6819243 (CTBP1)     
Age  0.620 40.19 14.12 42.38 11.78 
BMI  0.715 27.85 5.34 27.16 7.03 
Purity 0.671 89.26 5.86 90.00 3.54 
Viability  0.633 93.33 5.68 94.12 2.38 
Sex  0.595 F (53 %) M (47%) F (38%) M (62%) 
Ethnicity  0.020 white (83%) other (17%) white (31%)  other (69%) 
      
rs10758593 
(GLIS3)     
Age  0.966 41.08 15.04 40.88 12.25 
BMI  0.130 26.27 4.14 29.07 5.80 
Purity 0.633 89.46 4.96 88.50 6.26 
Viability  0.133 94.81 3.09 92.33 5.37 
Sex  0.269 F (39%) M (62%) F (42%) M (58%) 
Ethnicity  0.916 white (69%) other (31%) white (73%)  other (27%) 
      
rs7177055 (HMG20A)    
Age  0.371 39.97 13.95 43.69 12.35 
BMI  0.355 27.83 5.63 29.87 9.46 
Purity 0.998 89.13 5.18 89.13 6.18 
Viability  0.986 93.37 4.03 93.34 6.70 
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Sex  0.547 F (47%) M (53%) F (38%) M (63%) 
Ethnicity  0.697 white (72%) other (28%) white (75%)  other (25%) 
      
 
rs1111875  (IDE)     
Age  <0.001 48.58 9.95 33.43 12.20 
BMI  0.088 30.05 8.52 26.50 4.80 
Purity 0.175 88.61 4.91 90.57 4.73 
Viability  0.374 94.57 3.30 93.57 4.20 
Sex  0.056 F (58%) M (42%) F (30%) M (70%) 
Ethnicity  0.733 white (67%) other (33%) white (74%)  other (26%) 
      
rs12427353 
(SPPL3)     
Age  0.137 39.68 14.15 46.80 9.02 
BMI  0.104 29.03 7.32 25.03 4.00 
Purity 0.267 89.98 5.22 87.78 5.65 
Viability  0.645 93.48 5.28 94.33 3.50 
Sex  0.092 F (40%) M (60%) F (70%) M (30%) 
Ethnicity  0.949 white (68%) other (33%) white (80%)  other (20%) 
      
rs10203174 (THADA)    
Age  0.802 42.18 13.62 43.36 13.38 
BMI  0.155 29.07 7.54 25.54 5.13 
Purity 0.754 89.64 4.50 89.09 6.25 
Viability  0.565 93.85 4.25 94.64 2.46 
Sex  0.546 F (47%) M (53%) F (36%) M (64%) 







4.2.3 Analysis of circRNA profiles 
RNase R and mock-treated sequence data were assembled and putative circular 
RNAs were identified using PTESFinder (Izuogu et al., 2016) with the human genome 
(hg19) reference files provided with the software, a segment size of 65 and a 
uniqueness score of 7. The remaining parameters were left to default settings. To 
calculate a comparable measure of circular RNA abundance between samples we 
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used a measure termed back spliced reads per million mapped reads (bpm) for each 
circular RNA i is defined as: 
𝑏𝑝𝑚𝑖 =  (
𝑗𝑖
∑ 𝑗𝑎 + 
𝑛
𝑎=1 ∑ 𝑐𝑏 
𝑛
𝑏=1
) . 106 
 
Where Ji is the number of reads mapped to the backsplicedd junction of the circular 
RNA, c is the number of reads mapped to canonical sites of the gene with the circular 
RNA and n is the number of circular RNAs identified. This measure is designed to be 
similar to the commonly used reads per kilobase per million mapped reads (RPKM) 
metric used regularly to estimate gene expression from RNA-Seq data. 
 
In addition to circular RNA detection using PTESFinder, reads from all samples were 
also mapped to the human genome reference (hg19) obtained from iGenomes using 
Tophat v2.1.0 with the pre-set sensitive alignment parameters in paired end mode 
(Trapnell et al., 2009). The number of reads mapping to each exon of each gene was 
then calculated using FeatureCounts v2.0.0 with parameters for unstranded 
alignment, paired reads, count multi-mapping reads and assigning reads to 
overlapping features (Liao et al., 2013; Liao et al., 2014). Counts were used to 
calculate RPKM per exon using the standard method to compare the expression of 
each exon across samples. 
 
  
4.2.4 Analysis of genes hosting differentially-regulated circRNA 
To determine whether circRNAs to date identified only in islets, or those representing 
the top 10% most abundant demonstrated enrichment in specific gene ontology 
pathways, we carried out a Cytoscape version 2.5.2 plug-in ClueGO analysis which 
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incorporates KEGG, REACTOME and WikiPathways (Bindea et al., 2009). Outputs 
were selected based on ‘enrichment/depletion’ through a two-sided hypergeometric 
test with Bonferroni step down for p-value correction with the selected ontologies 
reference set of chosen genes. The GO terms were used to group functional pathways 
and the leading functional grouping was based on highest significant kappa score.  
 
 
4.2.5 Selection of circRNAs for validation  
CircRNAs were selected for follow up on two criteria. Firstly, levels of individual 
circRNAs in the islet were ranked by abundance. We selected the 5 most abundantly 
expressed circRNAs (circCAMSAP1, circCIRBP, circRHOBTB3, circRPH3AL and 
circZKSCAN1) for further analysis. We also assessed the expression of the linear 
reference transcript for each circRNA in each case. The second class of circRNAs 
selected for follow up were those mapping to the GWAS loci for T2D.  
 
The circRNA profile in our study was mapped against the T2D susceptibility loci 
(Morris et al., 2012). The co-ordinates of the upstream and downstream exons 
predicted to constitute each circRNA were then cross-referenced against the T2D 
GWAS signals using Python 2.7 to determine whether any circRNAs co-localized 
within the recombination windows.  Pythoon codes used are shown in (Fig A3).13 
circRNAs fulfilled these criteria and were selected for follow up (circCTBP1_1, 
circCTBP1_2, circGLIS3, circHMG20A, circIDE1, circIDE2, circSPPL3_1, 
circSPPL3_2, circTHADA1, circTHADA2, circTHADA3, circTHADA4 and 




4.2.6 Design of qPCR assays for circRNA validation 
Custom designed quantitative qRTPCR assays for quantification of relative expression 
were designed to unique back-spliced circRNA junctions (ThermoFisher, Foster City, 
USA), the sequences of which are given in table 11. Each target sequence was 
checked for the presence of single nucleotide polymorphisms in potential primer or 
probe binding regions prior to ordering. Assays were ordered as custom single tube 
assays from ThermoFisher (Foster City, USA) or IDT (Iowa, USA). Each circRNA 
probe was validated for sensitivity and linearity using standard curves produced from 
1:10 serial dilutions of synthetic oligonucleotides corresponding to each back spliced 
junction (ThermoFisher, Foster City, USA). Standard curves for the assays are shown 
in appendix (Fig A2). 
 
Table 11 CircRNA probe and primer sequences 


















4.2.7 Expression of islet circRNAs in other tissues 
The expression of the 13 circRNAs co-localizing to T2D-GWAS loci and the 5 most 
abundant circRNAs expressed in pancreatic islets and their parent linear transcripts 
were assessed in 39 different commercially available RNA samples of various tissues 
by quantitative qRTPCR. Reaction mixes contained 2.5 μL Taqman® Universal PCR 
mastermix II, no AmpErase® UNG, (ThermoFisher, Foster City, USA), 1.75 μL dH2O, 
0.5 μL cDNA and 0.25 μL Taqman® gene expression assay (ThermoFisher, Foster 
City, USA) in a 5 μL final reaction volume on 384 well qRTPCR plates. qRTPCR was 
run at 50 °C for 2 min, 95 °C for 10 min and 50 cycles of 15 s at 95 °C for 30 s and 1 
min at 60 °C on the QuantStudio 12K Flex Real-Time PCR System. Each sample 
assay was conducted in 3 technical replicates.  
 
 
Gene Assay ID Supplier 
Endogenous controls
B2M Hs00187782_m1 Thermofisher Scientific
GUSB Hs00939627_m1 Thermofisher Scientific
PPIA Hs04194521_s1 Thermofisher Scientific
B2M Hs.PT.58v.18759587 Integrated DNA Technologies
GUSB Hs.PT.39a.2214857 Integrated DNA Technologies
PPIA Hs.PT.58v.38887593.g Integrated DNA Technologies
Linear transcripts
CIRBP Hs00154457_m1 Thermofisher Scientific
CAMSAP1 Hs00251465_m1 Thermofisher Scientific
RHOBTB3 Hs00208554_m1 Thermofisher Scientific
RPH3AL Hs01063755_m1 Thermofisher Scientific
ZKSCAN1 Hs00379174_m1 Thermofisher Scientific
CTBP1 Hs00972287_m1 Thermofisher Scientific
GLIS3 Hs00541450_m1 Thermofisher Scientific
HMG20A Hs00217047_m1 Thermofisher Scientific
IDE Hs00610452_m1 Thermofisher Scientific
SPPL3 Hs00293370_m1 Thermofisher Scientific
THADA Hs00736554_m1 Thermofisher Scientific
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4.2.8 Reverse transcription of circRNAs in islet RNA and EndoC βH1 cells 
cDNA synthesis for analysis of circRNA expression in islets and across a panel of 
tissues was carried out using the Superscript® VILO™ cDNA synthesis kit 
(ThermoFisher, Foster City, USA) according to manufacturer’s instructions. Reactions 
contained 100 ng/μL RNA in a final reaction volume of 20µL. Reaction conditions were 
25°C for 10 min, 42°C for 60min and 85°C for 5min.  
 
 
4.2.9 Assessment of associations between the islet expression of abundant circRNAs, 
insulin secretory index (SI), HbA1c or T2D status  
RNA samples and clinical data were available for islet preparation from 50 non-
diabetic donors and from 20 donors with T2D. Islet donor characteristics are given in 
table 10. We assessed the expression of the 5 most abundant circRNAs expressed in 
pancreatic islets as well as their host linear transcripts in relation to insulin secretory 
index, HbA1c or diabetes status in these samples by quantitative qRTPCR. Reaction 
mix contained 2.5 μL Taqman® Universal PCR mastermix II, no AmpErase® UNG, 
(ThermoFisher, Foster City, USA), 1.75 μL dH2O, 0.5 μL cDNA and 0.25 μL Taqman® 
gene expression assay (ThermoFisher, Foster City, USA) in a 5 μL final reaction 
volume on 384 well qRT-PCR plates. qRTPCR was run at 50 °C for 2 min, 95 °C for 
10 min and 50 cycles of 15 s at 95 °C for 30 s and 1 min at 60 °C. Each sample assay 
was conducted in 3 technical replicates on the    QuantStudio 12K Flex Real-Time 
PCR System. Differential expression by diabetic status was then assessed by one-
way ANOVA using StataSE15 (StataCorp, Texas, USA), with adjustment made for 




4.2.10 Determination of donor genotype at T2D risk SNPs 
Python programming was used to cross-match the coordinates of the exons at the 
backsplice junctions with the coordinates of the T2D GWAS-loci. This ensured if the 
coordinates of the circRNA overlapped or encompassed within the T2D loci. We then 
sought to relate genotype at the GWAS association loci for T2D with expression of 
circRNAs located in those regions. Small amounts of genomic DNA are co-eluted in 
RNA preparations upon RNA extraction. We used a whole genome amplification 
(WGA) approach to access this genomic DNA for genotyping using the REPLI-g Mini 
kit (Qiagen, Paisley, UK). WGA was carried out using 2.5µL RNA and was performed 
according to manufacturer’s instructions. Genotype was then determined by Sanger 
Sequencing of PCR amplicons containing the SNP in question. PCR reaction mixes 
included 2.4µL primer mix containing a 1:1 ratio of forward: reverse primers 
(ThermoFisher, Foster City, USA), 4µL MegaMix-Royal (Microzone ͧ, Brighton, UK), 
1.60µL cDNA in a final reaction volume of 8µL. Reaction condition for PCR were 95°C 
for 12 min, 40 cycles for 95°C for 30s, annealing for 1 min, 72°C for 1 min followed by 
72°C for 10 min. In one case, sequence analysis proved inconclusive. In this case, 
genotype at the SNP in question was determined by qPCR with TaqMan® Genotyping 
assay. Reactions contained 2.5 μL TaqMan® Genotyping Master Mix (ThermoFisher, 
Waltham, MA, USA), 0.25 μL Taqman® genotyping assay (rs6819243) 
(ThermoFisher, Waltham, MA, USA), 1.75 μL dH2O and 0.5 μL whole genome 
amplified template in a 5 μL final reaction volume.  
  
RNA samples and phenotypic data were available from 53 non-diabetic islet donors. 
Characteristics of participants are given in table 10. The expression of 13 circRNAs 
co-localising to the genomic regions containing the GWAS association loci for T2D 
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was assessed in relation to genotype. Expression levels were quantified by qRTPCR 
as described earlier. Expression levels were then correlated with genotype of the islets 
was assessed by one-way ANOVA using StataSE15 (StataCorp, Texas, USA) with 
adjustment for age, sex, BMI and ethnicity.   
 




4.2.11 Assessment of circRNA expression in EndoC βH1 under diabetomimetic 
conditions  
The expression levels of the 5 circRNAs chosen on the basis of islet abundance and 
their linear transcripts were also assessed in the human pancreatic beta cell line 
EndoC-βH1, following exposure to dysregulated glucose (2.5mM and 25mM), hypoxia 
(1% O2), dyslipidaemia (0.5mM palmitic acid) or proinflammatory cytokines (TNFα 
(1000 U/ mL, INFγ (750 U/ mL) and IL1β (75 U/ mL) as previously described (Jeffery 
et al., 2019). CircRNA expression was measured using qRTPCR as described above 
on the QuantStudio 12K Flex platform (ThermoFisher, Foster City, USA). Samples 
were run in 3 biological replicates and 3 technical replicates. Differential circRNA 
expression in treated cells was then assessed by one-way ANOVA using StataSE15 
(StataCorp, Texas, USA).   










4.3.1 CircRNA profiling in islets  
2619 circRNAs were expressed in islet donors in the present study (online resource 
1). 47 of these circRNAs not been previously identified in human data from human 
tissues (multiple brain regions, muscle, thyroid and liver), and multiple cell types 
(including stem cells, skin and lung fibroblasts, neurons, lung epithelia, hepatocytes, 
breast cancer cells, lymphocytes, muscle myoblasts, aortic and  vascular endothelial 
cells) analysed using the circBase circRNA database (Glazar et al., 2014). The five 
circRNAs demonstrating the highest expression in human islets derived from the 
CAMSAP1, CIRBP, RPH3AL, RHOBTB3 and ZKSCAN1 loci. 13 circRNAs co-
localized with the GWAS association signals for T2D; these comprised GLIS3 and 
HMG20A (1 circRNA each), CTBP1, IDE and SPPL3 (2 circRNAs each) and THADA 
(five circRNAs). We selected these 18 circRNAs for further follow up. CircRNA 
structures were predicted based on the sequencing read depth for each exon and are 




Figure 13 Predicted structures of circRNA expressed in the islets selected for 
this study.  CircRNA structures backsplice junctions were predicted based on the 
sequencing read depth for each exon from pooled samples from 5 non-daibetic islets. 
The relative read depth of each backspliced junction is shown by the number of bars 
above the respective backsplice junction.  
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4.3.2 Pathway Analyses for genes generating islet-specific or abundant circRNAs 
Pathway enrichment analysis was carried out to determine whether the genes hosting 
the 47 ‘islet-specific’ circRNAs were enriched in any specific gene ontology (GO) 
pathways. A similar analysis was also carried out the genes hosting the top 10% most 
abundant circRNAs. Pathways analysis was performed using ClueGO cytoscape 
(Bindea et al., 2009). The circRNAs that so far seemed to be exclusively identified in 
islets unsurprisingly demonstrated enrichment for genes in the ‘pancreatic secretion’ 
pathway (p = <0.001). The 10% most abundantly expressed circRNAs were derived 
from genes demonstrating enrichment in the lysine degradation (p = 0.03), attenuation 
phase (p = 0.02), RUNX3 (p = 0.02) carcinoma (p = 0.01) and stem cell gene regulation 






Table 13 Enrichment analysis of potential pathways targeted by genes generating circRNAs expressed predominantly in 
human pancreatic islets. GO pathways analysis was carried out on A. ‘islet-specific’ circular RNAs and B. the top 10% most 
abundantly expressed circRNAs in human islets are presented here aligned to the hg19 genome alignment. Number of genes = 
number of differentially-expressed genes in each pathway. 
A. 
Pathways enriched in genes hosting circRNAs expressed predominantly in islets 
  
Pathway  p-value  
Number of 
Genes Genes 
Pancreatic secretion <0.0001 5 CELA3A, CFTR, CPA1, KCNQ1, PNLIPRP2 
  
B.        
Pathways enriched in genes generating the top 10% most abundantly-expressed circRNAs in islets  
Pathway  p-value  
Number of 
Genes Genes 
Hematopoietic Stem Cell Gene Regulation <0.0001 4 CREBBP, EP300, FOXO3, GABPB1 
Pathways affected in Adenoid Cystic Carcinoma 0.010 6 
CREBBP, EP300, FOXO3, KANSL1, KMT2C, 
MAML3 
Attenuation phase 0.020 3 CREBBP, DNAJB1, EP300 
RUNX3 regulates NOTCH signaling  0.020 3 CREBBP, EP300, MAML3 




4.3.3 CircRNAs are differentially expressed in a tissue-specific pattern 
We assessed the expression patterns of the 18 circRNAs selected for further analysis 
across a panel of human tissues. We demonstrated that the expression patterns of 
circRNAs did not always correlate with levels of their corresponding linear transcripts. 
The expression levels of circular and linear forms of the gene were sometimes 
divergent, indicating that the circRNAs are regulated independently from the mRNAs 
also deriving from the parental linear gene (Fig. 14). For instance, while circSPPL3_2 
was upregulated in most tissues compared to its linear gene, both circCAMSAP1 and 
circRHOBTB3 roughly followed the pattern of expression of their linear transcript levels 
across divergent tissues.  
A.  
B.  
Figure 14 Tissue profile of islet and GWAS-located circRNAs. Relative expression 
of circRNAs and their cognate transcripts have been assessed in 39 different commercially 
available tissue samples. The expression profile of 13 GWAS-localizing circRNAs are shown 




4.3.4 The most abundant islet circRNAs are associated with insulin secretory index 
(SI) or T2D status in human islets  
4/5 circRNAs that showed marked expression in the islets demonstrated an 
association with T2D status (Fig. 15; table 14). Three of these circRNAs, 
circCAMSAP1, circCIRBP and circRPH3AL satisfied the multiple testing threshold (p 
= <0.001, <0.001 and <0.001 respectively). CircZKSCAN1 showed nominal 
association with T2D status in islet donors (p=0.030). Of these, the expression of the 
linear transcripts genes of three of these circRNAs, CAMSAP1, CIRBP and ZKSCAN1 
were also significantly associated with diabetic status (p = <0.001, <0.001 and <0.001 
respectively). RHOBTB3 (p<0.001) also demonstrated significant association with 
T2D status although its circRNA showed no association. The majority of these were 
positive associations, with the exception of CIRBP and circCIRBP, which were 
negatively correlated with T2D status. In addition, one circRNA (circCIRBP) 
demonstrated a nominal negative association with insulin secretory index (p = 0.028; 








Table 14 Differential expression of the 5 most abundant islet circRNAs with 
insulin secretory index (SI), donor HbA1c or T2D status.  We measured the 
expression of the 5 most abundantly-expressed circRNAs and their linear counterparts 
in human pancreatic islet preparations using regression analysis with respect to A. 
Insulin secretory index (n = 50), B. Donor HbA1c (n = 18) or C. T2D status (n = 50 
control islets and 20 islets from T2D donors). SD = Standard Deviation. 95% CI = 95% 
confidence intervals. Transcripts demonstrating associations with glycaemic 
parameters that are significant in regression analysis following adjustment for multiple 
testing are given in bold underlined type. Those demonstrating nominal associations 
only are indicated in bold italic type and asterisks. 
A 
CircRNA β-coefficient p-value 95% CI 
CAMSAP1 0.051 0.444 -0.184 - 0.082 
CircCAMSAP1 0.060 0.101 -0.133 - 0.012 
CIRBP 0.007 0.894 -0.112 - 0.098 
CircCIRBP* -0.153 0.029 -0.289 - -0.017 
RHOBTB3* 0.083 0.044 0.003 - 0.164 
CircRHOBTB3 -0.017 0.64 -0.088 - 0.055 
RPH3AL 0.026 0.626 -0.133 - 0.081 
CircRPH3AL 0.034 0.532 -0.075 - 0.143 
ZKSCAN1 0.085 0.272 -0.069 - 0.239 
CircZKSCAN1 0.028 0.357 -0.033 - 0.090 
 
B 
CircRNA β-coefficient p-value 95% CI 
CAMSAP1 -0.297 0.368 -1.005 - 0.412 
CircCAMSAP1 0.128 0.582 -0.379 - 0.635 
CIRBP -0.423 0.325 -1.342 - 0.496 
CircCIRBP -0.024 0.977 -2.084 - 2.035 
RHOBTB3 0.237 0.429 -0.410 - 0.884 
CircRHOBTB3 -0.228 0.420 -0.837 - 0.382 
RPH3AL 0.25 0.423 -0.424 - 0.925 
CircRPH3AL 0.067 0.873 -0.858 - 0.992 
ZKSCAN1 -0.096 0.872 -1.402 - 1.210 
CircZKSCAN1 0.067 0.793 -0.490 - 0.623 
 
C. 
CircRNA Mean SD Mean SD p-value 
      
CAMSAP1 0.049 0.550 0.658 0.424 <0.001 
CircCAMSAP1 -0.010 0.302 1.341 0.405 <0.001 
CIRBP -0.007 0.454 -2.218 0.434 <0.001 
CircCIRBP 0.070 0.530 -1.996 0.266 <0.001 
RHOBTB3 0.000 0.428 -0.034 0.380 <0.001 
CircRHOBTB3 -0.009 0.425 0.823 0.494 0.419 
RPH3AL 0.000 0.333 0.452 0.274 0.891 
CircRPH3AL -0.048 0.303 -0.001 0.377 <0.001 
ZKSCAN1 -0.216 0.663 0.907 0.510 <0.001 
CircZKSCAN1* 0.019 0.267 0.211 0.537 0.012 







Figure 15 Differential expression of circCAMSAP1, circCIRBP, circRPH3AL and 
circZKSCAN1 in diabetic islets. Expression levels of circular and linear transcripts 
of the top 5 most abundant circRNAs in human islets are given here in relation to T2D 
status. Islets from non-diabetic individuals are given in grey (n = 50), those from 
individuals with T2D are given in black (n = 20). Relative expression of each linear or 
circular RNA is given on the Y axis. Statistical significance in difference of expression 
assessed by one-way ANOVA between islets from donors with or without T2D is 
indicated by stars. * = <0.05, ** = <0.005, *** = <0.001.   
 
 
4.3.5 CircRNA expression is not driven by genotype 
We next assessed the expression of circRNAs located in regions of the genome linked 
to risk of T2D. 13 circRNAs co-localised with the genomic regions encompassing the 
GWAS association signals for T2D; 2 circRNAs from the CTBP1 gene (in rs6819243 
region), one circRNA from the GLIS3 gene (rs10758593), one circRNA from the 




circRNAs from the SPPL3 gene (rs12427353) and five circRNAs deriving from the 
THADA gene (rs10203174). We identified no associations between any of these 
circRNAs and genotype at these loci (table15).  
 
 
Table 15 Association of expression of circRNAs mapping to T2D-GWAS loci and 
their parental transcripts with genotype in primary non-diabetic islets. The 
association assessed by one-way ANOVA between circRNA/linear transcript 
expression and genotype for circRNAs located to GWAS loci for T2D are given. 
Heterozygous samples and minor allele homozygotes are combined into one category. 
N=53.  SD = standard deviation. Genotypes: GG = most common allele observed. Gg 
= heterozygotes, gg = minor allele heterozygotes. 
Transcript   
GG 
  
       Gg and gg 
  
  p-value Mean  SD Mean  SD 
rs6819243      
CTBP1 0.781 -0.11 0.32 -0.04 0.34 
CircCTBP1_1 0.274 -0.03 0.65 0.09 0.37 
CircCTBP1_2 0.293 0.00 0.85 0.11 0.85 
      
rs10758593      
GLIS3 0.139 -0.19 0.37 0.02 0.36 
CircGLIS3 0.535 0.03 0.37 0.04 0.41 
      
rs7177055      
HMG20A 0.502 -0.03 0.38 0.09 0.37 
CircHMG20A 0.952 0.03 0.36 0.03 0.38 
      
rs1111875      
IDE 0.578 -0.66 0.39 -0.46 0.35 
CircIDE1 0.953 -0.02 0.40 0.04 0.45 
CircIDE2 0.937 -0.02 0.23 0.02 0.36 
      
rs12427353      
SPPL3 0.808 -0.01 0.48 0.05 0.43 
CircSPPL3_1 0.677 -0.02 0.45 0.06 0.34 
CircSPPL3_2 0.595 0.01 0.48 0.21 0.48 
      
rs10203174      
THADA 0.369 -0.02 0.61 0.22 0.50 
CircTHADA1 0.672 0.05 0.40 0.10 0.42 
CircTHADA2 0.282 -0.01 0.86 -0.33 0.96 
CircTHADA3 0.133 0.11 0.32 0.16 0.45 
CircTHADA4 0.319 0.06 0.39 -0.24 0.46 




4.3.6 CircRNAs are differentially expressed upon exposure to stress conditions 
in EndoC-βH1 cells 
Although the 5 most abundant circRNAs expressed in human islets did not show overt 
responsiveness to altered glucose, hypoxia or pro-inflammatory cytokines when tested 
in the human beta cell line EndoC-βH1, two (circCIRBP and circRPHAL3) did 
demonstrate changes in expression following treatment with 0.5mM palmitate. 
CircCIRBP expression was increased following treatment (p = 0.021) whereas 
circRPHAL3 demonstrated reduced expression (p = 0.022; table 16). The expression 
of the linear transcripts from the RHOBTB3 and ZKSCAN1 genes also demonstrated 
increased expression in EndoC-βH1 cells treated with palmitic acid, in the absence of 






Table 16 Expression of most abundantly expressed circRNAs and their parental 
transcripts in EndoC-βH1 cells treated with diabetes-related stresses. We 
assessed the effect of diabetes-related cellular stresses (low/high glucose, elevated 
fatty acid, hypoxia and exposure to pro-inflammatory cytokines) on the expression of 
the 5 most abundant islet circRNAs in the EndoC-βH1 human beta cell line by one-
way ANOVA. N=9 sapmles for each treatment conditions. IQR = interquartile range. 
Results meeting the threshold for 4 test conditions are given in bold underlined type, 
those presenting nominal associations only are indicated in bold italic type.  
 
Transcript  Treatment  p-value  Median (IQR)  
CAMSAP1 
Control  1.11 (0.95-1.39) 
2.5mM glucose 0.313 1.03 (0.92-1.05) 
25mM glucose 0.444 0.96 (0.95-1.17) 
Control  0.92 (0.89-1.06) 
1% O2 0.694 0.97 (0.73-1.04) 
3% O2 0.347 0.88 (0.63-0.99) 
Control  1.05 (0.95-1.08) 
Palmitic acid 0.062 0.89 (0.77-0.94) 
Control  0.93 (0.25-1.21) 
Cytokines 0.635 0.95 (0.90-0.99) 
CircCAMSAP1 
Control  0.84 (0.79-1.11) 
2.5mM glucose 0.762 1.02 (0.75-1.12) 
25mM glucose 0.681 0.92 (0.78-1.29) 
Control  0.98 (0.92-1.14) 
1% O2 0.136 0.89 (0.76-0.93) 
3% O2 0.292 0.83 (0.63-1.07) 
Control  1.04 (1.02-1.23) 
Palmitic acid 0.090 0.82 (0.65-1.00) 
Control  0.77 (0.27-1.14) 
Cytokines 0.555 0.99 (0.69-1.02) 
 
CIRBP 
Control  1.06 (0.83-1.08) 
2.5mM glucose 0.080 1.38 (1.10-1.53) 
25mM glucose 0.077 1.30 (1.14-1.56) 
Control  1.01 (0.99-1.09) 
1% O2 0.146 0.79 (0.39-0.97) 
3% O2 0.129 0.84 (0.74-1.02) 
Control  0.88 (0.65-1.09) 
Palmitic acid 0.907 0.91 (0.64-1.15) 
Control  0.90 (0.03-1.34) 
Cytokines 0.593 0.95 (0.93-1.06) 
CircCIRBP 
Control  0.77 (0.61-1.42) 
2.5mM glucose 0.844 0.86 (0.32-1.37) 
25mM glucose 0.652 0.77 (0.72-0.94) 
Control  1.10 (1.00-1.23) 
1% O2 0.955 0.86 (0.56-2.00) 
3% O2 0.726 0.89 (0.68-1.48) 
Control  0.75 (0.72-1.04) 




Control  1.17 (1.00-1.33) 
Cytokines 0.180 0.73 (0.69-1.06) 
 
RPH3AL 
Control  1.05 (0.93-1.06) 
2.5mM glucose 0.503 0.99 (0.75-1.07) 
25mM glucose 0.441 0.93 (0.80-1.08) 
Control  1.09 (1.06-1.37) 
1% O2 0.357 1.55 (1.04-1.56) 
3% O2 0.205 1.32 (1.28-1.81) 
Control  0.95 (0.87-0.99) 
Palmitic acid 0.102 0.84 (0.70-0.87) 
Control  0.98 (0.02-1.01) 
Cytokines 0.354 1.02 (0.91-1.12) 
CircRPH3AL 
Control  1.00 (0.45-1.00) 
2.5mM glucose 0.941 0.85 (0.58-0.97) 
25mM glucose 0.867 0.76 (0.73-0.86) 
Control  1.09 (1.06-1.37) 
1% O2 0.357 1.55 (1.04-1.56) 
3% O2 0.205 1.32 (1.28-1.81) 
Control  1.66 (1.32-1.85) 
Palmitic acid 0.022 0.97 (0.95-1.11) 
Control  0.68 (0.47-0.77) 
Cytokines 0.295 0.97 (0.55-1.02) 
 
RHOBTB3 
Control  1.24 (1.23-1.31) 
2.5mM glucose 0.188 1.11 (1.00-1.27) 
25mM glucose 0.117 1.20 (0.72-1.14) 
Control  0.95 (0.69-1.06) 
1% O2 0.949 0.97 (0.77-0.98) 
3% O2 0.353 0.67 (0.65-0.93) 
Control  0.80 (0.72-0.90) 
Palmitic acid 0.003 1.18 (1.15-1.21) 
Control  1.17 (0.29-1.35) 
Cytokines 0.186 1.59 (1.22-1.72) 
CircRHOBTB3 
Control  0.74 (0.73-1.00) 
2.5mM glucose 0.836 0.89 (0.65-1.02) 
25mM glucose 0.351 0.77 (0.57-0.78) 
Control  1.04 (0.72-1.08) 
1% O2 0.182 0.78 (0.74-0.78) 
3% O2 0.288 0.79 (0.77-0.86) 
Control  1.16 (0.99-1.27) 
Palmitic acid 0.306 1.03 (0.83-1.13) 
Control  1.01 (0.95-1.08)  
Cytokines 0.628 0.97 (0.89-1.06) 
 
ZKSCAN1 
Control  1.24 (1.18-1.33) 
2.5mM glucose 0.632 1.23 (1.05-1.87) 
25mM glucose 0.997 1.23 (1.16-1.36) 




1% O2 0.388 1.06 (0.94-1.12) 
3% O2 0.218 0.72 (0.66-0.98) 
Control  0.50 (0.39-0.55) 
Palmitic acid 0.001 1.01 (0.94-1.12) 
Control  1.29 (0.24-1.33) 
Cytokines 0.378 1.30 (1.27-1.35) 
CircZKSCAN1 
Control  0.86 (0.81-1.17) 
2.5mM glucose 0.490 0.91 (0.83-1.17) 
25mM glucose 0.505 0.88 (0.83-1.28) 
Control  1.11 (0.99-1.42) 
1% O2 0.060 1.65 (1.41-1.79) 
3% O2 0.631 1.24 (1.02-1.57) 
Control  1.01 (0.81-1.45) 
Palmitic acid 0.252 0.83 (0.75-0.91) 
Control  1.05 (0.10-1.13) 







We present here the first enriched circRNA profile from human primary pancreatic islet 
RNA produced from a modified NGS ciiscrcleSeq protocol with enrichment for 
circRNAs. We have identified 2619 circRNAs expressed in human islets, including 47 
circRNAs which were not identified in profiles from multiple other tissues in circBase. 
As mentioned earlier, the circRNA profile was generated from pooled samples of RNA 
from 5 non-diabetic islet donor. After selection of circRNAs from the circRNA profile 
based on their abundance in the RNA-Seq circRNA profile, five circRNAs were 
followed up in islets of a diabetic human cohort.  
 
Of the 18 circRNAs selected for follow up on the basis of abundance or co-localisation 
to the GWAS association signals for T2D, many also show evidence of regulation 
independent of their parent gene. 4 out of 5 of the most abundant circRNAs in human 
islets demonstrate strong evidence of dysregulated expression in the islets of human 




secretory index. 2 out of 5 also show dysregulated expression in human EndoC-βH1 
beta cells treated with fatty acids although direction of effect was not conserved.  
 
It is interestsing that both EP300 and FOXO3 are amongst the most abundance 
candidate circRNAs in the circRNA profile for peripheral blood as well as islets in this 
thesis. rs7903146 TCF7L2 variant display genotypic association in diabetic patients. 
Interactome analysis reveal this variant interacts with Ep300 which is a histone 
acetyltransferase and regulates transcription via chromatin remodelling that play a 
fundamental role in susceptibility to diabetes and other age related disorders 
(Garagnani et al., 2013).  FOXO is a mediator of the effects of insulin and insulin-like 
growth factors affecting several cellular processes such as proliferation, apoptosis, 
metabolism and response to oxidative stress. FOXO3 variants rs13217795, 
rs2764264, and rs2802292 were associated with lower blood glucose level in T2D 
elderly women (Mao et al., 2019). DAF-16 increases the expression of manganese 
superoxide dismutase which confers  protection against free radicals and thereby 
ageing  FoxO3 is also a driver in maintaining stem cell pool in mammals, exhaustion 
of which is a key hallmark of ageing (Morris et al., 2015; Willcox et al., 2008) . FOXO 
may mediate insulin effects on metabolism, control response to ROS and maintain 
stem cells and these may cumulatively influence longevity through multiple 
mechanisms in humans. 
 
To date, there have been two circRNA profiles generated from human pancreatic 
endocrine cells or intact islets. The first provides a circRNA profile generated from 
publically-available NGS data from isolated β, α and δ cell transcriptomes (Kaur et al., 




shared across cell types. This study reports more islet circRNAs than identified in our 
dataset, but this profile is derived from conventional NGS data, with no pre-treatment 
to remove linear sequences. Back splicing events can be generated from tandem DNA 
duplications within genes, or from trans-splicing events during linear splicing (Izuogu 
et al., 2016), so it is likely that profiles derived from conventional NGS contain 
‘circRNAs’ that in fact represent aberrantly spliced linear transcripts rather than 
genuine circRNAs. Differences will also arise in that this previous circRNA profile 
derives from isolated β, α and δ cell populations, whereas ours is a profile derived from 
intact islets. Differences in gene expression patterns may thus reflect the effects of 
cell:cell crosstalk as occurs in vivo. Nevertheless, there was considerable overlap 
between our circRNA and the beta cell circRNA profile reported earlier; >25% of the 
top 20 circRNAs in the beta cell profile have counterparts generated from the same 
genes in the top 20 most abundant circRNAs in our profile.   
 
A second islet circRNA profile has also been reported (Stoll et al., 2018). This profile 
was based on a microarray approach, identified 3441 islet circRNAs from a study of 3 
human islet samples (two female and one male donor). Since this is a microarray-
based profile, it will only contain circRNAs that have been already annotated. The most 
abundant circRNA in this study derived from the HIPK3 gene. We also identified a 
circRNA deriving from this gene in the top 75 most abundant circRNA transcripts in 
our profile. This study differs from ours in that follow up work on circRNA expression 
in cell lines and in relation to T2D status occurred in animal models and not in human 





Our data, like those reported in previous islet studies (Kaur et al., 2018; Stoll et al., 
2018) suggests that many of the circRNAs we have identified are regulated 
independently of their linear counterparts; the expression pattern of circular transcripts 
does not always echo that of their linear counterparts (Fig. 14). In some cases, we 
have identified associations between cell treatments or T2D status with circRNAs in 
the absence of apparent effects on their linear transcripts. Comparison of circRNA 
expression across tissues showed expression patterns of many circRNAs were often 
higher in brain tissues compared to other tissues, which is in line with existing 
knowledge that circRNAs accumulate in the brain (Gokool et al., 2019).   
 
Some of our circRNAs are associated with glycaemic traits in human islets. The 
expression of circCIRBP demonstrates a negative association with insulin secretory 
index (SI) of the donor islets, is elevated in human EndoC-βH1 beta cells treated with 
palmitic acid and is reduced in islets from donors with T2D. The parent gene CIRBP 
(Cold Inducible RNA Binding Protein) has roles in genotoxic stress response, not only 
from cold, but also from other cellular stressors such as hypoxia (Lee et al., 2015). 
Elevated levels have been associated with maintenance of glucose metabolism and 
protection from cold exposure through effects on the AKT pathway (Liu et al., 2019). 
The elevated levels we demonstrate in the human beta cell line EndoC-βH1 treated 
with palmitate may therefore represent an acute stress response to altered lipid. The 
lower levels in the islets of individuals with T2D may reflect lower stress tolerance in 
diabetic islets, and the inverse correlation with SI may reflect a compensatory effort to 






We also identified elevated levels of both circCAMPSAP1 and its host gene CAMSAP1 
in the islets of donors with T2D. CAMSAP1 encodes an organisation protein involved 
in microtubule dynamics and localisation (Baines et al., 2009). The dynamics of 
microtubule assembly and disassembly has an impact on the insulin secretion 
machinery; translocation of insulin granules along microtubules can influence their 
availability for secretion and failure to disassemble can impede docking. Microtubule 
density is higher in the islets of diabetic mice compared with non-diabetic littermates 
(Zhu et al., 2015). CAMSAPs are active in multiple tissues, and also have roles in 
white blood cells, which rely on the tubulin-microtubule system for lymphocyte 
activation (Sherline and Mundy, 1977). ZKSCAN1 and its circular RNA circZKSCAN1 
have been described as inhibitors of cellular proliferation and survival (Yao et al., 
2017).  Both transcripts demonstrate elevated expression in islets from donors with 
T2D, which may perhaps reflect adverse effects on beta cell survival. CircRPH3AL 
was also upregulated in diabetic islets. Linear transcripts from RPH3AL are highly 
expressed in β-cells and have roles in calcium-dependent exocytosis during granule 
maturation and insulin secretion (Matsunaga et al., 2017).  
 
We hypothesised that dysregulation of circRNA expression may underpin some of the 
GWAS association signals for T2D. 13 circRNAs colocalise to the recombination 
windows surrounding the 6 of the GWAS index loci, but none of these demonstrated 
differential expression by risk genotype. This suggests that the genetic associations 
between individual genetic variants and T2D is probably not mediated by dysregulation 





We acknowledge that at present our data are largely correlative, and do not offer 
information on causality, definitive mechanistic proof or insight into the regulatory 
relationships between circRNAs and their host genes. CircRNAs can have effects in 
cis by regulating the transcription, linear splicing or translation of linear transcripts from 
their host genes (Abdelmohsen et al., 2008; Ashwal-Fluss et al., 2014; Chao et al., 
1998; Grigull et al., 2004; Gualandi et al., 2003; Jeck et al., 2013). In our data, we 
observe similar responses of linear and circular transcripts in response to challenge 
(CAMSAP1/circCAMSAP1, CIRBP/circCIRBP, ZKSCAN1/circZKSCAN1). This may 
be a manifestation of effects on transcription of common pre-RNAs from which both 
forms can be expressed. Other circRNAs show dysregulated expression for the 
circRNA alone (circRPH3AL). This suggests that the effect of circRNA regulation is 
post-transcriptional in these cases. CircRNAs can also act in trans, by virtue of 
sponging of other non-coding (nc) RNAs or RNA binding proteins (Abdelmohsen et 
al., 2017; Piwecka et al., 2017; Zheng et al., 2016). In these cases, it is impossible to 
deduce from our data what the molecular targets of dysregulated islet circRNAs may 
be. 
 
There can also be issues of uneven degradation of linear trasncipts. Washing cells 
from tissue culture with PBS before extraction with Trizol and adding beta-
mercaptoethanol to the lysis buffer can stabilize the tissues during extraction by 
inactivating RNAase and therefore minimize uneven degradation of linear transcripts 
or rRNA. The use of RNase inhibitors as has been done in this project to generate 
RNASqeq data to prevent degradation by endogenous RNase. Storing in RNase-free 




at -20°C. However, the use of ethanol should be avoided because RNA cannot be 
dispersed evenly in solution and used for direct quantitative experiments.  
 
In conclusion, we present here an enriched circular RNA profile in human pancreatic 
islets. Although we find no evidence that the associations between T2D and genetic 
variation are underpinned by effects on the circRNA milieu, we demonstrate that the 
majority of the most abundant islet circRNAs display associations between their 
expression and aspects of glucose homeostasis in human donors. Furthermore, two 
of the top 5 most abundant circRNAs derive from genes with known roles in the 
mechanics of insulin exocytosis. We propose therefore that the circular RNA milieu in 






























Chapter 5 – Data Chapter 
 
Islet-expressed circular RNAs are associated with 
























The prevalence and incidence of T2D is expected to rise to 629 million by 
2045.  Intervention through lifestyle changes like healthy diet and physical activity 
during the early stages of T2D can improve insulin sensitivity. However, the 
management of insulin resistance by diet ought to be very carefully assessed because 
of the risk collapsing due to hypoglycaemia. Therefore, biomarkers to predict those at 
risk for T2D can enable physicians to offer dietary alterations early on in order to delay 
the onset of T2D and its associated co-morbidities. Many biomarkers for T2D show 
associations with diabetes status. However, the associations seem to be due to 
manifestation of confounding factors rather than causality. Given the chronic and 
heterogeneity manner of this disease, the use of biomarkers may better characterize 
risk and greatly assist healthcare decision making. In addition to using biomarkers for 
future risk assessment, it is essential that they can also be used to identify causal 
pathways even in cases where the associations might be comparatively weak. This 
can throw light into the development of new drug targets for preventive or 
individualized targeted therapeutic interventions. An important pre-requisite for this is 
the characterisation of circRNA sequences in diabetes-relevant tissues such as 
pancreatic islets and in more accessible tissues such as peripheral blood. CircRNAs 
are highly nuclease-resistant and thus more stable than linear transcripts, by virtue of 
their covalently closed bonds at the backspliced junctions. The half-lives of circRNAs 
are approximately 2.5 times that of the median half-lives of their linear transcripts. 
Many circRNAs are enriched in blood compared to the level of expression of their 
linear mRNAs. I assessed whether any of the circRNAs differentially in the islets were 
similarly dysregulated in the peripheral blood of individuals with pre-diabetes or overt 
disease. 3/5 of the most abundant islet circRNAs were expressed in blood. Of these, 




of patients with T2D. It may have the potential as a biomarker as future molecular 





5.1 Introduction  
Biomarkers are molecular entities that can predict intermediate outcomes or endpoints 
of disease states. The use of these entities makes it easier and quicker through 
cheaper approaches to assess risk of diseases or stages of disease than that would 
be possible from direct measurement of clinical endpoint often in inaccessible tissues. 
They can be used to predict the onset or progression of diseases, for screening, 
diagnosis and prognosis to determine outcomes or predict mortality which can often 
help make decision on individualized targeted therapeutic interventions (Aronson and 
Ferner, 2017).  
 
The prevalence and incidence of diabetes is expected to rise from 463 to 700 million 
by 2045  (Atlas 2019). Although, intervention through lifestyle changes like healthy diet 
and physical activity during the early stages of T2DM can improve insulin sensitivity, 
the management of insulin resistance by diet ought to be very carefully assessed 
because of the risk collapsing due to hypoglycaemia. Biomarkers to predict those at 
risk for T2D can enable physicians to offer dietary alterations early on in order to delay 
the onset of T2D and its associated co-morbidities. 
 
A successful biomarker should show minimal variability, surpass the effect on 
confounding factors sometimes and change proportionately in response to changes in 
disease states or upon response to therapeutic intervention (Aronson and Ferner, 
2017). It is often very cumbersome to determine a good candidate biomarker due to 
the pathophysiological complexities and the technical difficulties in validating 




for sampling handling to cover broad spectrum patients with different genetic 
background and environmental factors.  
 
Many biomarkers for T2D are not assessed based on the measurement of fasting 
glucose, 2-hour glucose or HbA1c levels leading to underestimation of incident cases 
of T2D. In other cases, the potential mechanisms leading to the T2D has remained 
unanswered especially in relation to impaired β-cell function which is the key to 
pathogenesis of T2D. Only 35 biomarkers have been reported in large scale studies 
with sample size of more than 1000 T2D cases of which none has strong evidence of 
association from genetic association studies that explaining underlying causal 
association (Abbasi et al., 2016). Many biomarkers like adiponectin (Dastani et al., 
2012; Yaghootkar et al., 2013), C-reactive protein (Brunner et al., 2008; Jensen et al., 
2013), triglycerides  (De Silva et al., 2011), vitamin D (Ye et al., 2015; Buijsse et al., 
2013), IL-1Ra (Anon, 2015) and uric acid (Pfister et al., 2011)  which show 
associations with diabetes, seem to be due to  manifestation of confounding rather 
than a causality. 
 
Given the chronic and heterogeneity manner of this disease, the use of biomarkers 
may better characterize risk and greatly assist healthcare decision making (Yach et 
al., 2004; Biomarkers Definitions Working Group. 2001). Many studies predicting of 
future risk to diabetes have included people with existing undiagnosed diabetes at 
baseline and thus may not have addressed  the problem of potential reverse causality 
(Abbasi et al., 2012; Kengne et al., 2014). Molecular entities expressed in easily 
accessible body fluids such as blood may play a role in quantifying the future risk of 




process.  In addition to using biomarkers for future risk assessment, it is essential that 
they can also be used to identify causal pathways even in cases where the 
associations might be comparatively weak. This can throw light into the development 
of new drug targets for preventive or targeted therapeutic interventions (Biomarkers 
Definitions Working Group. 2001) 
 
CircRNAs are highly nuclease-resistant and thus more stable than linear transcripts, 
by virtue of their covalently closed bonds at the backspliced junctions (Suzuki et al., 
2006; Lasda and Parker, 2016a). The half-lives of circRNAs are approximately 2.5 
times that of the median half-lives of their linear transcripts. The half-lives of circRNAs 
can be as long as 50 hrs. (Enuka et al., 2016). 
 
Many circRNAs are enriched in blood compared to the level of expression of their 
linear mRNAs. This makes them useful tools for non-invasive diagnostics assays using 
samples from otherwise inaccessible tissues (Memczak et al., 2015).  CircRNAs may 
have potential as biomarkers for the development of diabetes or as future molecular 
targets for novel diabetes therapeutics (Fang et al., 2018; Wu et al., 2019; Zhang et 
al., 2017). An important pre-requisite for this would be the characterisation of circRNA 
sequences in diabetes-relevant tissues such as pancreatic islets and in more 
accessible tissues such as peripheral blood.  
 
We aimed to determine whether abundant islet circRNAs were differentially expressed 
in the peripheral blood of individuals with pre-diabetes or overt disease. 3/5 of the most 
abundant islet circRNAs were also expressed in blood, and the expression of one, 




blood of patients with T2D, but not impaired glucose tolerance (IGT). These may have 
future potential as biomarkers of disease. This circRNA can perhaps be considered 
for further complex longitutdinal studies adjusting for the time at diagnosis, amount of 
physical acivity and lifestyle habits and other factors that may influence response in 




5.2.1 RNA extraction from peripheral blood samples from control donors, donors with 
IGT and those with T2D  
We assessed the expression of the 5 most abundant islet circRNAs in relation to 
diabetes status in RNA extracted from 285 peripheral blood samples from the Exeter 
10K study. Our sample set consisted of 133 non-diabetic patients (fasting glucose 
<100.8 mg/dL), 46 individuals with impaired glucose tolerance (fasting glucose 100.8 
to 122.4 mg/dL) and 106 patients with overt diabetes (fasting glucose >122.4mg/dL). 
Participant characteristics are given in table 17. This collection is a cross sectional 
population study consisting of samples collected from volunteer individuals living in 
the South West of England and recruited since 2010. Whole blood samples were 
collected in 2011/2012 using the PAXgene system (Debey-Pascher et al., 2009) and 
extracted using the PAXgene Blood RNA kit (Qiagen, Paisley, UK). Written informed 
consent was obtained for all participants and ethical permission was granted through 









Table 17 Participant characteristics for circRNA expression in peripheral blood. 
A. Anthropometric characteristics of peripheral blood donors with normal blood 
glucose (n = 133) and those with impaired glucose tolerance (IGT; n = 46) B. 
Anthropometric characteristics of peripheral blood donors with normal blood glucose 
(n = 133) and those with overt T2D (n = 106). Differences in parameters between islet 
groups was determined by t-test. 
A. 
      
  p-value  Control IGT 
    Mean  SD Mean  SD 
Age  0.016 52.45 17.08 59.26 14.31 
BMI  <0.001 26.51 4.13 28.93 3.68 
HbA1c - 5.61 0.34 - - 
Glucose  - 4.85 0.40 - - 
Sex  0.004 F (60%);  M (40%) F (40%) M (60%) 
Ethnicity  0.611 white (99%) other (1%) white (100%)  other (0%) 
  
B. 
  p-value  Control T2D  
    Mean  SD Mean  SD 
Age  <0.001 52.45 17.08 68.74 10.65 
BMI  <0.001 26.51 4.13 30.61 5.99 
HbA1c - 5.61 0.34 - - 
Glucose  - 4.85 0.40 - - 
Sex  0.001 F (60%);  M (40%) F (57%) M (43%) 
Ethnicity  0.445 white (99%) other (1%) white (99%)  other (1%) 




5.2.2 Design of qPCR assays for circRNA validation 
Custom designed quantitative qRTPCR assays for quantification of relative expression 
were designed to unique back-spliced circRNA junctions (IDT, Iowa, USA). Each 
target sequence was checked for the presence of single nucleotide polymorphisms in 
potential primer or probe binding regions prior to ordering. Assays were ordered as 





5.2.3 Assessment of circRNA expression in peripheral blood of pre-diabetic and 
diabetic participants 
The expression levels of the 3 circRNAs chosen on the basis of their differential 
expression in donor islets. CircRNA expression was measured using qRTPCR.  
Reaction mix contained 2.5 μL Taqman® Universal PCR mastermix II, no AmpErase® 
UNG, (ThermoFisher, Foster City, USA), 1.75 μL dH2O, 0.5 μL cDNA and 0.25 μL 
Taqman® gene expression assay (ThermoFisher, Foster City, USA) in a 5 μL final 
reaction volume on 384 well qRT-PCR plates. qRTPCR was run at 50 °C for 2 min, 95 
°C for 10 min and 50 cycles of 15 s at 95 °C for 30 s and 1 min at 60 °C. Each sample 
assay was conducted in 3 technical replicates on the QuantStudio 12K Flex Real-Time 
PCR System. Differential expression by diabetic status was then assessed by one-
way ANOVA using StataSE15 (StataCorp, Texas, USA), with adjustment made for 
potential confounders including age, sex, BMI and ethnicity.  
 
 
5.2.4 Assessment of associations between the islet expression of abundant circRNAs, 
insulin secretory index (SI), HbA1c or T2D status  
RNA samples and phenotypic data were available for the 133 non-diabetic patients, 
46 individuals with impaired glucose tolerance and 106 patients with overt diabetes. 
The expression of the 3 circRNAs were quantified by qRTPCR as described earlier. 
We assessed the expression in the peripheral blood were correlated with HbA1c or 
diabetes status in the study cohort by one-way ANOVA using StataSE15 (StataCorp, 






5.3 Results  
5.3.1 CircCAMSAP1 is differentially expressed in T2D peripheral blood  
Of the 4 circRNAs demonstrating evidence of altered expression in the islets of donors 
with T2D, two (circIDE1 and circRPH3AL) were not expressed in peripheral blood. Of 
the three remaining circRNAs which did have expression in peripheral blood 
(circCAMSAP1, circCIRBP and circZKSCAN1), circCAMSAP1 demonstrated a 
nominal negative association with diabetes status in the peripheral blood of patients 
with T2D (Fig. 16; table 18). No difference in expression was detected for any circRNA 
between control patients and those with IGT, or between those with IGT and those 
with T2D). No associations were evident between circRNA expression in peripheral 




Figure 16 Differential expression of circCAMSAP1 in peripheral blood of T2D 
participants. Peripheral blood circRNA levels are given here for non-diabetic samples 
(labelled in mid-grey; n=133), samples from individuals who have overt diabetes 
(labelled in black; n = 106) and those with impaired glucose tolerance IGT (labelled in 
light grey; n = 46).  Relative expression of circRNAs is given on the Y axis. Statistical 
significance, from one-way ANOVA analysis, in difference of expression between early 




Table 18 The expression of islet circRNAs according to diabetes status in the 
peripheral blood of individuals with IGT or overt T2D, compared with non-
diabetic controls. The expression of the circCAMSAP1, circCIRBP and 
circZKSCAN1 circRNAs is given here in relation to A. fasting blood glucose (n = 130) 
and B. HbA1c (n = 80) in the peripheral blood of non-diabetic controls. C. The 
expression of the circCAMSAP1, circCIRBP and circZKSCAN1 circRNAs is also given 
in relation to diabetes status in the peripheral blood of patients without disease (n 
=133), those with IGT (Impaired glucose tolerance; n = 46) and those with overt T2D 
(n = 106). Association of circRNA expression levels with fasting blood glucose level 
(A) and HbA1c (B) was assessed by linear regression and relation of circRNA 
expression levels with diabetes status (C) was assessed by ANOVA. SD = Standard 
deviation. Results showing statistical significance are indicated in bold italic type.  
A 
CircRNA β-coefficient                    95% CI  p-value 
CircCAMSAP1 0.069 -0.085 - 0.222 0.378 
CircCIRBP 0.039 -0.276 - 0.353 0.808 
CircZKSAN1 0.052 -0.135 - 0.238 0.585 
 
B. 
CircRNA β-coefficient                    95% CI  p-value 
CircCAMSAP1 -0.012 -0.269 - 0.245 0.928 
CircCIRBP 0.303 -0.105 - 0.710 0.143 
CircZKSAN1 -0.257 -0.558 - 0.044 0.093 
 
C.  
  Control Case 
Transcript p-value Mean SD Mean SD 
 
Control vs T2D 
CircCAMSAP1 0.029 -0.04 0.32 -0.10 0.32 
CircCIRBP 0.260 -0.03 0.64 -0.11 0.53 
CircZKSCAN1 0.054 0.03 0.39 0.05 0.37 
 
Control vs IGT 
CircCAMSAP1 0.606 -0.04 0.32 -0.05 0.29 
CircCIRBP 0.913 -0.03 0.64 -0.12 0.68 
CircZKSCAN1 0.987 0.03 0.39 0.06 0.34 
 
IGT vs T2D 
CircCAMSAP1 0.495 -0.05 0.29 -0.10 0.32 
CircCIRBP 0.281 -0.12 0.68 -0.11 0.53 







5.4 Discussion  
Because of their stability and sustained expression in easily accessible body fluids 
(Enuka et al., 2016), circRNAs have the potential to serve as biomarker for diagnostic 
and therapeutic procedures.  They may also contribute to the alternative isoforms 
profile during the progression of disease. An exonic circRNA circ-UBR5 has been 
suggested to be a potential regulator of RNA splicing. It is thought that circ-UBR5 may 
bind to the KH domain containing RNA binding of splicing regulatory factor QKI and 
NOVA alternative splicing regulator 1 (NOVA1) and U1 small nuclear RNA (snRNA) in 
the nucleus (Qin, Wei, and Sun, 2018). Thus, their differential expression may imply 
the dysregulation of key genes through alternative splicing in diseases as well. This 
chapter addresses the query if circRNAs, whose expression in the islets are 
associated diabetic status, show a similar pattern of dysregulation in the peripheral 
blood of pre-diabetic and diabetic patients. Of the 4 most abundant circRNAs that were 
differentially expressed in the islets, 3 circRNAs were expressed in blood. One 
circRNA was associated with diabetic status in the current study.  While there is 
nominal difference in expression of circRNA between control and T2D, this needs to 
be studied in a longitudinal satudy with a bigger sample size to ensure if the circRNA 
could be used to predict diabetic status. This will allows us to counteract for the 
confounding effect of lifestyle changes made at the pre-diabetic stage or in general 
including bacis physical acivity, eating habits and depending on the cohort on the 
ethnicity which might affect the risk alleles. 
 
One study which reported a circRNA as a predictor of pre-diabetes (Zhao et al., 2017). 
The circRNA was selected from the pre-annotated circRNAs in a microarray platform 




in a very smaller cohort of 20 normal cases, 20 pre-diabetes patients and 20 T2DM 
patients and then followed up finally in a small cohort of 60 control, 63 pre-diabetes, 
and 64 T2DM participants. In contrast, in this thesis, circRNAs were chosen based 
most differentially expression in islet using RNA-Seq enrichment method for circRNA 
and more islets and finally followed up in the peripheral blood of a reasonably larger 
cohort. 
 
Various stimulants mimicking the diabetic milieu is associated with dysregulation of 
circRNA expression. For instance, one study showed high glucose exposure leads to 
differential expression of 95 circRNAs in human endothelial cells (Shang et al., 2018). 
High glucose-induced human umbilical vein endothelial cells (HUVECs) also have 214 
differentially expressed circRNAs including hsa_circ_0008360, hsa_circ_0005741, 
hsa_circ_0003250, hsa_circ_0045462, hsa_circ_0064772, hsa_circ_0007976, and 
hsa_circ_0005263  (Jin et al., 2019). Other studies show high glucose induced RSC96 
cell have circRNA ACR sequestering miR-145-3p and activating PI3K/AKT/mTOR that 
lead to cell apoptosis and autophagy (Liu et al., 2019). Other findings show high 
glucose stimulates glomerular endothelial cells (GECs) to secrete exosomes enriched 
in circRNAs compared with normal glucose GECs. CircRNF169 and circSTRN3  in the 
exosomes enhances α-smooth muscle actin (α-SMA) expression and inhibits 
proliferation leading to epithelial-mesenchymal transition in glomerular mesangial cells 
implying the role of intercellular transfer of circRNAs  in diabetic nephropathy   (Ling 
et al., 2019). In addition, high-glucose exposed cardiomyocytes have enhanced 
expression of circRNA CACR like that of the serum of diabetic patients. It modulates 
miR-214-3p regulated expression of caspase-1 silencing pyroptosis i.e. the 




inflammation leading to cardiac hypertrophy and fibrosis in diabetic cardiomyopathy 
(Yang et al., 2019). CircRNA_15698 modulates expression of miR-185/TGF-β1 and 
promotes extracellular matrix related protein synthesis in mesangial cells in 
diabetic nephropathy mice. It is upregulated in high glucose induced mouse mesangial 
cells and diabetic mice (Hu et al., 2019, 1). CircACTR2 is also upregulated in high 
glucose-induced cells and regulate cell death and inflammation as its knockdown 
causes decreased pyroptosis, interleukin (IL)-1β release and collagen IV and 
fibronectin production (Wen et al., 2020).  
 
Apart from hyperglycaemia exposure, β-cells isolated from rat islets of high fat and 
high sugar diet induced T2D in rat model have 825 differentially expressed circRNA of 
which 388 are upregulated and 437 downregulated. Pathways analysis indicate these 
circRNAs, including rno_circRNA_008565, may regulate of  β-cell autophagy (Bai et 
al., 2019). One circRNA, circHIPK3, has been shown to contribute to hyperglycaemia 
and insulin resistance in a miR-192-5p-dependent manner. Fatty acid oleate 
stimulation leads to upregulation of circHIPK3 which enhances the stimulatory effect 
of oleate on adipose deposition as well as increases triglyceride and cellular glucose 
content in HepG2 cells. CircHIPK3 asserts its effect by decreasing miR-192-5p and 
thereby increasing transcription factor forkhead box O1 (FOXO1) which is a 
downstream regulator of miR-192-5p. These cells have increased levels of 
forskolin/dexamethasone (FSK/DEX) , phosphoenolpyruvate carboxykinase (PEPCK) 






Other studies indicate differential expression of several circRNAs in diabetes-related 
complications. For example, hsa_circRNA_103410  upregulated in diabetic 
retinopathy patients and is thought to  promote endothelial injury in the retina, while 
hsa_circRNA_100192, could, by sequestering miR-146, promote NF-κB activation, 
adenosine deaminase-2 expression and inflammatory cytokines (Gu et al., 2017). 
Another circRNA, circHIPK3 is thought to lead to miR-30a-3p dependent elevation in 
expression levels of VEGFC, FZD4, and WNT2 in diabetic retinas (Shan et al., 2017). 
Downregulation of circDNMT3B associated with vascular dysfunction in retinas of 
diabetic patients and in vitro models in a miR-20b-5p and BMBI dependent manner 
(Zhu et al., 2019). Other reports indicate more than 1000 circRNAs are differentially 
expressed in diabetic cataract tissues. (Fan et al., 2019) . 183 circRNAs are 
upregulated while 64 downregulated in the T2D depressed patients compared those 
who are T2D without depression (Jiang et al., 2017). Another study shows 
hsa_circ_0084443, in the cytoplasm of human epidermal keratinocytes, is upregulated 
in diabetic foot ulcer.  It reduces motility while enhancing the growth of keratinocytes 
(Wang et al., 2020).  
 
Other studies related to diabetic complication show circRNA cPWWP2A disrupts the 
crosstalk between vascular pericytes and endothelial cells and causes lethal vascular 
damage in diabetes as a result of disrupted microvascular stabilization and 
remodelling. Overexpression of circRNA and subsequent miR-579 inhibition leads to 
decreased expression of angiopoietin 1, occludin, and SIRT1 which 
alleviates diabetes -induced retinal vascular dysfunction (Liu et al., 2019) . 
Circ_0005015 is also upregulated in the plasma and fibrovascular membranes of 




and STAT3 expression in patients. Circ_0005015 is thus thought to facilitate retinal 
endothelial angiogenic function via regulating endothelial cell proliferation, migration, 
and tube formation (Zhang et al., 2017). 
As many as 227 circRNAs are up-regulated and 255 circRNAs are down-regulated in 
diabetic pregnancy (Yan et al., 2018). Hsa_cirRNA_0054633 expression,  amongst 
others, associate with gestational HBA1c levels in maternal blood , placental tissue 
and umbilical cord blood samples during various stages of gestational diabetes (Wu 
et al., 2019). Other circRNAs like circ_5824, circ_3636, and circ_0395 are 
downregulated in gestation diabetics (Wang et al., 2019). 
 
Recent findings imply as many as 497 circRNAs are conserved in mouse and human 
islets. Of these at least, circHIPK3 and ciRS-7/CDR1as are downregulated in the islets 
of diabetic diabetic mouse islets, impair insulin secretion, reduce β-cell proliferation, 
and survival. CircHIPK3 sequesters miR-124-3p and miR-338-3p resulting in 
modulation of expression of key β-cell genes like as Slc2a2, Akt1, and Mtpn (Stoll et 
al., 2018) . CircHIPK3 is downregulated in HUVECS and primary aortic endothelial 
cells from diabetic patients. It modifies miR-124 expression and inhibits high glucose-
induced cell death and apoptosis in HUVECs and  prevents high glucose-induced 
vascular endothelial cell injury (Cao et al., 2018).  CircHIPK3 blocks miR-30a and  
enhances proliferative retinopathy and vascular dysfunction in diabetes related retinal 
vascular dysfunction (Shan et al., 2017). It is also upregulated in serum from diabetics 
with neuropathic pain and is positively associated with the grade of neuropathic pain 
in patients. It is also upregulated in in dorsal root ganglion and contributes to  pain and 
neuroinflammation in diabetic rats (Wang et al., 2018) . Another circRNA, Cdr1as, 




insulin, content and secretion in islet cells. It also modulates Pax6 expression to 
enhance insulin transcription (Xu et al., 2015).  Additionally, electroacupuncture which 
is known to reduce islet β-cell apoptotic rate in T2DM mice also lead to  165 differential 
expression of circRNAs in plasma exosomes and thus may be involved in preserving 
islet function in T2DM mice (Shou et al., 2019) . 
 
As many as 30 circRNAs are upregulated in the serum of diabetic retinopathy which 
includes hsa_circRNA_063981, hsa_circRNA_ 404457, hsa_circRNA_100750, 
hsa_circRNA_406918, hsa_ circRNA_104387, hsa_circRNA_103410 and 
hsa_circRNA_ 100192 (Gu et al., 2017). Recent study shows 489 circRNAs are 
differentially expressed in the peripheral blood of patients with T2D while another 
suggest almost differential expression of 900 circRNA in T2D. Of them circRNA 
hsa_circ_0054633 seem to have a predictive potential for diagnosing pre-diabetes 
(Zhao et al., 2017c). Findings from this chapter indicate CircCAMSAP1 have the 
potential to be used for diagnostics using relatively non-invasive procedures with 
peripheral blood. The observations from this chapter raise the exciting possibility that 
circRNAs expressed in accessible tissues may be useful markers of disease in 
inaccessible organs such as pancreas.  
 
Microtubules are cellular polymers that are important for cargo transport and mitotic 
spindle formation in cells.  Different CAMSAPs can bind to the end of microtubules 
and allow the addition of new tubulins at different rates. CAMSAPs are involved in 
multiple processes in the cell which include promoting cell polarity, regulation of 
neuronal differentiation and axonal regeneration as well as definition of spindle 




et al., 2019). While CAMSAP2 and CAMSAP3 remain tightly bound to the microtubules 
after tubulin incorporation, CAMSAP1 dissociate after allowing tubulin incorporation 
and microtubule elongation (Hendershott and Vale, 2014). CAMSAPs are active in 
multiple tissues, and also have roles in white blood cells, which rely on the tubulin-
microtubule system for lymphocyte activation (Sherline and Mundy, 1977). We 
identified an association between the expression of circRNA generated from 
CAMSAP1, circCAMSAP1, and diabetes status in the peripheral blood of individuals 
with T2D, although this was the inverse of that seen in islets mentioned in the previous 
chapter.  
 
In conclusion, we present here an evidence that circRNAs have tissue-specific pattern 
of expression. We also report that some circRNAs, that are dysregulated in disease-
relevant tissue, are similarly dysregulated in easily accessible body fluid. However, 
this study is limited by samples size and power. It is possible that beside 
circCAMSAP1, circZSCAN1 could also be used as diagnostics (p=0.054) which we 
did not detect. Despite that, circCAMSAP1 seems to have potential to serve as 
biomarkers using relatively non-invasive procedures for predictive and therapeutic 
purposes. These circRNA may be further followed-up up in longitudinal studies   
accounting for pre and post phases of T2D diagnosis and by monitoring the effect of 














































Ageing is a gradual decline of physical and physiological homeostasis at the cellular, 
tissue and organ levels over the course of an organism’s life. It is the main risk factor 
for chronic diseases of ageing such as cancer, sarcopenia, diabetes, and 
cardiovascular and neurodegenerative illnesses (Goldman et al., 2013; Kirkland, 
2016). Although, improvements in medical technologies and healthcare have resulted 
in an increase in lifespan, a vast proportion of long-lived people continue to suffer from 
multiple comorbidities and thus have reduced disability-adjusted life years (Kehler, 
2019). The processes that decline with advancing age can cumulatively affect 
phenotypes that become evident in ageing and ageing-related chronic diseases such 
as T2D. NcRNAs have been shown to modulate gene expression and are 
dysregulated in ageing. Despite the fact that circRNAs accumulate in older organisms 
(Gruner et al., 2016) and have been implicated in cellular senescence (Du et al., 2017; 
Du et al., 2016), their role in ageing has been largely unexplored. In this thesis, I 




Chapter 3       CircRNAs expressed in human peripheral blood are associated 
with human ageing phenotypes, cellular senescence and mouse lifespan 
The primary objective of this chapter was to determine whether circRNAs are 
dysregulated during normal ageing. I addressed this question by assessing the 
expression of the 15 most dysregulated circRNAs in a study of ageing and the 
pathways they might be involved in. Our NGS data from young and old donors from 
the ageing cohort showed that >2000 circRNAs are expressed in human blood. Some 




Pathway enrichment analysis of genes hosting the top 10% most abundant circRNAs 
in aged donors indicated their involvement in phagocytosis and cancer pathways.  
 
I further investigated the 15 most dysregulated circRNAs and assessed their 
expression in the ageing human cohort to determine if they are associated with ageing 
and measures of ageing. I found that four circRNAs correlated with each measure of 
ageing. Of the four, circFOXO3 and circEP300 negatively associated with parental 
longevity score, while CircDEF6 positively (although nominally) associated with 
parental longevity score. In our study, circFNDC3B also nominally associated with 
another measure of ageing, i.e. hand grip strength. In contrast to a circRNA from 
FOXO3, which has been reported before, this study reports circEP300 for the first time. 
It is possible that circEP300 may modulate the expression of its host gene or 
downstream FOXO, and thereby serves to modify lifespan in humans through a variety 
of modes of action by affecting the performance of the immune system, and playing a 
role in stem cell exhaustion and senescence.  
 
Because ncRNAs have been reported to be involved in senescence, I determined 
whether any of the 15 circRNAs were differentially expressed in human peripheral 
blood or were dysregulated in other tissues relevant to ageing. To do this, I assessed 
their expression during senescence using in vitro cultures of senescent human primary 
astrocytes, endothelial cells, fibroblasts and cardiomyocytes. I found that while three 
circRNAs were not expressed, seven circRNAs demonstrated dysregulated 
expression in one or multiple cell types. Interestingly, most circRNAs were upregulated 
in astrocytes, somewhat reflecting previous findings that circRNAs accumulate in the 




Since mice are good in vivo models for the study of ageing and ageing-related 
disorders, I investigated whether the expression of circRNAs that are differentially 
expressed in humans in mouse models would mirror the median lifespans observed, 
and therefore serve as a model to dissect the role of circRNAs in vivo. I found that four 
circRNAs were conserved in mice. CircPlekhm1 expression in spleen associated with 
median lifespan, but only in young mice. This suggests that circPlekhm1 may be a 
driver of longevity instead of being a result of ageing. Since this circRNA was found in 
spleen, it is possible that it drives the ageing process though modulation of the immune 
responses of lymphocytes and phagocytes. It is possible that the differential 
expression observed in peripheral blood from the human cohorts reflects dysregulation 
in disease-relevant inaccessible tissues, since some of these were also differentially 
expressed in in vitro models.  
 
Importance 
In summary, the findings of this chapter make available one of the first comprehensive 
circRNA profiles for the peripheral blood of ageing humans. In addition, evidence of 
differential expression of circRNAs in the blood is presented, as is their predictive 
potential and dysregulation in various in vitro models of senescence, which itself is 
one of the hallmarks of ageing. I also demonstrate that mouse models can be used to 
explore the roles of some circRNAs in mammalian lifespan, and hence ageing 
outcomes. These circRNAs may have potential as diagnostic targets, or predictive 






In this study we determined circRNA expression in some samples from the InChianti 
study of ageing. Future work would focus on characterising circRNA expression in 
even more samples comparable to other large epidemiological data sets. In the future, 
it may be useful to assess the association of circRNAs with ageing in a larger ageing 
population sample, perhaps with various ageing-related diseases. This may lead us to 
not only reaffirm the findings of this study, but also investigate whether any of these 
circRNAs could represent potential biomarkers of ageing-associated disorders. 
Whether the dysregulation of circRNAs is a consequence or a driver of ageing, or 
ageing-related outcomes, could be validated though manipulation of in vitro and in vivo 
models. CircRNAs may enforce multilayered control of gene expression, including 
transcriptional, post-transcriptional and translational events. It would also be 
interesting to investigate how circRNA profiles correlate with the expression of their 
host gene isoforms, RBPs or miRNAs, since these are thought to be avenues through 
which circRNAs exercise their cis/trans-regulatory effects on gene expression. In the 
human cohort, it would be interesting to know if the host isoforms expressed 
predominantly exclude exons within in the circRNAs or have an inverse relationship 
with linear isoforms containing the same exons.  
 
In this study, differential expression of circRNA with median lifespan was asseses in 
mouse of 6 different strains in a diversity of tissue samples tested, i.e. spleen and 
muscle. It would be interesting if we could unravel whether tissue-specific 
dysregulation of circRNAs is relevant to other ageing outcomes for tissues such as 
brain, heart or kidney in the current work. It is also noteworthy that while we assessed 




determine the same in blood samples for the mouse models when samples are 
available. It is also possible that we did not detect effects caused by the genetic 
backgrounds of each strain, as we did not assess background levels of expression of 
these entities in young animals or compare them with older animals for each strain. 
 
 
Chapter 4         Islet-expressed circular RNAs are associated with type 2 diabetes 
status in human primary islets  
The findings from the first chapter show that circRNAs are differentially expressed in 
an ageing cohort, senescent cells and in mouse models with varying median lifespans. 
Therefore, I wanted to determine whether circRNA expression would be similarly 
dysregulated in a chronic disease of ageing. As an exemplary chronic disease of 
ageing, I investigated the expression patterns of circRNAs in T2D and their potential 
role in the pathology of T2D. In order to address my queries, I generated a tissue panel 
to assess how circRNAs align with the expression of their host genes in a wide variety 
of tissues. Then, I assessed the differential expression of circRNAs in diabetic and 
non-diabetic islets, and determined whether their expression correlated with measures 
of glycaemia. Finally, I determined if these circRNAs were differentially expressed in 
human β-cells exposed to various diabetomimetic stresses to explore their potential 
modes of action in the diabetic pancreas.  
 
Through this work, we present one of the first comprehensive circRNA profiles from 
human pancreatic islets. Of these circRNAs, 47 are exclusively expressed in the islets. 
Data from the tissue expression profile indicate that these circRNAs have a tissue-




The expression patterns of many circRNAs in this study were often higher in brain 
tissues compared to other tissues. This somewhat reflects existing knowledge that 
circRNAs accumulate in the brain. 
 
Of the five most abundant circRNAs in human islets, four demonstrated significant 
correlation with diabetic status. Three of their host genes also demonstrated 
association with diabetic status, although the other one did not. As such, some of these 
associations were irrespective of a relationship of the host gene with diabetic status. 
Of the three, the expression of circCAMPSAP1 in peripheral blood also associated 
with diabetic status in a human cohort. Another circRNA, circCIRBP, correlated with 
the insulin secretory index in human islets. This circRNA, along with circRPH3AL, 
displayed altered expression with elevated fatty acids in treated β-cells. It is possible 
that these differentially regulated circRNAs operate by regulating genes involved in 
insulin function and β-cell survival. 
 
Importance 
Through this research, we report one of the most comprehensive global circRNA 
profiles of human islets. Two other studies have previously reported circRNA profiles 
of islets (Izuogu et al., 2016 , Kaur et al., 2018). However, unlike in this study, they 
either did not include pre-treatment to exclude linear RNAs or only included previously 
annotated circRNAs in their profiles. Thus, the islet circRNA profile generated as part 
of the current study is the first global circRNA profile of human islets. I also report that 
the expression of many of these circRNAs is associated with different aspects of 




transcription through various mechanisms and may affect the performance of 
endocrine function in human islets. 
 
Future work 
In this study, I present evidence that while some circRNAs are dysregulated alongside 
their host genes in islets or β-cells, others are dysregulated irrespective of the host 
genes. In the future, these circRNAs could be taken forward to investigate whether 
they have modulate transcription by affecting the transcriptional or post-trancriptional 
events of their host genes or other genes. This may also help us understand whether 
they are responsible for driving, or are after-effects of, diabetic pathology.  
 
 
Chapter 5      Islet-expressed circular RNAs are associated with type 2 diabetes 
status in peripheral blood 
Having found that circRNAs are dysregulated in diabetic islets and under 
diabetomimetic stress in human β-cells, I investigated whether any of these circRNAs 
were differentially expressed in the peripheral blood of humans with pre-diabetes or 
T2D. CircCAMSAP1 was differentially expressed in peripheral blood samples from the 
diabetic cohort. However, the effect was in the opposite direction to that seen in human 
islets. It is possible that this circRNA is engaged in two distinct modes of function in a 
tissue-specific manner, i.e. immune function and different aspects of insulin secretion 






Most pre-diabetic individuals eventually develop diabetes, and diabetic complications 
can develop at the pre-diabetic stage almost a decade before actual T2D diagnosis. It 
is important that we find novel biomarkers that can identify people who are at risk via 
a minimally invasive approach (Bansal, 2015; Tabak et al., 2012). We know that 
circRNAs are almost 2.5 times more stable than linear RNAs because of their closed 
covalent structures. In addition, they are exonuclease-resistant (Cocquerelle et al., 
1993; Schwanhausser et al., 2011; Jeck et al., 2013; Lan et al., 2016; Lasda and 
Parker, 2016b). The fact that I have shown that circCAMSAP1 is dysregulated in the 
islets as well as in the blood suggests that it may have potential as a diagnostic 
biomarker for diabetic patients via routine screening. A longitudinal study with a larger 
sample size could done to ensure its potentiality as a biomarker for diabetes.  
 
Future work 
In order to ensure that our findings could be applied to all ethnic groups, future work 
would focus on increasing the sample size. The sample cohort in this study was 
predominately one ethnic group. Therefore, the findings after adding more ethnic 
groups, perhaps, could be use to extrapolate to diabetics in all ethnic groups. In the 
future, we could conduct a follow-up study on a larger-sized population with diverse 
ethnicity to determine whether this circRNA is unanimously dysregulated in the 






Discussion of the thesis 
Age-linked differential transcriptional noise has been reported by many groups as well 
as our own. Dysregulation of gene expression in cellular ageing can affect different 
aspects of cellular function such as the modulation of expression of genes engaged 
with mitochondrial proteins, protein synthesis machinery, the immune system, growth 
factor signalling and stress, as well as the DDR and mRNA processing. Regulation of 
gene expression by ncRNAs has already been established. CircRNAs have the 
potential to operate in multiple ways in modulating the expression of genes. These 
include serving as sponges for miRNAs and RBPs, and acting as transcriptional 
regulators. Hence, the circRNAs reported in this thesis may have regulatory roles in 
driving outcomes of ageing. They could also be used as potential predictive and 
diagnostic, or therapeutic, biomarkers for ageing and ageing-related outcomes.  
 
Because circRNAs are closed structures, they are comparatively resistant to 
degradation.  This makes them have longer half-lives than linear genes. They also 
demonstrate differential expression in a tissue specific manner and vary in time and 
state of cells. This makes them a good for prognostic tool of predicting the stages of 
diseases and a potential new diagnostic biomarker for predicting disease. For 
instance, circFNDC3 seems not only be associated with handgrip cross-sectionally but 
also have predictive potential longitudinally. In other cases, circRNAs, which are 
differentially regulated in islets as well as peripheral blood like circCAMSAP1, can be 
used a therapeutic tool after validation in a longitudinal study with larger sample size 






Current publications on circRNA are predominantly on their use as biomarkers in 
different diseases. Not much is known about their mode of action in the cellular level. 
However, few circRNAs have the ability to sequester multiple miRNAs. Thus, one 
circRNA in some instances may be able to modulate multiple genes and pathways. 
Similar to miRNAs, they could also be sponging multiple RNA binding proteins and 
affect the expression of their own host genes or other genes. It is possible that by 
targeting one circRNA as a therapeutic machinery, we may be able to successfully 
optimize several pathways relevant to a disease.  
 
The current study provides an insight into the potential role of non-coding circRNAs in 
ageing and in age-related diseases such as type 2 diabetes and provides the first 
comprehensive catalogue of circRNAs expressed in peripheral blood of ageing 
humans and human islets. RNA regulation is not only a good potential target for 
biomarkers, but also a potential area that could be used for targeted therapeutic 
intervention in the future for a healthier longer life span that could bring down the 
economic burden for treating the elderly population. Identification of circRNAs as 
biomarkers from easily accessible bodily fluid like blood would minimize the need for 
invasive procedures in ageing population and in individuals otherwise, not only making 
it more comfortable to patients but also reducing the cost of invasive diagnostic 
procedures for the healthcare.  
 
Future work 
In this study, I assessed the circRNA expression profile at one follow-up point of the 




profile at successive follow-up points from the same participants where RNA is 
available. Whether the dysregulation of circRNAs is a consequence or a driver of 
ageing, or ageing outcomes, could be validated through the manipulation of in vitro 
and in vivo models. The circRNAs may facilitate multilayered control of gene 
expression including transcriptional, post-transcriptional and translational events. It 
would also be interesting to investigate how the circRNA profile correlates with 
expression of the relevant host gene isoforms, RBPs or miRNAs, since these are 
thought to be avenues through which circRNAs exercise their cis/trans-regulatory 
effects on gene expression. In the human cohort, it would be interesting to know if the 
host isoforms expressed predominantly exclude exons within in the circRNAs or have 
an inverse relationship with linear isoforms containing the same exons.  
 
Conclusion 
This thesis provides insights into potential roles of circRNAs in normal ageing as well 
as ageing-associated chronic comorbidities in humans, cellular models and rodent 
models. It also presents two of the most comprehensive global circRNA profiles 
generated to date from different tissues from human donors. I have assessed the 
differential expression of circRNAs in the peripheral blood of a relatively healthy ageing 
cohort and shown their potential as predictors of measures of ageing. These 
differentially expressed circRNAs may be predictive biomarkers for the prediction of 
progression to future ageing outcomes through minimally invasive procedures that are 
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Figure A1 Standard curves for circRNA assays used in ageing study. Standard 
curves were generated using  standard oligos against the backsplice junction of each 
circRNA as proxy of cDNA (shown in X-axis). Log dilution of representative cDNA 
concentration are shown on the X-axis and cycle thershold (Ct) as expected in qPCR 
shown on the Y-axis. Assays are circAFFA1 (I), circASAP1 (II), circATP6V0A1 (III), 
circBCL11B (IV), circCDYL (V), circDEF6 (VI), circEP300 (VII), circFNDC3B (VIII), 
circFOXO3 (IX), circITGAX (X), circMETTL3 (XI), circMIB1 (XII), circPLEKHM1 (XIII), 
































Figure A2 Standard curves for circRNA assays used in diabetes study. Standard 
curves were generated using  standard oligos against the backsplice junction of each 
circRNA as proxy of cDNA (shown in X-axis). Log dilution of representative cDNA 
concentration are shown on the X-axis and cycle thershold (Ct) as expected in qPCR 
shown on the Y-axis. Assays are circCAMSAP1 (I), circCIRBP (II), circCTBP1_1 (III), 
circCTBP1_2 (IV), circGLIS3 (V), circHMG20A (VI), circIDE1 (VII), circIDE2 (VIII), 
circRHOBTB3(IX),  circRPH3AL(X), circSPPL3_1(XI), circSPPL3_2(XII), circTHADA1 


























cir49 = pd.read_csv(ptes_islet, sep='\t', header=None) 




SNPGWAS = '//isad.isadroot.ex.ac.uk/UOE/User/Desktop/SNPGWAS.txt' 
 
#df = pd.read_csv(SNPGWAS, sep='\t', header=None) 
SNPloci = pd.read_csv(SNPGWAS, sep='\s+', header=None) 
SNPloci.columns = ['Chr' ,'start' , 'stop'] 
print(SNPloci.head()) 
 
    subset_cir = cir49.loc[cir49['Chr'] == 'chr1'] 
    print(subset_cir.head()) 
 
subset = SNPloci.loc[SNPloci['Chr'] == 'chr1'] 
print(subset.head()) 
 
for index1, row1 in subset_cir.iterrows(): 
    for index2, row2 in subset.iterrows(): 
        print('loci-start:{1}\tcir-start:{0}\tcir-stop:{2}\tloci-
stop:{3}'.format(row1['start'], row2['start'],row1['stop'], row2['stop'])) 
 
Figure A3 Python code used to detect circRNA that co-localised with known T2D 
GWAS signal. The co-ordinates of the circRNA were cross-refrenced with the co-
ordinates of the windows of established T2D risk GWAS loci. The lead SNP of the 
GWAS signal within which circRNAs mapped were used as the genotype to examine 
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Abstract: Splicing events do not always produce a linear transcript. Circular RNAs 
(circRNAs) are a class of RNA that are emerging as key new members of the gene 
regulatory milieu, which are produced by back-splicing events within genes. In 
circRNA formation, rather than being spliced in a linear fashion, exons can be 
circularised by use of the 30 acceptor splice site of an upstream exon, leading to the 
formation of a circular RNA species. circRNAs have been demonstrated across 
species and have the potential to present genetic information in new orientations 
distinct from their parent transcript. The importance of these RNA players in gene 
regulation and normal cellular homeostasis is now beginning to be recognised. They 
have several potential modes of action, from serving as sponges for micro RNAs and 
RNA binding proteins, to acting as transcriptional regulators. In accordance with an 
important role in the normal biology of the cell, perturbations of circRNA expression 
are now being reported in association with disease. Furthermore, the inherent 
stability of circRNAs conferred by their circular structure and exonuclease resistance, 
and their expression in blood and other peripheral tissues in association with 
endosomes and microvesicles, renders them excellent candidates as disease 
biomarkers. In this review, we explore the state of knowledge on this exciting class 
of transcripts in regulating gene expression and discuss their emerging role in health 
and disease. 
Keywords: Circular RNAs; back-splicing; gene regulation; biomarkers; human disease 
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Circular RNAs (circRNAs) are an emerging class of RNA species that are present in 
species as diverse as archaea, flies, and humans [1–4]. circRNAs in higher organisms 
are reported to be produced by back-splicing events and can be synthesized from all 
regions of the genome, deriving mostly from exons but, less commonly, from 
antisense, intergenic, intragenic, or intronic regions [5]. circRNAs are both spatially 
and temporally regulated and evidence is emerging that they may have importance in 
normal development of tissues or organs but also in disease pathogenesis. Most 
circRNAs have been reported in the brain [2,6–8]. They can be found in most cell sub-
compartments, but the majority localize predominantly to the cytoplasm [9]. circRNAs 
are inherently stable by virtue of their closed covalent structure and exonuclease 
resistance and are thought to be stable in exosomes [2,5,10–12]. This observation 
opens up the interesting possibility that circRNAs, like micro RNAs (miRNAs), may 
have roles in paracrine signalling or have roles in cell-to-cell cross talk. 
2. circRNAs Are Formed from Back-Splicing Events of Linear Genes 
In conventional linear splicing, the spliceosome joins exons in a 50 to 30 configuration. 
In contrast, circRNAs arise when the 30 ‘tail’ of a downstream exon of a gene is back-
spliced to the 50 ‘head’ of an earlier exon (which may include itself) leading to the 
circularization of exons in between (see Figure 1) [10]. These splicing decisions are, 
as in linear splicing, regulated by trans-acting splicing factors and cis sequence 
elements [13]. Several sequence features influencing circRNA formation have 
Genes2017, 8, 353; doi:10.3390/genes8120353 www.mdpi.com/journal/genes 
been described. Firstly, intron length has been reported to play a part; introns flanking 
back-spliced sites tend to be comparatively longer than those flanking non-circularised 
exons [4]. This may be because larger introns may form more RNA–RNA interactions, 
facilitating circularization of embedded exons; the double-stranded RNA-editing 
enzyme ADAR1, which is capable of melting stem structures within these RNA–RNA 
interactions, is associated with suppression of circRNA expression in Caenorhabditis 
elegans [14]. Secondly, exon length may also be a factor; exons of single-exon 
circRNAs are on average 3-fold longer compared with those of non-circularised exons; 
longer exons may be sterically preferentially favoured for 30–50 splicing at canonical 




sequences [14]. Finally, sequence content may also be important. Repetitive 
sequences are known to promote back splicing; back-spliced exons that form 
circRNAs are frequently enriched in paired ALU tandem repeats that have been shown 
to promote circularization [2]. Miniature introns with as few as 30 to 40-nt inverted 
repeats are also sufficient to promote circularization [17]. 
 
Figure 1. The biogenesis of circular RNA (circRNA). The linear primary transcript contains exons 
(blue boxes), introns (black lines), and possibly repetitive elements or sequence motifs (grey boxes). 
Circular exons are generated from back-splicing events between the splice donor site of a downstream 
exon and the splice acceptor site of an upstream exon. This can be mediated by specific sequence 
elements (grey boxes) or by interaction with RNA binding proteins (RBPs). Splicing events are indicated 
by dashed lines with double arrowheads. This may result in the production of a circular RNA and a linear 
RNA which lacks the circularised exons. 
circRNA formation may also be dependent on the specific binding of regulatory 
proteins. RNA binding proteins such as Quaking (QKI) and Muscleblind (MBL/MBNL1) 
have been described to bind to introns flanking back-spliced sites and may drive 
circularization [18,19]. The MBL gene itself encodes a circular form which regulates 
the expression of its linear transcript and modulation of MBL levels strongly affects 
circMBL expression [18]. circRNA formation has also been shown to depend on the 
rate of transcription of their parent genes. circRNA producing genes are generally 
longer and exhibit faster transcription than genes that do not produce circRNAs, and 
artificially slowing the rate of transcription with mutant RNA polymerases results in 




Intronic circRNAs (ciRNAs) can also be generated form lariat introns. ciRNAs are 
devoid of linear fragments spanning the 30 end of the intron to the branch point, but 
are produced by a 20,50-phosphodiester bond arising from canonical linear splicing 
[21]. A 7-nt GU-rich element occurring close to a 50 splice site and with an 11-nt C-rich 
motif around the branch point within intronic sequences has been reported to be 
important for formation of ciRNAs [21]. 
3. circRNA Online Resources 
Over the past few years, at least eleven circRNA detection software systems have 
been developed. These tools can recognize circRNA sequences from RNA-Seq data 
based on two different strategies. One approach is the candidate-based approach, 
also known as the pseudo-reference based approach. KNIFE, NCLScan, and 
PTESFinder all abide by this approach where putative circRNA sequences need to be 
provided with information for gene annotation. Although KNIFE can directly retrieve 
back-spliced junctions prior to gene annotations, the other two software systems 
generate putative circRNA sequences post-alignment with the genome or 
transcriptome [22–24]. 
circRNA_finder, CIRCexplorer, DCC, MapSplice, Segemehl, find-circ, and 
UROBORUS detect circRNA sequences based on the second approach for 
identification of circRNA sequences which is the fragmented-base or segmented read 
approach. In this approach, the software detects back-spliced sites based on reads 
mapped to alignment of multiple split reads against the genome. While find-circ and 
UROBORUS detect back-spliced sequences using the first and last 20 bp after 
mapping the sequences against the genomes, the rest of the detection tools generate 
splice alignment algorithms to identify back-spliced junctions [22–24]. CIRI is a distinct 
detection tool in that it extracts information from local alignment with Burrows-Wheeler 
Aligner-MEM (BWA-MEM) and detects paired chiastic clipping signals from mapped 
reads (arXiv:1303.3997). Comparisons of the different circRNA detection algorithms 
have now been made, which add information on the relative strengths and caveats of 
these different approaches [25]. Searchable repositories for circRNA sequences such 
as circBase are also now emerging [26], which should prove useful to researchers 




4. Molecular Mechanisms of Gene Regulation by circRNAs 
circRNAs have been proposed to act through several mechanisms, including miRNA 
sponges, 
modifiers of transcription or translation, and as splicing modifiers (Figure 2). 
 
Figure 2. Proposed roles of circRNA in the regulation of transcription and translation. circRNAs may 
regulate genes at several levels. (A) Firstly, nuclear circRNAs can interact with promoter regions of 
target genes and interact with RNA polymerase II (Pol2) to repress or enhance transcription; (B) 
Secondly, circRNAs can sequester RBPs that regulate mRNA processing and, thus, alter the splicing 
patterns of the genes in question, or moderate mRNA stability. RBP binding sites are given by dark blue 
boxes; (C) Thirdly, the biogenesis of circular RNAs may results in the production of a linear RNA lacking 
the circularised exons. The formation of circRNAs can thus reduce the amount of linear transcript 
produced; (D) circRNAs can act as micro RNA (miRNA) sponges, sequestering them away from their 
binding sites in target genes, which are given by dark blue boxes; (E) Circular RNAs can also be 
translated. The initiation codon is given by a black oval, and the translating ribosome and nascent 
polypeptide are indicated. 
4.1. circRNAs as miRNA Sponges 
CircRNA can bind specific miRNAs or groups of miRNAs, sequestering them and 
suppressing their function [27], in a phenomenon termed the competitive endogenous 
RNA hypothesis [28]. circRNA CDR1as has been documented to contain up to 74 
binding sites for the miRNA miR-7, and also binds Argonaute (AGO) proteins of the 
RNA-induced silencing complex (RISC) that regulate miRNA action [29]. There is also 
some suggestion that the relationships between circRNAs and miRNAs may be partly 
autoregulatory; CDR1as also binds miR-671, which induces AGO-mediated cleavage 




multiple binding sites for single miRNAs may be the exception rather than the rule 
since most circRNAs identified to date do not contain enrichment of binding sites for 
specific miRNAs [31]. Emerging evidence suggests that circRNAs may act by 
sequestration of modules of coordinately regulated miRNAs; the circRNA circHIPK3 
contains binding sites for nine miRNAs with growth-suppressive properties [32]. The 
presence of multiple binding sites may not be a prerequisite for efficient miRNA 
regulation, however, since circHIPK3 contains only two binding sites for miR-124, yet 
retains the ability to regulate this miRNA [32]. Most of the research investigating the 
role of the circRNA–miRNA interaction has been performed through correlation of the 
levels of miRNA and circRNA expression in vitro. Evidence for circRNAs acting as 
miRNA sponges can also be seen in data arising from the CDR1as knockout mouse. 
Levels of both miR-7 and miR-671 were seen to be lower in knockout animals, and 
these changes were also correlated with defects in synaptic transmission [33]. It is 
likely that a circRNA with multiple binding sites will affect the expression of a larger 
number of miRNA targets. However, experimental validation of the minimal number of 
miRNA binding sites for a candidate circRNA to be functional is still required for many 
circRNAs. An arena to explore is whether a single miRNA binding site would be 
sufficient for efficient circRNA:miRNA sponging interactions. It would be also 
interesting to know what levels of circRNA expression is required for the optimal 
miRNA sequestration ability of these entities. The interaction between circRNAs and 
miRNAs may also go beyond their role in miRNA sequestration; they may also be 
important for the storage, sorting, and localization of miRNAs, adding an additional 
level of regulation to miRNA-controlled regulation of target genes [27,34]. 
4.2. circRNAs as Transcriptional and Translational Regulators 
A specific category of circRNAs, nuclear exon-intron circRNAs (EIciRNAs) can also 
interact with the transcription machinery. These variant circRNAs, which retain some 
intronic sequence from their linear gene, can interact with the U1 component of the 
spliceosomal machinery, recruiting RNA polymerase II to the promoter region of genes 
and enhancing expression of its target genes [35]. circRNAs can also modulate the 
expression of the cognate transcript if the circularisation event includes the translation 
initiation codon of its native gene. This may cause their cognate linear mRNAs arising 
from the same gene to escape translation, thus regulating protein expression as in the 




reported to supress binding of PABPN1 mRNA to HuR. PABPN1 translation is positively 
associated with HuR and the interaction of circPABPN1 interaction with HuR reduces 
the translational efficiency of PABPN1 transcripts. Thus, circRNAs like circPABPN1 can 
act as competitors with their cognate mRNA for RBPs and can also modulate the rate 
of translation of target mRNAs [39]. 
4.3. circRNAs as Competitors of Linear Splicing 
All isoforms produced from a given gene arise from a common pre-mRNA. It follows, 
therefore, that the production of a circRNA may have consequences for the 
abundance of the remaining transcripts encoded by that gene. An example of this lies 
in the Muscleblind (MBL) gene. MBL contains sequences that form a circRNA transcript 
that contains binding sites for MBL itself. Production of the circMBL therefore forms 
an autoregulatory loop that regulates the production of the linear transcript in favour 
of the circular form [18]. In Arabidopsis, a circRNA derived from the SEPALLATA3 gene 
has been shown to interact with its cognate DNA, forming a R-loop and causing a 
pause in transcription and also affecting recruitment of splicing factors to the nascent 
transcript and affecting alternative splicing through exon-skipping [40]. 
4.4. circRNAs as Sponges (RBPs) 
In addition to their role as miRNA sponges, circRNAs can also act as sponges for 
other entities such as RBPs that can regulate gene expression. RBPs, like miRNAs, 
bind specific sequences within their target genes and control all stages within the 
lifecycle of an mRNA from splicing and nuclear export to stability and subcellular 
localisation [36]. circRNAs interacting with RNA binding protein components of the 
gene regulatory machinery such as HuR have been reported [39]. 
5. Translation of circRNAs 
Recent in vitro studies have shown that circRNAs have potential to encode proteins. 
Ribosome footprinting studies in vivo in Drosophila clearly demonstrate that circRNAs 
are associated with translating polysomes [41]. Accordingly, some circRNA-derived 
proteins have been identified. For example, circ-FBXW7 has been shown to encode a 
novel protein in human U251 and U373 cell lines [42]. The inclusion of N6-meythyl 
adenosine residues is sufficient to promote the initiation of translation of circRNAs in 
the human cell lines in the presence of initiation factor eIF4G2 and YTHDF3 [43]. 
Methyltransferase METTL3/14 also accelerates the initiation of translation of this 




that the human transcriptome commonly harbours many circRNAs with coding 
potential. Smaller circRNAs with relatively fewer exons but longer open reading frames 
(ORFs) have been reported to be associated with polysomes [43]. For example, circ-
ZNF609 has been demonstrated to encode a protein in a splicing-dependent but cap-
independent manner in human and murine myoblasts. In vitro analysis of circ-ZNF609 
(which contains two start codons) revealed that the circRNA could generate two 
protein isoforms corresponding to the two ORFs [6]. 
6. The Roles of circRNAs in Normal Homeostasis 
circRNAs are emerging as important regulators of many cellular processes, such as 
embryonic 
development, control of cell cycle, cellular senescence, cell signalling, and response 
to cellular stress. 
6.1. circRNAs in Embryonic Development 
Approximately 10.4% of human circRNAs and 34.3% of mouse circRNAs are 
expressed in a tissue specific or age-specific manner, which indicates their potential 
role in tissue development or differentiation [44]. The difference in abundance of 
circRNAs between human and mouse is interesting and may represent a real species 
difference, but may also be a reflection of limited power due to smaller sample 
numbers of ex vivo human studies because of the inherent difficulties in procuring non-
accessible tissues. The albumin (ALB) gene generates up to 160 circRNA species, of 
which 95 are specific to adult liver and only 33 are expressed in developing foetal liver 
[44]. circRNAs are enriched in the brain and appear to have particular importance in 
brain development of this organism. CiRS-7 has been shown to be highly expressed in 
the cerebellum at embryonic stage E115, but reduced in the cerebral cortex at E60 in 
embryonic pigs [7]. Embryonic, early postnatal, postnatal, and late postnatal 
hippocampus from brain samples from embryonic mice also had increased levels of 
circDlgap1, circMyst4, circKlhl2, and circAagab. Expression was localized to the punctate 
in the dendrites, and abundance fluctuated depending on the stage of synaptogenesis, 
suggesting that these circRNAs might be involved in synaptic function during 
developmental stages [45]. CDR1as may have important roles in development, since 
transgenic expression of this circRNA in zebrafish embryos produces fry with smaller 




is located in the sex-determining region of the Y chromosome. Mutations in the coding 
regions of SRY can lead to change in sex [46,47]. Mouse circSRY has multiple miR-138 
binding sites suggesting a potential role for this circRNA in the regulation of sex 
determination in mice [29,30]. 
6.2. circRNAs in Metabolism 
High CDR1as expression has been shown to have effects on beta-cell function through 
its regulation of miR-7 in pancreatic beta cells. miR-7 targets include the protein kinase 
C beta (PKCB) gene involved in cellular signalling, the profilin 2 (PFN2), and 
phosphatase and actin regulator 1 (PHACTR1) genes involved in cytoskeletal 
organisation and the gene encoding the transcription factor paired box 6 (PAX6). This 
may have profound implications for beta cell function; up-regulation of murine Pax6 
expression through the sponging action of CDR1as on miR-7 has been shown to lead 
to increased insulin secretion in mouse islets [48]. miR-7 is abundant in adult islets 
and may prevent β cell proliferation by inactivating the mTOR pathway [49]. 
6.3. circRNAs in Regulation of Cell Cycle 
circRNAs have been found to be involved in the progression of the cell cycle. 
circFOXO3 has been 
shown to engage with p21 and cyclin-dependent kinase 2 (CDK2) proteins to form a 
ternary structure. The complex formed prevents CDK2 from interacting with cyclin E 
and p27, which eventually blocks transition from G1 to S phase and cell cycle 
progression. Similarly, p21, like CDK2, is unavailable for interaction with cyclin A, 
which leads to cell cycle arrest at G1 phase [50]. Depletion of circHIPK3 in HEK293T 
cells has also been shown to supress cell proliferation and is indicative of a role in 
cellular growth [32]. 
6.4. circRNAs in Regulation of Cellular Stress 
It is vital for living organisms to maintain homeostasis at the cellular level to sustain 
viability. circRNAs have been reported to be involved with cellular homeostasis both 
positively and negatively, by regulating aspects of cellular growth, apoptosis, immune-
response, and resistance to therapeutics. CDR1as has been shown to have potential 
roles in the regulation p21-activated kinase 1 (PAK1), promoting DNA repair and 
preventing apoptosis [51]. Mouse embryonic fibroblasts exposed to reactive oxygen 
species demonstrate upregulation of circFOXO3, promoting senescence via reducing 




localization of focal adhesion kinase (FAK), all of which are involved in cellular survival 
[50]. A circRNA derived from the DENND4C gene has also been reported to have roles 
in adaptation to hypoxic conditions in breast cancer cells [52]. Overexpression of a 
circRNA produced from the locus encoding the lncRNA ANRIL has been shown to 
induce prolonged nucleolar stress in cultured human cells [53]. circRNAs have also 
been reported to have roles in macrophage activation and antimicrobial response via 
positive regulation of the intracellular adhesion molecule 1 (ICAM1) gene in the Toll-
like receptor 4 (TLR4) pathway [54]. 
7. circRNAs in Disease 
In accordance with a pivotal role in gene regulation, perturbation of circRNA 
expression is beginning to be reported in association with disease. Altered circRNA 
expression has been reported in several diseases like cancer, heart disease, 
neurological disorders, diabetes and atherosclerosis, although the precise 
mechanisms by which they operate are yet to be disclosed. 
7.1. circRNAs in Cancer 
In accordance with their known role in modulating cell cycles, proliferation and cellular 
senescence as demonstrated in vitro studies, circRNAs have been implicated in 
cancer. circRNA hsa_circ_001569 (circABCC) may play a role in modulating gene 
expression in colorectal cancer by virtue of its action on miR-145. miR-145 is a 
negative regulator of target genes such as E2F5, BAG4, and FMNL2 which are known to 
be involved in the suppression of proliferation [55]. Similarly, CDR1as has also been 
implicated in several cancer subtypes including hepatocellular carcinoma (HCC). 
CDR1as expression is known to be correlated with hepatic microvascular invasion in 
HCC tissue [56] and hsa_circ_0000520 (circRPPH1), hsa_circ_0005075 
(circEIF4G3), hsa_circ_0066444 (circADAMTS9), and hsa_circ_0001649 
(circSRPRH) have all been shown to be expressed at different levels in HCC 
compared to adjacent normal liver tissues [57,58]. hsa_circ_0005075 (circEIF4G3) 
correlated with tumour size while hsa_circ_0001649 (circSRPRH) was downregulated 
and also correlated with tumour size in addition to the prevalence of tumour embolus 
and could be involved in tumorigenesis and metastasis of HCC [57,58]. circRNA 
circZKSCAN1 has also been shown to be lower in tumours and correlated 




Large-scale dysregulation of circRNA expression has been noted in bladder 
carcinoma, where microarray analysis revealed that 469 circRNA were differentially 
expressed, 285 showing increased expression in bladder cancer compared with 184 
showing downregulation. Of these, circTCF25 regulates miRNAs miR-103a-3p/miR-
107, with circTCF25 upregulation being associated with increased levels of 13 targets 
associated with cell proliferation, migration, and invasion in bladder cancer [60]. 
Similarly, increased expression of circRNA circMYLK in bladder cancer leads to 
overexpression of DNMT3B, VEGFA, and ITGB1 genes, which are involved in promotion 
of proliferation and are molecular targets of miRNA-29a-3p [61]. circRNA circHIAT1 has 
also been reported to respond to signalling through the androgen receptor to promote 
tumour migration and invasion in clear cell renal cell carcinoma by enhancement of 
CDC42 expression through regulation of miR-195-5p/29a-3p and miR-29c-3p target 
genes [62]. Recently, fusion-circRNAs (f-circRNA) have been shown to accelerate 
proliferation rate and instigate cellular transformation. Furthermore, f-circRNAs f-
circM9 and f-circPR have been shown to confer resistance to therapeutics due to 
protective effects of drug-induced apoptosis in cancer cells in vitro via a MAPK/AKT 
dependent signalling pathway [63]. 
7.2. circRNAs in Neurological Disease 
CDR1as has been associated with neurodegenerative conditions such as Alzheimer’s 
disease 
(AD). In patients with moderate to advanced stages of sporadic AD, CDR1as expression 
has been reported to be reduced, which may lead to elevated miR-7 expression and 
consequent downregulation of miR-7 dependent mRNAs. One target, ubiquitin protein 
ligase A, is responsible for the clearance of amyloid peptides in AD and other 
degenerative disorders [64]. Although most studies with circRNAs have been 
conducted in vitro, recently, Piwecka et al.,generated a knockout murine model for 
Cdr1as. The brains of these transgenic mice had upregulated expression of miR-7 
genes, such as c-Fos. Cdr1as knockout mice demonstrate impaired synaptic 
transmission and information processing defects [33]. circRNAs also have potential 
roles in memory; circPAIP2 has been suggested to upregulate memory-related gene 
PAIP2 through the poly A binding protein (PABP)-associated pathway [65]. A role for 




significant change of hsa_circRNA_103636 expression was noted in patients after 
eight weeks on antidepressant therapies [66]. 
7.3. circRNAs in Osteoarthritis 
Osteoarthritis (OA) occurs because of degenerative changes in the joint cartilage. 
Seventy-one circRNAs were seen to be differentially expressed in the cartilage of 
patients with OA compared with those of non-OA controls. The circRNA circ-CER 
appears to be of particular importance. circ-CER expression was shown to increase with 
increased expression of pro-inflammatory signalling molecules such as interleukin 
(IL)-1 and tumour necrosis factor (TNF)α. Suppression of circ-CER resulted in reduced 
matrix metalloproteinase-13 (MMP13) expression and remodelling of the extracellular 
matrix (ECM). The authors suggest that this observation arises from a sponging effect 
of circ-CER on miR-136, which is known to target the MMP13 gene [67]. 
7.4. circRNAs in Cardiovascular Disease 
The CDKN2A/CDKN2B locus expresses an alternatively spliced non-coding transcript, 
ANRIL, which encodes a circular form in addition to its linear form. circANRIL has been 
reported to regulate the pescadillo homologue 1 (PES1) gene transcript, which is 
involved in pre-rRNA processing and ribosome biogenesis. Sequestration of this 
essential factor and suppression of these key processes in vascular smooth muscle 
cells and macrophages was shown to cause nucleolar stress and p53 activation, 
resulting in apoptosis and features of atherosclerosis [68]. Some circRNAs have been 
shown to be protective in heart function; the circRNA heart-related circRNA HRCR has 
been implicated in protection from cardiac hypertrophy and heart failure, by virtue of 
its binding of the inflammatory onco-miR miR-223 [69,70]. Some RNA inding Motif 
Protein 20 (RBM20)-dependent circRNAs have also been reported to be differentially 
regulated in dilated cardiomyopathy [71]. Similarly, circRNA MFACR has been shown 
to sponge miR-652-3p in the cytoplasm, promoting mitochondrial fission and 
cardiomyocyte cell death by enhancing translation of MTP18 in animal models [72]. 
Similarly, high levels of circRNA_000203 and circRNA_010567 have been reported in 
cardiomyocytes from diabetic mice treated with angiotensin II. These circRNAs are 
thought to downregulate miR-26b-5p, miR-141, and miR-141, thereby upregulating 




collagen 1 (Col I), collagen 3 (Col III), and α-smooth muscle actin (α-SMA), promoting 
fibrosis in the myocardium [73,74]. 
7.5. circRNAs in Type 2 Diabetes 
In addition to the role of CDR1as in regulation of insulin secretion through modulation 
of PAX6, recent studies have suggested that circRNAs may have utility as biomarkers 
of diabetes. Four hundred eighty-nine circRNAs were found to be differentially 
expressed in the peripheral blood of patients with type 2 diabetes, and furthermore, 
circRNA hsa_circ_0054633 was found to be capable of predicting pre-diabetes with 
an area under the curve (AUC) of 0.84 (p ≤ 0.001) [75]. In other studies, several 
circRNAs have been shown to be differentially expressed in serum of patients with 
diabetic retinopathy compared to that of both controls and diabetes patients without 
retinopathy. Of these, hsa_circRNA_100750 is derived from stromal interaction 
molecule 1 which is upregulated in diabetic patients. hsa_circRNA_104387 is known 
to sequester miR-29a which prevents the loss of renal function in diabetic patients. 
hsa_circRNA_103410 is known as a regulator of miR-126, which is known to inhibit 
VEGF and MMP9 expression. Thus, hsa_circRNA_103410 could promote endothelial 
injury in the retina, while hsa_circRNA_100192 could, by sequestering miR-146, 
promote necrosis factor (NF)-κB activation, adenosine deaminase-2 expression, and 
inflammatory responses as is observed in vitro [76]. These observations raise the 
exciting possibility that circRNAs expressed in accessible tissues may be useful 
markers of disease in inaccessible organs such as pancreas. circHIPK3 has been found 
to be dysregulated in diabetic retinas, which may contribute to elevated levels of 
VEGFC, FZD4, and WNT2 expression by virtue of its effects on miR-30a-3p [77]. 
7.6. circRNAs and Pre-Eclampsia 
A study has implicated circRNAs in the development of preeclampsia. Qian et 
al.,identified 143 up-regulated and 158 down-regulated circRNAs in placental tissues 
from women with pre-eclampsia, 
which included upregulated hsa_circRNA_100782 (circHIPK3), hsa_circRNA_102682 
(circCRIM1), and hsa_circRNA_104820 (circFAM120A) circRNAs [78]. Altered 
circ_101222 expression before 20 weeks of pregnancy was seen to correlate with 




signalling pathway, which is associated with pre-eclampsia, than women who did not 
have pre-eclampsia. circRNA circ_101222, in combination with endoglin levels, may 
therefore have the potential to predict pre-eclampsia very early on in pregnancies [79]. 
7.7. circRNAs and Infection 
Microbial lipopolysaccharide induces the activation of TLR pathways leading to 
activation of NF-κB and modulation of genes which are key to antimicrobial defences 
and adaptive immunity. circRasGEF1B has been suggested to modulate the expression 
of ICAM-1 as part of the lipopolysaccharide response. Knock down of this circRNA in 
vitro leads to 27%–39% reduction in ICAM-1epression in vitro [54]. In mouse 
macrophage cells, activation of TLR4, TLR9, TLR3, TLR2, and 
TLR1 receptors all regulate the expression of circRasGEF1B [54]. Genetically modifying 
circRasGEF1B expression was shown to reduce ICAM1 expression levels, which under 
normal conditions would promote binding of leukocytes to endothelium cells and their 
transmigration into target tissues [54]. Thus, deficiency of circRasGEF1B may prevent 
migration of leukocyte cells to inflammatory sites and interfere with the healing 
process, and in cancer cells may additionally affect the activation of cytotoxic T-
lymphocytes needed for driving release of cytolytic granules into tumour cells [54]. 
A potential role for circRNA in response to viral infection has been reported. HeLa cells 
transfected with circRNA demonstrated induced expression of 84 innate immunity-
related genes, such as RIGI and OASl, which were upregulated by as much as 500-fold 
and 200-fold, respectively [80]. Concurrent with these changes was a 10-fold decrease 
in infection rate against Venezuelan equine encephalitis virus, 
which was shared by nearby non-transfected cells, indicating some paracrine action 
[80]. circRNAs can also act as competitors with viral mitochondrial RNA (mtRNA) for 
binding to RNA-binding domain containing immune factor NF90 and its isoform NF110. 
These factors can promote circularization by stabilizing the binding of intronic RNA 
pairs in the nucleus. Viral infection results in transportation of these factors from the 
nucleus to the cytoplasm resulting in decreased circRNA expression in infected cells. 
This acts to render the circRNA available for binding to viral mRNA and prevents viral 
infection of the host cell [81]. 
7.8. circRNAs in Ageing and Cellular Senescence 





endonuclease-resistant nature of circRNA molecules, but at least two circRNAs have 
been previously described to have a role in ageing or cellular senescence. circRNA 
circPVT1 has been demonstrated to suppress cellular senescence by sequestration of 
miRNA let-7, which lifts its inhibitory action on its target genes IGF2BP1, KRAS, and 
HMGA2, which act to promote cell proliferation [83]. Conversely, the circFOXO3 circRNA 
was found to promote senescence in the heart muscle of aged mice and humans 
through its action on the ID1, E2F1, FAK, and HIF1A target genes [9]. This circRNA is 
also known to silence cell proliferation through its regulation of the cell division kinase 
2 (CDK2) gene and the cyclin dependent kinase inhibitor p21 [9]. 
8. circRNAs as Diagnostic and Prognostic Markers 
Because circRNAs are highly nuclease-resistant, they are more stable than linear 
transcripts and may be released into the extracellular space via the exosomes [12,84]. 
Half-lives of circRNAs can vary significantly, but can be as long as 50 h. On average, 
their half-lives are around 2.5-fold longer than the median half-lives of their linear 
counterparts [85]. A substantial number of circRNAs are expressed in blood at 
comparatively higher levels than their linear mRNAs, thus making circRNAs attractive 
tools for diagnostics to trace the mechanism of coded genes otherwise inaccessible 
by the canonical RNA pathway-dependent assays [86]. A selection of circRNAs 
reported as potential biomarkers for different diseases are summarized in Table 1. 
Over 400 circRNAs have been detected to be present in cell-free saliva and could 
potentially be used for non-invasive diagnostics approach [87]. circRNAs have been 
suggested as potential biomarkers for several types of cancer. In murine models, 
tumour-derived exosomal circRNAs in the serum correlate with tumour mass [88], and 
thus may be promising biomarkers for cancer detection. circRNA hsa_circ_0001649 
(circSHPRH) has shown some utility as a biomarker for hepatocellular carcinoma, is 
downregulated with tumour status, and is associated with the occurrence of the tumour 
embolus as well as the size of the tumour [57]. hsa_circ_002059 (circKIAA0907) is 
downregulated in gastric cancer and is associated with grade and distal metastasis 
and could, therefore, be used as a prognostic marker [89]. Another circRNA, 
hsa_circ_0000190 (circDYRK1A), is downregulated in plasma samples of patient with 
gastric cancer, where its expression levels correlated with tumour diameter, lymphatic 
metastasis, and distal metastasis [90]. Similarly, hsa_circ_0001895 (circPRRC2B) 




differentiation and Borrmann type [91]. In hepatitis B infected hepatocellular carcinoma 
(HCC) patients, circRNA_100338 (circSNX27) has been shown to regulate levels of 
miR-141-3p, and its expression correlated with low cumulative survival rate and 
metastatic progression [92]. 
Table 1. Examples of circRNA and their potential role in disease. 








May sequester miRNAs associated 
with RNF213 and BRCA1/BRCA2-
containing complex subunit 3 
Potential biomarker expressed in blood [93] 
CDR1as hepatocellular carcinoma May be a sponge for miR-7 
Biomarker with the ability to predict hepatic 
microvascular invasion; expressed in 
hepatocellular carcinoma tissues [56] 
hsa_circ_0001017, hsa_circ_0061276 gastric cancer  
Prognostic, with the ability to predict 











coronary artery disease 
May promote expression of 
transient receptor potential cation 
channel subfamily 
M member 3 by inhibiting hsa-miR-
130a-3p Potential biomarker expressed in plasma 
[95] 





May act as sponge for miR-7 
regulating target genes PRKCB, 
EPHA3, BRCA1, and ABCC1; 
potential role in lung metastasis 





May be involved in response to 
oxidative stress; endocytic traffic in 
actin cytoskeleton; could 
promote lipid breakdown and 
increase free fatty acid levels; 
could alter lipopolysacccharide 
(LPS) immune response 
Potential biomarker expressed in peripheral 






 May predict the early recurrence of stage III 
gastric cancer after radical surgery; 
expressed in tumour tissues [99] 
circPVT1 gastric cancer 
May act as sponge for miR-125 
family; may promote 
cell proliferation 
Potential prognostic marker with the ability to 
predict overall survival and disease-free 
survival; expressed in gastric cancer tissues 
[100] 




circRNA Pathologic Condition Possible Mode of Function Potential Application 
circRNA_104871, circRNA_003524, 
circRNA_101873, circRNA_103047 
rheumatoid arthritis  
Potential biomarker expressed in peripheral 
blood mononuclear cells [101] 
hsa_circ_0058246 gastric cancer  
Potential prognostic marker with the ability to 
predict clinical outcome; expressed in tumour 
tissues [102] 
circ-ITCH hepatocellular carcinoma May inhibit Wnt/β-Catenin pathway 
Potential prognostic marker with the ability to 
predict survival; expressed in hepatocellular 
carcinoma tissues [103] 
hsa-circ-0005870 hypertension 
May act as sponge for miRNAs, 
hsa-miR-6807-3p, hsa-miR-5095, 
hsa-miR-1273g-3p, hsa-miR-
5096, and hsa-miR-619-5p, 
possibly affecting transforming 
growth factor beta (TGF-beta) 
pathway important in hypertension 
Potential biomarker expressed in plasma 
[104] 
hsa_circ_0124644, coronary artery disease  Potential diagnostic biomarker; expressed in blood [105] 
circR-284 carotid disease and 
ischemic stroke 
May act as an inhibitor of miR-
221/miR-222 
Potential diagnostic biomarker:expression 
demonstrated in serum [106] 
circ_0005402, circ_0035560 multiple sclerosis  Potential biomarker; expressed in leucocytes [107] 
circZKSCAN1 hepatocellular carcinoma 
May modulate expression of 
apoptotic genes RAC2, EFNA3, and 
caspase 3 and cell 
proliferation related genes 
TGFB1, ITGB4, CXCR4, BIRC5, and 
CCND1; may modulate 
promoted cell proliferation, 
migration, and invasion in vitro 
Expressed in tumour tissues [59] 
circ_101222 pre-eclampsia  Potential biomarker; expressed in blood [79] 
hsa_circ_0054633 diabetes 
 Potential biomarker with the ability to predict 
pre-diabetes and type 2 diabetic 
status; expressed in blood [75] 
9. Conclusions 
circRNAs are a class of non-coding RNAs which appear to regulate the expression of 
genes by a variety of mechanisms and might also have the potential of encoding 
proteins, the mechanisms of which are not yet completely understood. Despite this, 
circRNAs are emerging as potentially important regulators of cellular physiology and 
as potential biomarkers of disease onset or progression. The state of the current 
knowledge of circRNA biology is as yet at a very early stage, and further research is 
urgently required to completely understand their function and potential. Despite this, it 
is likely that these novel circRNAs will emerge as important players in gene regulation 




of co-ordinated regulation of modules of genes in a cell, tissue, and developmental 
stage specific pattern, adding another level of regulation to the already complex field 
of non-coding RNA (ncRNA) regulation of gene expression. In future years, circRNAs 
could be exploited as therapeutics. Over-expression of specific circRNA constructs 
could act to modulate cell behaviour and physiology by sponging oncogenic miRNAs 
such as miR-21 and miR-221 in cancer cells [108]. Antisense approaches such as 
morpholino technologies to influence splicing patterns are already in development for 
diseases such as Duchenne muscular dystrophy [109] and could in theory be 
developed to target exons that may be circularized to bring about higher expression 
of beneficial circRNAs once their modes of action have been elucidated. 
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Summary of research publications  
Circular RNAs (circRNAs) are non-coding RNAs that may have the portential to 
regulate gene expression . CircRNAs  have been shown to accumulate during  ageing 
models. The research publications associated with this thesis  assessed wheher 
circRNAs were dysregulated of in ageing human peripheral blood of a  relatively 
ageing human cohort and in a disease related to ageing ie. T2D.  Whether the 
expression of circRNA were associated with various ageing outcomes in human, 
mammalian longevity and senescence in human cell types of various lineages, and in 
blood as well as islet samples from patients was assessed.  
 
Of the 15 candidate circRNAs followed up in the ageing InCHIANTI population study 
study, four were associated with parental longevity or hand grip strength.  Some of 
tehse circRNA wrere also differentially expressed in one or more human senescent 
cell types and one nominally correlated with median strain lifespanin rodent models.  
 
As type 2 diabetes is an exemplar chronic disease of ageing, I also aimed to examine 
the role of circRNA in this disorder. I first defined the circRNA repertoire in human 
pancreatic islets and assessed their differential expression in conjunction with type 2 
diabetes status and genotype at T2D risk loci.  Following this, I determined their 
responsiveness to diabetomimetic stimuli in the human EndoC-βH1 beta cell line, and 
the potential for use as biomarkers of T2D in human peripheral blood. 4 of the five 
most abundant circRNAs expressed in human pancreatic islets circCIRBP, 
circZKSCAN, circRPH3AL and circCAMSAP1, were associated with diabetes status 
in islets.  CircCIRBP and circRPH3AL were also differentially expressed in β-cells in 




loci was identified.  Cumulatively, the data generated from my work suggest that 
circRNAs have potential as regulators of gene expression during ageing and age-
related disease, raising the possibility that they may have future utility as biomarkers 
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Abstract Circular RNAs (circRNAs) are an 
emerging class of non-coding RNA 
molecules that are thought to regulate 
gene expression and human disease. 
Despite the observation that circRNAs 
are known to accumulate in 
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older organisms and have been reported 
in cellular senescence, their role in aging 
remains relatively unexplored. Here, we 
have assessed circRNA expression in 
aging human blood and followed up age-
associated circRNA in relation to human 
aging phenotypes, mammalian longevity 
as measured by mouse median strain 
lifespan and cellular senescence in four 
different primary human cell types. We 
found that circRNAs circDEF6, circEP300, 
circFOXO3 and circFNDC3B demonstrate 
associations with parental longevity or 
hand grip strength in 306 subjects from 
the InCHIANTI study of aging, and 
furthermore, circFOXO3 and circEP300 
also demonstrate differential expression 
in one or more human senescent 
celltypes.Finally,fourcircRNAs tested 
showed evidence of conservation in 
mouse. Expression levels of one of 
these, circPlekhm1, was nominally 
associated with lifespan. These data 
suggest that circRNA may represent a 
novel class of regulatory RNA involved in 
the determination of aging phenotypes, 
which may show future promise as both 
biomarkers and future therapeutic 
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Introduction 
Aging is a multifactorial process leading 
to gradual deterioration of physical and 
physiological functionality at the cellular, 
tissue and organ levels. It is the primary 
risk factor for chronic aging pathologies 
such as cancer, sarcopenia, diabetes, 
cardiovascular disorders and 
neurodegenerative illnesses that account 
for the bulk of morbidity and mortality in 
both the developed as well as developing 
world (Kirkland 2016 ). Physiological 
parameters such as loss of muscle mass, 
frailty, immobility and cognitive 
impairment increase the risk of 
developing geriatric syndromes (Fabbri 
et al., 2016; Narici and Maffulli 2010). 
The molecular processes that decline 
with advancing age underpin the 
phenotypes of aging. At the cellular level, 
hallmarks of aging include genomic 
instability, telomere attrition, epigenetic 
alterations, loss of proteostasis, 
deregulated nutrient sensing, 
mitochondrial dysfunction, cellular 
senescence, stem cell exhaustion and 
altered intercellular communication 
(Lopez-Otin et al., 2013). 
Changes in gene expression have 
been reported in many age-related 
diseases (Yang et al., 2015). In addition 
to an increase in transcriptional noise 
and aberrant production and maturation 
of mRNA transcripts (Bahar et al., 2006; 
Harries et al., 2011), studies report 
associations between gene expression 
and the development of age-associated 
syndromes of the muscle (Noren Hooten 
et al., 2010; Welle et al., 2004) as well as 
neurodegenerative conditions such as 
Alzheimer’s disease and Parkinson’s 
disease (Miller et al., 2017; Shamir et al., 
2017). Differential expression of genes 
involved in inflammatory, mitochondrial 
and lysosomal degradation in aging 
tissues has also been reported (de 
Magalhaes et al., 2009). Gene 
expression is regulated at many levels. 
Changes in the regulation and pattern of 
alternative splicing are associated with 
age in several human populations and 
are also evident in senescent cells of 
different lineages, where they may drive 




levels reverses multiple senescence 
phenotypes (Latorre et al., 2017; Latorre 
et al., 2018a; Latorre et al., 2018b; 
Latorre et al., 2018c; Lye et al., 2019). 
Notably, non-coding RNAs also 
demonstrate associations with aging or 
senescence and may be of equal 
importance (Abdelmohsen et al., 2012; 
Boulias and Horvitz 2012; Gorospe and 
Abdelmohsen 2011). 
Circular RNAs (circRNAs) are a 
recently discovered class of non-coding 
RNA molecules that are thought to have 
important roles in regulation of gene 
expression and human disease (Haque 
and Harries 2017). circRNAs are formed 
by the back splicing of downstream 
exons to the 3′ acceptor splice site of 
upstream exons and result in a covalently 
closed circular structure containing one 
or more exons. They have been 
proposed to be key regulators of gene 
expression by various mechanisms 
including sequestration of RNA-binding 
proteins and miRNAs or by acting as a 
competitor of linear splicing of their 
cognate genes (Memczak et al., 2013). 
The possibility that a single circRNA 
could sequester several such RNA 
regulators suggests that this class of 
non-coding RNAs could modulate many 
cellular and physiological processes 
through multiple pathways. circRNAs are 
known to accumulate in older organisms 
(Gruner et al., 2016), and some have 
been reported to be implicated in cellular 
senescence (Du et al., 2017; Du et al., 
2016). Despite these promising findings, 
their role in aging remains relatively 
unexplored. 
We hypothesized that expression of 
some circRNAs may be associated with 
advancing age, aging phenotypes, 
lifespan or cellular senescence. Changes 
in circRNA expression over a 5-year 
period were assessed in relation to age, 
combined parental longevity score (PLS) 
and hand grip strength. We then 
assessed expression levels of 15 
circRNAs in early passage and late 
passage primary human dermal 
fibroblasts, cardiomyocytes, astrocytes 
and vascular endothelial cells. Finally, 
the junction sequences of relevant exons 
were examined for conservation between 
mouse and humans and where evidence 
was present that the back-spliced 




conserved; we assessed expression in 
relation to longevity in six strains of mice 
with differential median strain longevities. 
We present here evidence 
thatalthough effects on age itself did not 
replicate in the wider sample set, the 
expression levels of circEP300 (β = − 
0.065, P = 0.001) and circFOXO3 (β = − 
0.060, P = 0.002) were negatively 
associated with parental longevity score. 
circDEF6 was positively associated with 
parental longevity score (β = 0.070, P = 
0.024) although this did not reach 
multiple testing thresholds. circFNDC3B 
was also nominally associated with hand 
gripstrength(β = 0.004, P = 0.039). 
circRNAs (7/12 (58%)) expressed in 
senescent human primary astrocytes, 
endothelial cells, fibroblasts or 
cardiomyocytes also demonstrated 
dysregulated expression in one or more 
cell types. Comparative sequence 
analysis suggested that four circRNAs 
may be conserved in mice. When 
assessed, circPlekhm1 transcript level in 
spleen was also demonstrated to be 
positively associated with mouse median 
strain lifespan (β = 0.0025; P = 0.017). 
These results suggest that some age-
related circRNAs may play roles in 
molecular drivers of aging such as 
cellular senescence, and hence may 
represent potential contributors to 
lifespan or other human aging 
phenotypes. 
Methods 
InCHIANTI cohort and selection of 
participants 
The InCHIANTI study of Aging is a 
population study of aging (Ferrucci et al., 
2000). Participants undertook detailed 
assessment of health and lifestyle 
parameters at baseline, and again at 
three subsequent follow-ups (FU2 2004–
2006, FU3 2007–2010and FU4 2012–
2014).The present study used 
participants from the third and fourth 
follow-up visits (FU3 and FU4). RNA 
samples and clinical/phenotypic data 
were already available for 698 
participants at FU3. The collection of the 
FU4 samples and data comprise part of 
this study. During the FU4 interviews in 
2012/2013, blood and clinical/phenotypic 
data were collected from 455 study 




checked against RNA samples and 
clinical/phenotypic data already held 
from FU3, to ensure that sample and 
phenotypic data was available from both 
collections. Sample-associated data 
included measures of potential 
confounding factors such as BMI, sex, 
level of education (none, elementary, 
secondary, high school and university), 
study site, smoking and white blood 
counts (neutrophil, lymphocyte, 
monocyte, eosinophil percentages). 
Characteristics of the study 
populationare given inTable 1. 
Informedconsent was obtained from all 
participants. Ethical approval was 
obtained from the Instituto Nazionale 
Riposo e Cura Anziani institutional 
review board, Italy. 
Generation of circRNA profiles from old 
and young human peripheral blood 
Circular RNA profiles were initially 
generated in parallel from two sets of 
pooled peripheral blood total RNA 
samples using a modified ‘CircleSeq’ 
procedure (LopezJimenez et al., 2018). 2 
μg RNA (RNA integrity number (RIN) = 
6.4) was assessed in two separate pools 
from 20 ‘young’ samples (median age = 
33 years, range 30–36 years, 55% 
female, 45% male; RIN 5.6) and 20 ‘old’ 
samples (median age 87 years, range 
86–95 years, 90% female 10% male, RIN 
7.7). Each pooled sample was divided 
into two aliquots, one of which was 
treated with 20 units RNAse R 
(Epicentre, Madison, USA) at 30 °C for 
30 min to remove linear RNA, the other 
sample being mock-treated using 1 μL 
RNase-free water in place of the 
enzyme. Both aliquots were cleaned and 
concentrated using 2 volumes of RNA 
clean beads (Beckman Coulter, 
Indianapolis, USA) to remove the 
enzyme. The results of the RNase R 
treatment were confirmed on a 
highsensitivity RNA screentape (Agilent, 
Santa Clara, USA). Ribosomal RNA was 
removed, and indexed sequencing 
libraries made using the libraries were 
determined by qPCR and adjusted for 
size using Tapestation D1000 analysis 
(Agilent, Santa Clara, USA). Ribosomal 
RNA was removed, and indexed 
sequencing libraries made using the 
Illumina RNASeq protocol. The library 




qPCR and adjusted for size using the 
data from the Tapestation D1000 
analysis. Libraries were pooled in 
equimolar quantities, denatured and 
diluted to 12.0 pM + 1% PhiX for 
clustering and then underwent 125 
paired-end Illumina sequencing in four 
lanes using TruSeq SBS reagents (V3). 
Analysis of circRNA profiles 
RNase R and mock-treated sequence 
data were assembled, and putative 
circular RNAs were identified using 
PTESFinder (Izuogu et al., 2016) with the 
human genome (hg19) reference files 
provided with the software, a segment 
size of 65 and a uniqueness score of 7. 
The remaining parameters were left to 
default settings. To calculate a 
comparable measure of circular RNA 
abundance between samples, we used a 
measure termed back-spliced reads per 
million mapped reads (bpm) for each 
circular RNA defined as 
bpmi ¼∑na¼1ja þji ∑nb¼1cb  106 
where Ji is the number of reads mapped 
to the backspliced junction of the circular 
RNA, c is the number of reads mapped to 
canonical sites of the gene with the 
circular RNA and n is the number of 
circular RNAs identified. This measure is 
designed to be similar to the commonly 
used reads per kilobase per million 
mapped reads (RPKM) metric used 
regularly to estimate gene expression 
from RNA-Seq data. 
In addition to circular RNA detection 
using PTESFinder, reads from all 
samples were also mapped to the human 
genome reference (hg19) obtained from 
Table 1 Participant demographics, population 
demographics and clinical characteristics of InCHIANTI 
study participants assessed in this work, (A) 
demographics and (B) clinical characteristics 
 




 306 100 
30–39  24 7.84 
40–49  37 12.09 
50–59  31 10.13 
60–69  32 10.46 
70–79  116 37.91 






 3 0.98 
Male  143 46.73 
Female 
Pack years smoked (lifetime) 
 163 53.27 
None   164 53.59 
< 20   79 25.82 
20–39   43 14.05 
40+ 
Study site 
  20 6.54 
Greve   146 47.71 
Bagno 
Education level attained 
  160 52.29 
Nothing    22 7.19 
Elementary    124 40.52 
Secondary    56 18.30 
High school    50 16.34 
Professional 
school 
   34 11.11 
University or 
equivalent 
   20 6.54 
B n Mean SD Min Max 
Age (years) 306 66.96 16.06 30.00 94.00 
BMI 305 27.15 4.35 15.01 42.99 
White blood cell 
count (n, K/μLs) 
305 6.40 1.59 2.10 13.00 
Neutrophils (%) 305 56.59 8.35 34.20 81.20 
Lymphocytes (%) 304 31.69 7.67 9.80 51.20 
Monocytes (%) 304 8.04 2.20 3.90 21.30 
Eosinophils (%) 304 3.18 2.17 0.00 21.50 
Parental longevity 
score 
206 − 0.02 0.81 − 2.46 1.71 
Mean hand-grip strength (kg) 
Follow-up 3 305 29.65 12.49 2.50 70.75 
Follow-up 4 291 28.66 12.30 5.00 65.50 
 
iGenomes using Tophat v2.1.0 with the 
pre-set sensitive alignment parameters 
in paired-end mode (Trapnell et al., 
2009). The number of reads mapping to 
each exon of each gene was then 
calculated using FeatureCounts v2.0.0 
with parameters for unstranded 
alignment, paired reads, count 
multimapping reads and assigning reads 
to overlapping features (Liao et al., 2013; 
Liao et al., 2014). Counts were used to 
calculate RPKM per exon using the 
standard method to compare the 
expression of each exon across 
samples. 
Pathway analysis of differentially 
regulated circRNA host genes 
circRNAs showing expression 
differences between the pooled old and 
the pooled young samples were ranked 
by RPKM and fold change. To assess 
whether circRNAs demonstrating 
expression differences between young 
and old pools were enriched in genes 





wecarriedouta Cytoscape version 2.5.2 
plug-in ClueGO analysis. This platform 
queries over-representation of query 
genes in specific KEGG, REACTOME 
and WikiPathways 
(Bindea et al., 2009). The linear genes 
hosting the top 10% most abundantly 
expressed circRNAs in young and old 





were selected based on 
‘enrichment/depletion’ through a two-
sided hypergeometric test with 
Bonferronistep down for P value 
correction with the selected ontology 
reference set of chosen genes. The GO 
terms were used to group functional 
pathways, and the leading functional 
grouping was based on highest 
significant kappa score. 
Design of qPCR assays for circRNA 
validation 
Levels of individual circRNA in young 
and old pools were ranked by 
abundance. circRNAs demonstrating 
evidence of altered expression with age 
fell into three classes: those expressed 
exclusively in old, those expressed 
exclusively in young, and those 
expressed in both young and old, but with 
evidence that levels were different 
between the pools. 
WeselectedfivecircRNAsexclusivelyexpr
essedinyoung (circITGAX, 
circPLEKHM1, circDEF6, circATP6V0A1 
and circASAP1), five exclusively 
expressed in the old (circFOXO3, 
circFNDC3B, circAFF1, circCDYL and 
circXPO7), as well as five expressed in 
both pools but demonstrating evidence of 
altered expression (circMIB1, 
circMETTL3, circBCL11B, circZC3H18 
and circEP300), where sequence and 
assay design constraints allowed for to 
design specific assays to unique back-
spliced junction for qRTPCR follow-up. 
circRNA probe design 
Custom-designed qRTPCR assays for 
quantification of relative expression were 
designed to unique backspliced circRNA 
junctions (Thermo Fisher, Foster City, 
USA), the sequences of which are given 
in Online Resource 1. Each target 




of single nucleotide polymorphisms in 
potential primer or probe binding regions 
prior to ordering. Assays were ordered as 
custom single-tube assays from Thermo 
Fisher (Foster City, USA). Each circRNA 
probe was validated using standard 
curve analysis using 1:10 serial dilutions 
of synthetic oligonucleotides 
homologous to the back-spliced 
junctions. 
Assessment of associations between 
circRNA expression and aging 
phenotypes in the InCHIANTI cohort 
RNA samples and phenotypic data were 
available from 306 individuals at both 
follow-up 3 (FU3) and followup 4 (FU4) of 
the InCHIANTI study of aging. 
Characteristics of participants are given 
in Table 1. We assessed the expression 
of 15 age-associated circRNAs 
demonstrating the most marked 
differential expression with age between 
young and old pools as described above. 
Aging parameters assessed were age 
itself, parental longevity score (PLS) and 
hand grip strength. Participants aged 65 
+ years were categorised for PLS based 
on the age at death of their parents. 
Short, intermediate and long-lived cut-
offs were calculated separately for 
mothers and fathers based on the normal 
distribution of age at death in the cohort, 
as described in Dutta et al.,(2013a). 
Mothers and fathers aged < 49 years or 
< 52 years at death respectively were 
classed as premature and excluded. To 
standardize parental age of death, a Z 
score was generated for combined 
maternal and paternal measures of 
parental longevity. Hand-grip strength 
was measured in kilograms using a 
dynamometer, with repeated 
measurements at both FU3 and FU4. 
Reverse transcription and pre-
amplification of circRNAs in 
human peripheral blood RNA 
cDNA synthesis was carried out using 
100 ng total RNA using the High-
Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher, Foster City, USA) 
according to manufacturer’s instructions 
(Fisher Scientific, New Hampshire, USA) 
in a final reaction volume of 10.0 μL per 
sample. Reactions (samples in 96-well 
plates) were run at 25 °C for 10 min, 37 
°C for 120 min, 85 °C for 5 min followed 




min. Pre-amplification of circRNA 
expression was carried out using 5 μL 
TaqMan PreAmp master mix (Thermo 
Fisher, Foster City, USA), 2.5 μL pooled 
assay mix and 2.5 μL cDNA in a final 
reaction volume of 10 μL per sample. 
Cycling conditions were one cycle of 95 
°C for 10 min followed by 14 cycles of 95 
°C for 15 s with 60 °C for 4 min followed 
by 95 °C for 10 min. Pre-amplified 
samples were then diluted 1:10 and 
maintained on ice prior to analysis. 
Assessment of associations between 
circRNA expression in peripheral blood 
RNA and human aging phenotypes 
The expression profiles of selected 
circRNAs were then measured in total 
peripheral blood mRNA using 
customdesigned OpenArray plates on 
the Thermo Fisher 12K 
Flexplatform(ThermoFisher,FosterCity,U
SA).Reaction mixes contained 2.5 μL 2✕ 
OpenArray Real-Time Master 
Mix,dilutedpre-
amplifiedcDNA(1.2μL)andRNase-free 
dH2O (1.3 μL) (Thermo Fisher, Foster 
City, USA). circRNA expression was 
measured relative to the geometric mean 
of the entire set of transcripts, with the 
expression of each individual circRNA 
normalised to the global mean 
ofexpressionofthatcircRNA 
acrossthesamples.Samples were run in 
three technical triplicates. Association of 
circRNAs with age in InCHIANTI was 
carried out by multivariate linear 
regression, adjusted for potential 
confounders BMI, sex, level of education 
(none, elementary, 
secondary,highschoolanduniversity),stu
dysite,smoking and white blood counts 
(neutrophil, lymphocyte, monocyte, 
eosinophil percentages) while age was 
additionally adjusted for all other 
measures of association in the aging 
human cohort. We assessed association 
of circRNA with hand grip strength and 
parental longevity score (PLS) (Dutta et 
al., 2013b; Dutta et al., 2013c) as a proxy 
measure of longevity in humans. 
Statistical analysis was completed using 
StataSE15 (StataCorp, TX, USA). 
Figures were generated using GraphPad 





Assessment of circRNA expression in 
human primary senescent cells of 
different lineages 
The expression levels of the 15 
candidate circRNAs analysed above 
were also assessed in relation to cellular 
senescence, in senescent and early 
passage primary human primary 
fibroblasts, endothelial cells, astrocytes 
and cardiomyocytes using high-
throughput qRTPCR on the 12K Flex 
OpenArray platform (Thermo Fisher, 
Foster City, USA). Samples were run in 
three biological replicates and three 
technical replicates. Senescent cells had 
been generated and characterised in 
previous work by our group, and culture 
conditions and details of assessment of 
senescence are reported elsewhere 
(Latorre et al., 2017; Latorre et al., 
2018a; Latorre et al., 2018b; Latorre et 
al., 2018c; Lye et al., 2019). RNA 
samples from this work were available for 
use. circRNA levels were assessed in 
three biological and three technical 
replicates from early and late 
passagehumanprimarycells offour 
differentcell types. Early passage young 
cells were at population doubling (PD) of 
24 for astrocytes, 28 for cardiomyocytes, 
24 for endothelial cells and 25 for 
fibroblasts, whilst late passage 
senescent cells were at PD = 84 for 
astrocytes, 75 for cardiomyocytes, 65 for 
endothelial cells and 63 for fibroblasts. 
Senescent cell load in these samples 
was ~ 75% for fibroblasts, ~ 55% for 
endothelial cells, ~ 38% for 
cardiomyocytes and ~ 36% for 
cardiomyocytes (Latorre et al., 2017; 
Latorre et al., 2018a; Latorre et al., 
2018b; Latorre et al., 2018c; Lye et al., 
2019). In all cases, growth of the culture 
had slowed to less than 0.5 PD/week. 
Differential circRNA expression in 
senescent cells was then assessed by 
one-way ANOVA using StataSE15 
(StataCorp, TX, USA). Figures were 
generated using GraphPad Prism 8.1.2 
(GraphPad Software, San Diego, USA). 
Assessment of circRNA conservation 
between mouse and human 
We assessed whether the 15 circRNAs 
identified in our human study were likely 
to be conserved in mouse by aligning the 




sequences using the Blat tool in the 
UCSC genome browser 
(https://genome.ucsc.edu). Quantitative 
real-time PCR assays were developed to 
unique back-spliced junctions of 
conserved circRNAs. Probe and primer 
sequences are given in Online Resource 
2. circRNA expression was then 
measured in mouse spleen and muscle 
tissue and assessed in relation to 
lifespan by analysis of levels in six strains 
of male mice (A/J, NOD.B10Sn-H2b/J, 
PWD/PhJ, 129S1 /SvlmJ, C57BL/6J and 
WSB/EiJ) selected on the basis of 
divergent median strain longevity (Yuan 
et al., 2009). Animal husbandry, 
handling, animal characteristics and 
sample preparation protocols have been 
previously described (Lee et al., 2016). 
Tissue samples were obtained from 
cross-sectional study conducted in the 
same compartment and in the same 
period of time as described in Yuan et 
al.,(2009). Spleen and quadricep muscle 
tissues were excised immediately after 
sacrifice and shipped from the Jackson 
Laboratory using RNAlater-ICE 
Collection protocol (Life Technologies, 
Carlsbad, CA). In this method, tissues 
are submerged in RNAlater stabilization 
solution; an aqueous tissue storage 
reagent used to rapidly permeate tissues 
and stabilize RNA from fresh specimens 
and stored at – 20 °C or below for later 
use. 
RNA extraction and reverse transcription 
from mouse 
tissues 
Total RNA was extracted using the TRI 
Reagent/ chloroform phase separation 
according to manufacturer’s instructions. 
Briefly, tissues stored in RNA later were 
drained, and then placed in 1 mL TRI 
Reagent solution containing 10 mM 
MgCl2. Samples were homogenized for 
15 min (spleen) or 30 min (muscle) using 
bead mills (Retsch Technology GmbH, 
Haan, Germany). This was followed by a 
phase separation using chloroform. Total 
RNAs in the separated RNAs were 
precipitated from the aqueous phase 
through overnight incubation with 
isopropanol at − 20 °C. The following 
morning, RNA pellets were washed twice 
with ethanol and resuspended in RNase-
free dH2O. Complementary DNA (cDNA) 




the Evocript Universal cDNA Master 
Synthesis kit according to the 
manufacturer’s instructions (Roche, 
Switzerland). 
Assessment of circRNA expression in 
mouse spleen and muscle 
circRNAs selected on the basis of 
interspecies sequence conservation 
were validated in mouse spleen and 
muscle tissue. Expression levels of 
conserved circRNAs were assessed in 
relation to median strain lifespan by 
relative quantification. Quantitative 
qRTPCR was carried out for circRNAs 
(circFoxo3, circMib1, circPlekhm1 and 
circXpo7) in relation to the Pol2ra, Trfc 
and Ipo8 endogenous control genes, 
selected on the basis of lack of age 
association in a previous study (Harries 
et al., 2011). Reaction mixes contained 
cDNA (0.5 μL), TaqMan Universal PCR 
mastermix II (2.5 μL, no AmpErase UNG 
(Thermo Fisher, Foster City, USA), dH2O 
(1.75 μL, Fisher Scientific, USA), and 
TaqMan gene assay (0.25 μL, Thermo 
Fisher, Foster City, USA) in a 5 μL final 
reaction volume. The reaction mixes 
were centrifuged at 3000 rpm, vortexed 
and centrifuged again at 3000 rpm and 
transferred to 384-well qRTPCR plates. 
qRTPCR was run at 50 °C for 2 min, 95 
°C for 10 min and 50 cycles of 15 s at 95 
°C for 30 s and 1 min at 60 °C. Each 
sample assay was conducted in three 
technical triplicates. Expression levels of 
circRNAs in young and old mouse 
tissues were measured relative to the 
geometric mean of the entire set of 
transcripts, with the expression of each 
individual circRNA normalised to the 
global mean of expression of each 
circRNA across the samples. Linear 
regression analysis was carried out to 
assess the association of expression of 
circRNA using StataSE15 (StataCorp, 
TX, USA). 
Results circRNA profile in peripheral 
blood of aging humans 
One hundred sixty-six to 167M reads 
were obtained from the RNAse R-treated 
pools and 157–163M reads from the 
mock-treated pools with a mean Q score 
of 34.6–35.1 and total error rate of 0.47–
0.53%. A total of 2207 circRNAs were 




these, 184 circRNAs were found in both 
the young and old samples, 431 were 
exclusively expressed in the young 
sample pool and 1592 were exclusively 
expressed in the old sample pool (Online 
Resource 3). We selected 15 circRNAs 
for further analysis: 5 expressed 
exclusively in the young pool, 5 
expressed exclusively in the old pool and 
5 expressed in both pools but showing 
the most discrepant expression for 
further study. These were circITGAX, 
circPLEKHM1, circDEF6, circATP6V0A1 
and circASAP1 which showed exclusive 
expression in the young; circFOXO3, 
circFNDC3B, circAFF1, circCDYL and 
circXPO7 which showed exclusive 
expression in the old; and circMIB1, 
circMETTL3, circEP300, circZC3H18 and 
circBCL11B that were expressed, but 
differentially so in both sample pools. 
Pathway analysis of circRNA expressed 
in aging humans 
Pathway enrichment for the genes 
hosting the top 10% most abundant 
circRNAs in each of young and old 
pooled peripheral blood samples was 
performed using ClueGO cytoscape 
(Bindea et al., 2009). In the young 
peripheral blood, the top 10% most 
abundant circRNAs derived from genes 
associated with negative regulation of 
ATP metabolic processes and in 
transmission of synaptic signals. The 
leading edge genes hosting circRNAs for 
negative regulation of ATP processes 
were SNCA, STAT3 and UFSP2, whilst 
those associated with synaptic vesicle 
endocytosis were FCH02, PICALM, 
PIP5K1C and SNCA. Genes hosting 
circRNAs were primarily localised in 
pathways involved in phagocytosis, 
circadian regulation, cancer pathways 
and golgi-associated vesicle budding in 
the blood from aged donors (Table 2). 
circPLEKHM1, circMETTL and 
circFNDC3B expression levels are 
associated with aging phenotypes in 
humans 
The structures of the 15 circRNAs 
selected for follow-up were predicted 
based on the sequencing read depth for 
each exon and are presented in Fig. 1. 
Exon structures presented as read depth 
plots are given in Online Resource 4. 
Although we demonstrated no 




identify associations between some 
circRNAs and human aging phenotypes. 
circEP300 and circFOXO3 both 
demonstrated negative associations with 
combined parental longevity score (β = − 
0.065 and − 0.060; P = 0.001 and 0.002 
respectively), after adjustment for 
multiple testing. circDEF6 was positively 
correlated with parental longevity scores 
but demonstrated nominal significance 
only (β = 0.070, P = 0.024) (Table 3, Fig. 
2). A positive association was also 
identified both cross-sectionally (β = 
0.004, P = 0.039) and longitudinally (β = 
0.004, P = 0.038) between circFNDC3B 
expression and hand grip strength (Table 
4, Fig. 3), although these were nominal 
only. 
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Expressed only in old 
Fc gamma R-mediated phagocytosis 0.005 4 ARPC1B, ASAP1, PIP5K1C, VASP 
Exercise-induced Circadian Regulation 0.006 3 CRY2, NCOA4, TAB2 
Pathways Affected in Adenoid Cystic 
Carcinoma 
0.018 4 ERBB2, FOXO3, KANSL1, MGA 
Endometrial cancer 0.041 3 AXIN1, ERBB2, FOXO3 
trans-Golgi Network Vesicle Budding 0.035 3 DNAJC6, IGF2R, PICALM 
Clathrin derived vesicle budding 0.049 3 DNAJC6, IGF2R, PICALM 
Golgi Associated Vesicle Biogenesis 0.069 3 DNAJC6, IGF2R, PICALM 
Cargo recognition for clathrin-mediated 
endocytosis 
0.062 5 FCHO2, IGF2R, PICALM, REPS1, UBQLN1 
Clathrin-mediated endocytosis 0.049 8 DNAJC6, FCHO2, GAPVD1, IGF2R, PICALM, PIP5K1C, 
REPS1, UBQLN1 
Expressed only in young 
Negative regulation of ATP metabolic 
process 
0.004 3 SNCA, STAT3, UFSP2 
Synaptic vesicle recycling 0.009 4 FCHO2, PICALM, PIP5K1C, SNCA 
Presynaptic endocytosis 0.018 4 FCHO2, PICALM, PIP5K1C, SNCA 
Synaptic vesicle endocytosis 













0.037 1 HAGH 
Notch signaling pathway_Homo 
sapiens_hsa04330 
0.045 1 EP300 
The ClueGo pathway results for pathways potentially targeted by genes generating the top 10% of circRNAs differentially 
expressed with age are presented here aligned to the hg19 genome alignment. Number of genes = number of differentially 
expressed genes in each pathway 
circRNAs are differentially expressed in 
early passage and late passage cells 
Twelve of 15 circRNAs tested were 
expressed in astrocytes, endothelial 
cells, fibroblasts or astrocytes. Seven 
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(58%) of these demonstrated differential 
expression between early and late 
passage cells of one or more cell type 
(Table 5). circAFF1 and circFOXO3 
demonstrated associations in more than 
one cell type although direction of effect 
was concordant only for circFOXO3 (in 
cardiomyocytes and fibroblasts). 
circCDYL, circEP300, circMIB1, 
circZC3H18 and circMETTL3 were 
differentially expressed in only one cell 
type. circBCL11B, circDEF6 and 
circITGAX were not expressed in any cell 
type tested. 
Differential expression of circRNAs 
between mice of different median strain 
longevities 
In silico analyses suggested that four 
circRNAs (circFoxo3, circMib1, 
circPlekhm1 and circXpo7) may have 
conserved back-spliced junction in the 
mouse. Associations with longevity were 
then assessed in spleen and muscle 
tissue from young (6 months) and old 
(20–22 months) mouse strains of six 
different median strain longevities. 
circMib1 and circXpo7 were expressed 
only in spleen, whereas circFoxo3 and 
circPlekhm1 were expressed in both 
tissues (Table 6). The expression of 
circPlekhm1 demonstrated a nominal 
positive correlation with median lifespan 
in young and old (β = 0.0013, P = 
0.016) as well as in spleen of young mice 
(β = 0.0025, P = 
0.017),althoughthesewerenotsignificanta
fteradjustment 
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for multiple testing (threshold P = 0.013). No associations were seen between muscle 
circRNA expression levels and median 
strain longevity. 
a circASAP1 circATP6V0A1 circDEF6 circITGAX circPLEKHM1 
 
b circAFF1 circCDYL circFNDC3B circFOXO3 circXPO7 
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Fig. 1 Circular RNA junction schematics for the top 5 most 
abundant circular RNAs uniquely found in young (a) and 
old samples (b). Also shown are junction schematics for 
the top 2 and 3 most abundant common circular RNAs 
found in young and old samples respectively (c). Each 
schematic shows the identified back-spliced exon or 
exons. The relative read depth at each backspliced 
junction is shown by the number of bars above each 
junction and is scaled by linear interpolation, where the 
backspliced junctions with 1 and 10 bars represent the 
junctions with the lowest and highest readdepth 
respectively. Black and greybars show relative read depth 
at junctions in young and old samples respectively 
Discussion 
Circular RNAs (circRNAs) are an 
emerging class of regulatory RNA 
molecule thought to play a role in human 
disease (Haque and Harries 2017). 
These molecules have no free ends, and 
as such are exonuclease resistant. 
circRNAs accumulate in aged organisms 
(Gruner et al., 2016) and have been 
suggested to play a role in cellular 
senescence (Du et al., 2017; Du et al., 
2016). We hypothesised that the human 
circRNAome may differ in aged humans 
compared with younger subjects and that 
these changes may also be associated 
with cellular senescence or with longevity 
in animal models. We identified > 2000 
circRNAs in total RNA from human blood, 
some of which were expressed 
exclusively in samples from older donors. 
GSEA pathways enrichment analysis of 
genes hosting the top 10% most 
abundant circRNAs in elderly donors 
suggested that pathways involved in 
phagocytosis, circadian regulation, 
cancer pathways and golgi-associated 
vesicles were the most enriched in these 
genes. We demonstrated that three 
circRNAs (circDEF6, circFOXO3 and 
circEP300) were associated with 
measures of parental 
Table 3 circRNA expression in relation to combined 
parental longevity score 
 
circRNA β-Coefficient p value 95% CI 
circAFF1 − 0.012 0.485 − 0.048–0.023 
circASAP1 − 0.044 0.064 − 0.090–0.003 
circATP6V0A1 0.036 0.223 − 0.022–0.094 
circBCL11B 0.042 0.136 − 0.013–0.097 
circCDYL − 0.030 0.109 − 0.067–0.007 
circDEF6 0.070 0.024 0.009–0.131 
circEP300 − 0.065 0.001 − 0.103–− 0.026 
circFNDC3B 0.025 0.239 − 0.016–0.066 
circFOXO3 − 0.060 0.002 − 0.098–− 0.021 
circITGAX 0.019 0.440 − 0.030–0.068 
circMETTL3 0.007 0.730 − 0.034–0.049 
circMIB1 − 0.018 0.310 − 0.052–0.017 
circPLEKHM1 − 0.009 0.493 − 0.035–0.017 
circXPO7 0.038 0.162 − 0.016–0.093 
circZC3H18 − 0.036 0.078 − 0.077–0.004 
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Beta coefficients, p values and 95% confidence intervals 
(95% CI) are given for associations between circRNAs 
expression and combined parental longevity (PLS) score. 
Two hundred ninety-one samples were assessed. Genes 
demonstrating statistically significant results below the 
multiple testing limit of 0.003 are indicated initalics, whilst 
those demonstrating nominal associationsonly are given 
in bold type 
 
Fig. 2 circRNA expression is associated with combined 
parental longevity. Forest plot illustrating the association 
between peripheral blood circRNA expression and 
combined human parental longevity score (PLS) in 
participants from the InCHIANTI study of aging. N = 306 
individuals. The beta-coefficient of the association is given 
on the X-axis, and the identity of the gene is given on the 
Y-axis. Lines attached to each data point represent 95% 
confidence intervals (95% CI). Statistical significance is 
indicated by stars, *< 0.05, **< 0.005 
longevity, and one (circFNDC3B) was 
associated with hand grip strength both 
longitudinally and cross-sectionally. 
Furthermore, 7 of 12 circRNAs 
expressed in human senescent cells 
ofdifferentcell types demonstrated 
dysregulated expression in one or more 
cell type and 1 of 4 circRNAs 
demonstrating conserved expression 
were associated with median strain 
longevity in spleen tissue from young 
mice. These findings are consistent with 
the hypothesis that some circRNAs have 
roles in molecular aging and the 
determination of mammalian aging 
phenotypes. 
circRNAs generated from the FOXO3 
and EP300 genes were negatively 
associated with measures of human 
parental longevity and also demonstrated 
dysregulated expression in human 
senescent cells. circRNAs deriving from 
the FOXO3 gene have previously been 
demonstrated to regulate cell cycle when 
manipulated by gene knockdown in 
mouse embryonic fibroblasts, cardiac 
fibroblasts or mammary cancer cell lines 
(Du 
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Table 4 circRNA expression in relation to grip strength    
circRNA Grip strength β-Coefficient p value 95% CI 
circAFF1 Cross-sectional − 0.001 0.508 − 0.004–
0.002 
 Longitudinal − 0.003 0.081 − 0.007–
0.000 
circASAP1 Cross-sectional − 0.001 0.713 − 0.005–
0.004 
 Longitudinal 0.000 0.854 − 0.005–
0.004 
circATP6V0A1 Cross-sectional 0.000 0.965 − 0.005–
0.005 
 Longitudinal − 0.002 0.403 − 0.008–
0.003 
circBCL11B Cross-sectional 0.002 0.443 − 0.003–
0.007 
 Longitudinal 0.000 0.914 − 0.006–
0.005 
circCDYL Cross-sectional − 0.001 0.665 − 0.004–
0.003 
 Longitudinal 0.000 0.828 − 0.004–
0.003 
circDEF6 Cross-sectional 0.000 0.903 − 0.005–
0.006 
 Longitudinal 0.002 0.599 − 0.004–
0.008 
circEP300 Cross-sectional − 0.004 0.060 − 0.007–
0.000 
 Longitudinal − 0.003 0.112 − 0.007–
0.001 
circFNDC3B Cross-sectional 0.004 0.039 0.000–0.008 
 Longitudinal 0.004 0.038 0.000–0.008 
circFOXO3 Cross-sectional 0.002 0.402 − 0.002–
0.005 
 Longitudinal 0.000 0.834 − 0.004–
0.003 
circITGAX Cross-sectional 0.000 0.997 − 0.004–
0.004 
 Longitudinal − 0.001 0.658 − 0.006–
0.004 
circMETTL3 Cross-sectional − 0.003 0.139 − 0.007–
0.001 
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given in bold 
et al., 2016). Furthermore, FOXO3 
circular RNAs also demonstrate elevated 
expression and association with 
cellularsenescenceinthehearttissue 
ofmice andhumans (Du et al., 2017). It is 
not clear whether the previously reported 
circular FOXO3 transcripts have the 
same structure as the one we have 
identified, since previous studies do not 
give its exon structure. A circRNA from 
the FOXO3 gene identical to the one we 
have identified has also previously been 
demonstrated to inhibit myoblast 
differentiation in mouse cells (Li et al., 
2019). Genetic variation in the FOXO3 
gene itself has previously been 
associated with extreme longevity 
(Flachsbart et al., 2017; Fuku et al., 
2016) and has also been associated with 
maintenance of telomere length (Davy et 
al., 2018). 
circRNAs deriving from the EP300 gene 
have not been previously reported. EP300 
encodes the repressor histone 
acetyltransferase protein p300, which 
also has roles as a transcriptional 
corepressor protein. EP300 has been 
implicated in modulation of FOXO3 
activity (Mahmud et al., 2019) and in 
Fig. 3 Peripheral blood circFNDC3B expression is 
nominally associated with hand grip strength Forest plot 
illustrating the association between circRNA expression 
and hand grip strength in participants from the InCHIANTI 
study of aging. Associations with grip strength are shown 
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both a cross-sectionally from followup 3 (FU3) and b 
longitudinally, from follow-up 4 (FU4). N = 306 individuals. 
The beta-coefficient of the association is given on the X-
axis, and the identity of the gene is given on the Y-axis. 
Lines attached to each data point represent 95% 
confidence intervals (95% CI). Statistical significance is 
indicated by stars, *< 0.05, 
**< 0.005 
antagonism of the FOX03a/SIRT1 
signalling axis (Jeung et al., 2016). 
Inhibition of EP300 has been shown to 
mimic calorific restriction in human and 
mouse cells (Pietrocola et al., 2018); 
calorific restriction is of course a well-
known modifier of lifespan in many 
species (Austad 1989; Hansen et al., 
2008; Kapahi et al., 2004; Mitchell et al., 
2010). This protein is also a master 
regulator of autophagy, which is a pivotal 
factor in stem cell maintenance and 
evasion of cellular senescence 
(Vijayakumar and Cho 2019). 
circFNDC3B was positively associated 
with hand grip strength. Although these 
associations were nominal only, they 
were present both cross-sectionally and 
longitudinally. An average person may 
lose ~ 20–40% of skeletal muscle mass 
as well as muscle strength from by the 
time they reach 80 years of age (Carmeli 
et al., 2002; Doherty 2003) and decline in 
skeletal muscle strength is predictive of 
disability and mortality in humans 
(Giampaoli et al., 1999; Rantanen et al., 
1999; Rantanen et al., 2012). Circular 
RNAs originating from this gene have 
been reported previously, and suggested 
to possess tumour suppressor activity 
(Liu et al., 2018). 
The results generated from our mouse 
data suggest that circPlekhm1, which was 
associated with median strain longevity, 
may drive longevity, rather than being 
consequential to it, since the 
associations are present in the spleen 
RNA of young mice alone. The Plekhm1 
gene encodes a multivalent adaptor 
protein that integrates endocytic and 
autophagic pathways at the lysosome 
(McEwan and Dikic 2015). Its role in 
lifespan may therefore stem from 
moderation of lysosomal trafficking since 
lysosomes play a critical part in 
successful aging and longevity 
(Carmona-Gutierrez et al., 2016; 
Simonsen et al., 2007). 
Our study has both strengths and 
weaknesses. It represents one of the first 
circRNA profiles in aging human 
peripheral blood and provides data not 
only population-level epidemiological 
evidence for a role in human aging 
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phenotypes, or mammalian lifespan, but 
also in vitro evidence that some circRNA 




Table 5 circRNA expression in early and late passage primary human cells 
 
circAFF1 0.58 (0.55–0.68) 0.84 (0.79–1.09) 0.040 
circASAP1 1.39 (0.97–1.48) 1.22 (1.18–1.36) 0.878 
circATP6V0A1 1.60 (1.14–1.87) 1.14 (1.05–1.41) 0.229 
circCDYL 0.71 (0.67–0.74) 0.90 (0.90–0.93) 0.001 
circEP300 1.01 (0.95–1.04) 1.05 (1.00–1.07) 0.329 
circFNDC3B 0.96 (0.85–1.10) 1.38 (1.20–1.48) 0.059 
circFOXO3 0.88 (0.80–0.89) 0.89 (0.80–0.98) 0.646 
circMETTL3 0.97(0.92–1.08) 0.69 (0.66–1.02) 0.180 
circMIB1 0.71(0.69–0.86) 1.03 (0.99–1.04) 0.008 
circPLEKHM1 1.05 (1.00–1.09) 0.76 (0.61–1.17) 0.306 
circXPO7 1.25 (1.12–1.58) 1.54 (0.81–1.62) 0.987 
circZC3H18 
Cardiomyocytes 
1.50 (0.67–2.24) 0.88 (1.00–1.07) 0.346 
circAFF1 1.15 (1.09–1.26) 1.42 (1.04–1.52) 0.357 
circASAP1 0.74 (0.71–1.05) 0.84 (0.83–1.02) 0.643 
circATP6V0A1 0.57 (0.44–0.80) 0.41 (0.39–0.54) 0.249 
circCDYL 1.47 (1.29–1.48) 1.42 (1.25–1.64) 0.855 
circEP300 1.27 (1.02–1.48) 1.10 (0.84–1.45) 0.596 
circFNDC3B 1.03 (0.83–1.09) 1.93 (0.96–1.97) 0.139 
circFOXO3 1.00(0.99–1.07) 0.82 (0.79–0.92) 0.015 
circMETTL3 0.88(0.69–0.99) 0.66 (0.63–0.79) 0.186 
circMIB1 0.96 (0.81–1.02) 1.16 (0.97–1.25) 0.129 
circPLEKHM1 0.85 (0.84–1.05) 0.82(0.71–1.22) 0.983 
circXPO7 0.89 (0.74–0.94) 1.32 (0.75–1.63) 0.227 
circZC3H18 
Endothelial cells 
0.83 (0.63–1.43) 0.85 (0.77–1.12) 0.862 





circAFF1 0.94 (0.91–1.27) 1.07 (0.49–1.11) 0.548 
circASAP1 1.03 (0.94–1.28) 1.69 (0.68–1.76) 0.467 
circATP6V0A1 0.37 (0.16–0.58) 0.48 (0.48–0.48) 0.821 
circCDYL 0.90 (0.76–1.11) 0.89 (0.84–1.02) 0.942 
circEP300 0.99 (.75–1.45) 0.58 (0.53–0.80) 0.128 
circFNDC3B 1.74 (1.49–3.18) 7.84 (3.18–9.97) 0.080 
circFOXO3 0.38 (0.20–1.98) 0.14 (0.04–0.22) 0.275 
circMETTL3 1.02 (0.54–1.08) 0.39 (0.39–0.56) 0.072 
circMIB1 1.36 (0.98–1.54) 1.11 (1.03–1.43) 0.640 
circPLEKHM1 1.02 (0.99–1.42) 1.47(0.83–4.85) 0.380 
circXPO7 0.97 (0.72–1.18) 0.87 (0.31–1.22) 0.620 
circZC3H18 
Fibroblasts 
1.02 (0.98–1.15) 1.51 (1.51–1.51) 0.047 
circAFF1 1.06 (0.95–1.16) 0.58 (0.52–0.65) 0.003 
circASAP1 0.51 (0.38–1.07) 1.05 (0.85–1.10) 0.196 
circATP6V0A1 1.39 (1.00–1.41) 1.10 (0.46–1.35) 0.375 
Table 5 (continued) 
 
 Early passage Late passage 
circCDYL 1.13 (0.72–1.17) 0.90 (0.81–1.06)  0.640 
circEP300 0.96 (0.78–0.98) 0.38 (0.38–0.69)  0.023 
circFNDC3B 0.50(0.48–0.94) 0.90 (0.85–0.91)  0.182 
circFOXO3 1.91 (1.72–2.01) 1.60 (1.47–1.61)  0.025 
circMETTL3 1.23(1.00–1.26) 1.39 (1.58–1.66)  0.030 
circMIB1 1.20 (1.14–1.47) 0.85 (0.69–1.11)  0.072 
circPLEKHM1 1.00(0.90–1.00) 0.84 (0.79–1.14)  0.716 
circXPO7 1.03(0.48–1.08) 0.57 (0.39–1.18)  0.645 
  p  
 320 
 
circZC3H18 0.93 (0.72–1.21) 0.74 (0.53–0.94)  0.432 
Results reaching statistical significance are indicated in bold 
typeface IQR interquartile range 
Table 6 Differential expression of conserved circRNAs in mice of differential 
median strain longevities 
  
circRNA Tissue β-Coefficient p value 95% CI  
circFoxo3 Muscle 0.00 0.403 − 0.0010 0.0024 
 Young (muscle) 0.0001 0.936 − 0.0028 0.0031 
 Old (muscle) 0.0008 0.478 − 0.0015 0.0031 
 Spleen − 0.0003 0.815 − 0.0027 0.0021 
 Young (spleen) 0.0002 0.922 − 0.0039 0.0043 
 Old (spleen) − 0.0005 0.757 − 0.0037 0.0027 
circMib1 Muscle ND ND ND ND 
 Young (muscle) ND ND ND ND 
 Old (muscle) ND ND ND ND 
 Spleen 0.0001 0.924 − 0.0023 0.0026 
 Young (spleen) − 0.0018 0.150 − 0.0044 0.0008 
 Old (spleen) 0.0021 0.299 − 0.0020 0.0062 
circPlekhm1 Muscle 0.0003 .813 − 0.0022 0.0028 
 Young (muscle) − 0.0022 0.161 − 0.0054 0.0010 
 Old (muscle) 0.0016 0.365 − 0.0020 0.0053 
 Spleen 0.0013 0.016 0.0002 0.0024 
 Young (spleen) 0.0025 0.017 0.0005 0.0046 
 Old (spleen) 0.00001 0.967 − 0.0008 0.0009 
 321 
 
circXpo7 Muscle ND ND ND ND 
 Young (muscle) ND ND ND ND 
 Old (muscle) ND ND ND ND 
 Spleen 0.0009 0.509 − 0.0019 0.0038 
 Young (spleen) 0.0003 0.894 − 0.0040 0.0045 
 Old (spleen) 0.0020 0.333 − 0.0023 0.0063 
circRNA expression is reported here in relation to median strain longevity. Data are assessed separately for young and 
old animals of each strain. N = 67 (muscle); 90 (spleen). Results reaching statistical significance are indicated in bold 
typeface 






include a relatively low power to detect effects of in the population study, which might 
be attributed to the biological variation in circRNA levels and limitations in samples 
size and power. Nevertheless, we were able to identify some interesting associations, 
which likely represent the largest effects. Future work could include validation of 
epidemiological data in larger sample sets and also functional delineation of the 
molecular effects of the circRNA in question. Our data provide evidence that circRNAs 
may play an important role in the determination of mammalian aging phenotypes. 
circRNAs are inherently stable, due to their exonuclease resistance, and are found not 
only in tissues relevant to human diseases, but also in the circulation, raising the 
possibility that they may prove useful as biomarkers of disease or targets for molecular 
therapies in the future. 
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